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Companion biomarkers for targeted therapies have increased the expectation that 
biomarkers can improve health outcomes or potentially save health resources without 
compromising patient outcomes. However, few countries provide health economic 
assessment methods guidance (e.g. health technology assessment guide) specifically for 
co-dependent technologies such as companion diagnostics.  
Aim 
This thesis aims to explore good practices for evaluating companion biomarker tests as 
part of health economic assessments of their co-dependent targeted therapies in cancer.  
Scope of the study 
Cancer biomarkers for targeted therapies investigated in this thesis are restricted to 
companion biomarkers, classifying patients into responders and non-responders for a 
specific targeted therapeutic agent.  
Methods  
Four research activities were designed: two systematic literature reviews (SLR) and two 
health economic models. The first SLR (Chapter 2) was conducted to demonstrate the 
impact of companion biomarker tests on the cost-effectiveness of targeted therapies, 
focusing on metastatic colorectal cancer (mCRC). The second SLR (Chapter 3) considered 
all cancer areas. It investigated current and best practice for modelling and incorporating 





therapies. The findings from these two SLRs were then applied to the cost-effectiveness 
modelling of a novel candidate companion biomarker test, Heat Shock Protein 27 (HSP27) 
expression (Chapter 4). The final work (Chapter 5) developed a practical guide to modelling 
companion biomarker tests as part of economic evaluations of corresponding targeted 
therapies; a global model was constructed and provided as a worked example coupled with 
step-by-step guide for readers to follow.  
Results  
The first SLR study showed that the use of companion biomarker tests saved some costs 
however, the saving was not high enough to change materially the cost-effectiveness of 
co-dependent therapeutic agents. The second SLR found that there was inconsistency in 
the methods for evaluating companion biomarker tests in the appraisal of co-dependent 
agents. The cost-effectiveness analysis of HSP27 expression showed conflicting results 
depending on the structure of the comparative analysis. Finally, the modelling guide 
coupled with a worked example of a global model demonstrated how to model 
characteristics of companion biomarker tests in economic evaluations of test-guided 
therapies.  
Conclusion  
This thesis highlights the need to reach a consensus on the methods of evaluating 
companion testing technologies as part of economic evaluations of their corresponding 
test-guided therapies. Built upon the consensus, a methods guide for co-dependent 
technologies needs to be developed and introduced, providing a coherent and unified 
guidance on good practices, reference case, evidentiary standards and data requirements 
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1.1. Aim, objectives, and scope of the study  
 
1.1.1. Aim of the study  
 
Overall, this thesis aims to explore good practices for conducting economic evaluations of 
companion biomarkers for targeted therapies in cancer. It intends to examine current and 
good practices for incorporating companion diagnostics when assessing the cost-
effectiveness of their co-dependent therapies.  
1.1.2. Objectives of the study  
 
▪ Objective 1. To demonstrate the interaction between companion biomarker 
tests and targeted therapies in terms of the cost-effectiveness of biomarker-
guided therapies. To show how the use of companion diagnostics affects the 
cost-effectiveness of their co-dependent targeted therapies. To discover 
whether or not the incorporation of companion diagnostics has led the co-
dependent targeted therapies to be cost-effective. (Chapter 2).  
▪ Objective 2. To explore current and best practices for modelling and 
incorporating companion biomarker tests when assessing the cost-
effectiveness of the targeted therapies in cancer. To investigate current 
methods in modelling the characteristics of companion diagnostics based on 
the existing economic evaluations of biomarker-guided therapies in cancer. 





▪ Objective 3. To apply study findings from previous literature reviews (Chapters 
2,3) in a case study of modelling a novel companion biomarker test for targeted 
cancer therapy. To assess the cost-effectiveness of a novel candidate 
companion biomarker, Heat Shock Protein27 (HSP27) expression, for the use 
of bevacizumab in patients with metastatic melanoma; the treatment of 
patients with bevacizumab according to HSP27 expression status (intervention 
strategy arm) is compared with treating patients either with dacarbazine or 
bevacizumab without biomarker testing (comparator strategy arms). (Chapter 
4).  
▪ Objective 4. To provide a practical guide on how to conduct a cost-
effectiveness analysis of cancer biomarkers for targeted therapies with worked 
examples of a core model. To demonstrate practically how to model and 
incorporate the characteristics of cancer biomarker tests as part of economic 
evaluations of the co-dependent targeted therapies. (Chapter 5).   
1.1.3. Scope of the study 
 
The cancer biomarkers for targeted therapies investigated in this thesis are restricted to 
companion biomarker tests (interchangeably, companion diagnostics) guiding the safe and 
effective use of therapeutics with its approved label restricting drug access (1). Companion 
biomarker tests inform on classifying/stratifying patients into responders and non-
responders for the prescription of a specified therapeutic agent (in other words, 
biomarker-guided therapy). The technologies can be also the platforms used to deliver the 
companion diagnostic test. Different technologies can be used to provide the same 
diagnostic (2). Any other type of cancer biomarker tests such as complementary diagnostic 





by labelling are beyond the scope of this study. The study type focused in this study is 
limited to model-based economic evaluations.   
1.2. Background 
 
The optimisation of treatment strategies has now become possible based on the 
information provided by biomarkers prior to treatment especially in oncology. With the 
increased knowledge in genetics and molecular biology, healthcare providers can be 
guided by biomarker tests when selecting treatments. This advance has raised 
expectations over personalised medicine or precision medicine, which aims to provide the 
right treatment to the right patient.  
In this respect, biomarker-guided therapies may improve patient outcomes while helping 
to achieve efficient resource allocation in healthcare (4-7). In other words, companion 
biomarkers for targeted therapies have increased the expectation that biomarkers can 
improve health outcomes or potentially save health resources without compromising 
patient outcomes.  
However, there is widespread scepticism about the research and development (R&D) of 
biomarkers and personalised medicine because the number of biomarkers successfully 
entering into routine clinical practice is very low compared to the number of biomarkers 
published (8-11). It might imply a significant time-lag between the development of rapidly 
evolving medical technologies and the implementation of them being actually used in 
clinical practice. Such lagged integration may potentially delay the improvement of patient 
outcomes or may even cause harms especially for patients unresponsive to the 
corresponding therapies. However, decision-making bodies for reimbursement of health 





reimbursing or funding intervention A over intervention B under the fixed budget in health 
care systems. “The opportunity cost of funding an intervention A would be the potential 
value or the difference (incremental benefits) of A compared to B and the difference in 
cost (incremental cost) of A compare B” (12). Therefore, it is important to prioritize which 
intervention to be funded over the other ones based on health economic evidence 
generated by the comparative analysis of alternative courses of actions in terms of costs 
and benefits (i.e. economic evaluations). In economic evaluations, the opportunity cost of 
investing in a new intervention over standard care (or alternative interventions/health 
services) is measured by health benefits such as life years saved or QALYs gained (3). 
However, additional costs required by the introduction of new biomarker tests need to be 
justified by robust evidence of health economic benefits such as the value for money or 
cost-effectiveness (11, 13, 14). Therefore, the small number of biomarkers integrated into 
clinical practice could simply be a reflection on the quality of many of the biomarkers 
published. Then, the delayed integration or no introduction of new biomarker tests might 
be appropriate because the biomarkers published may not necessarily mean that they 
were worthwhile additions to clinical practices.   
Therefore, it is of public interest to ensure the appropriate integration of new technologies 
into clinical use through adequate levels of reimbursement and coverage. However, it 
needs test developers or manufacturers to provide robust evidence on the health 
economic impact of biomarkers for targeted therapies. However, few countries provide 
health economic evaluation methods guide specifically to co-dependent technologies such 







1.3. Companion cancer biomarkers for targeted therapies  
 
The scope of this thesis is restricted to companion biomarkers that are essential for the 
safe and effective use of co-dependent health technologies (drugs or biological products) 
in cancer. A biomarker is defined as ‘a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention’ (5). A biomarker is not an 
assessment of how an individual feels, functions, or survives (17). Biomarkers have 
multiple uses in clinical practice, ranging from diagnostic, to prognostic and predictive 
purposes (5). Their clinical uses include screening the stage of disease, diagnosing the 
presence of disease, monitoring patients with regard to the intended effect or adverse 
effects of the treatment administered. Companion biomarkers for targeted therapies are 
used to predict response to specific treatments. Such predictive biomarkers are the key to 
integrate co-dependent health technologies such as biomarker-guided therapies into 
clinical use. Predictive biomarkers are used to identify individuals who are more likely to 
experience a favourable or unfavourable effect from a medical product or environmental 
agent than similar individuals without the biomarker (17). Companion diagnostics are 
predictive biomarker assays which are co-licensed with corresponding therapeutics and 
are linked to the use of a specific drug, so called ‘test-drug’ technology or co-dependent 
health technology. Recently, a new class of predictive biomarker assays emerged, called 
complementary diagnostics, along with the new regulatory approval of PD-1/PD-L1 
immune checkpoint inhibitors for nivolumab or atezolizumab (18). However, in contrast 
with companion diagnostics, complementary diagnostics do not restrict patients from 
receiving co-dependent therapeutics because the therapeutic effect of complementary 





to US FDA, companion diagnostic is defined as a medical device, often an in vitro device 
(IVD), which provides information that is essential for the use and effective use of a 
corresponding drug or biological product (1). HER2 assay for trastuzumab was the first 
companion diagnostic approved by US FDA in 1988 (20, 21). HER2 for trastuzumab is one 
of the examples of companion biomarker testing routinely used in clinical practice prior to 
the administration of targeted therapies to patients with breast cancer. In summary, 
companion diagnostics are required to prescribe the corresponding therapies only to 
responder subgroups of patients, whereas complementary diagnostics do not restrict the 
access to specific therapeutics but aid clinicians in benefit-risk decision-making. Therefore, 
this study focuses on the methods of economic evaluations of companion biomarker tests 
for targeted therapies in cancer.  
 
 
1.4. Economic evaluations of biomarker-guided therapies 
 
Economic evaluation is defined as a ‘comparative analysis of alternative courses of action 
in terms of both their costs and their consequences’ (3). Economic evaluations are 
conducted in order to provide health economic evidence to payers by comparing the 
health benefits and costs of new health technologies against those of existing technologies. 
They aim to assess the value for money of different strategies and to assist payers to make 
an informed decision on the resource allocation of scarce health services. In many 
countries, including the United Kingdom, economic evaluation is an integral part of health 
technology assessment (HTA) for new health technologies to be reimbursed and covered 





and Care Excellence (NICE) provides a methods guide on technologies (with the general 
focus on medicines) (24), while providing a separate method guide on diagnostics and 
medical devices (25). In addition, for biomarker-guided therapies with rare incidence or 
low prevalence of biomarker status in the population, the NICE guide on highly specialised 
technologies for very rare conditions is applied (26).  
Economic evaluation is also increasingly used to assess the value for money of diagnostics 
including cancer biomarker tests, although cancer biomarker tests are often assessed as a 
small component of economic evaluations of the corresponding drugs. Despite most 
countries providing clear guidance on the methods of economic evaluations for drugs (e.g. 
guide to the methods of technological appraisal (22, 23, 27)), only a few HTA methods 
guidelines exist for medical devices or diagnostics such as biomarker testing kits (28, 29) .  
Furthermore, to our best knowledge, we found that very few countries provide a guide to 
the methods of health economic evaluation for co-dependent health technologies such as 
cancer biomarkers for targeted therapies such as, for example,  Australia (15). Or, Scottish 
Medicine Consortium (SMC) includes a list of items to be completed if the applicant’s 
health technology is companion diagnostics (16). However, for example, in England,  NICE 
does not provide a specific guide to the methods of appraising the health economic 
evaluation of cancer biomarkers for targeted therapies (i.e. personalized medicine or 
precision medicine) but evaluates them  according to the guide to the methods of 
technology appraisal, a document primarily (although not exclusively) developed with 
respect to the appraisal of  pharmaceutical drugs (30, 31). This reflects the current reality 
that reimbursement bodies in many countries do not keep pace with the rapidly evolving 






Reimbursement bodies make decisions based on robust evidence of clinical evidence and 
cost-effectiveness whether such introduction of new technologies provide more cost-
effective health benefits to patients in comparison with existing technologies. In other 
words, the lack of evidentiary standards for cancer biomarkers influences payers’ 
willingness to pay and cover the cost of new technologies (32, 33). Despite the increasing 
number of new biomarkers discovered, no agreement exists whether existing economic 
evaluation methods are sufficient to evaluate the health economic impact of biomarker 
tests (34, 35).   Furthermore, it is not known whether different methodological approaches 
might produce conflicting results with regard to the cost-effectiveness of biomarkers or 
biomarker-guided therapies.  
It is thus important to review and to suggest best practice for economic evaluation in 
assessing the value for money of cancer biomarkers for targeted therapies in the light of 
both methodological approaches and data requirements in constructing the health 
economic model.   
 
1.5. Structure of the thesis 
 
This thesis has been written as a series of individual research articles that can be read as 
stand-alone pieces of work but are integrated into a single document. The individual 
research articles are aligned with respective research objectives of this PhD thesis.  
The thesis consists of six chapters that describe the studies that have been conducted to 
address the aim and objectives of this PhD research. Four research activities were designed 
to address the four specific objectives (Section 1.1.2) and presented in four respective 





analyses were performed and presented. Each separate objective has been answered by 
the following chapters, alongside original manuscripts published or prepared for 
publication.  
First of all, Chapter 1 provides the overview of this thesis including aim and objectives, 
study focus/scope, study background and structure of the thesis. This chapter serves as an 
introduction to this thesis, guiding readers how individual articles are connected to each 
other and how they have contributed to the overall aim of the thesis. Besides, my 
contributions to the thesis, research funding and ethics approval have been declared in 
this chapter.  
The first research article (Chapter 2) is a systematic literature review (SLR) titled “Do 
Cancer Biomarkers Make Targeted Therapies Cost-Effective? Systematic Review in 
Metastatic Colorectal Cancer,” published in PLOS One (36). This first SLR aimed to critically 
appraise economic evaluations of biomarker-guided therapies and to demonstrate the 
impact of biomarker tests on the cost-effectiveness of their corresponding targeted 
therapies, namely co-dependent health technologies, using the case of metastatic 
colorectal cancer (mCRC). All economic evaluations assessing companion diagnostics for 
targeted therapies in mCRC were searched and reviewed by two independent reviewers. 
Study selection was performed following the pre-defined criteria formulated by the PICOS 
framework (population, intervention, comparator, outcome, study type). This first SLR 
demonstrated whether the incorporation of companion biomarker tests has led the co-
dependent targeted therapies to be cost-effective. It then informed me to the research 
question of the interaction between companion biomarkers and targeted drugs in terms 
of cost-effectiveness of biomarker-guided therapies. Furthermore, the quality of health 





identify and develop key areas of methods to be focused on and investigated in the next 
SLR study. 
The second research article (Chapter 3) is another SLR study titled “How Are We Assessing 
the Value for Money for Cancer Biomarkers in Economic Evaluations?”, which is ready to 
submit for publication. This SLR aimed to investigate current and good practices for 
modeling and incorporating companion biomarker tests when assessing the cost-
effectiveness of targeted cancer therapies. Extended from the first SLR study in one specific 
cancer case, this second SLR examined economic evaluations of companion biomarker 
tests in all cancer areas where companion diagnostics are routinely used prior to provision 
of the corresponding therapeutic agents. This review of companion biomarker tests was 
restricted to the companion diagnostics approved by the US Food and Drug Administration 
(37). Studies were selected according to pre-defined criteria of eligibility based on the 
PICOS framework. Studies that failed to report important information related to the 
companion biomarker test (e.g. biomarker characteristics or biomarker testing related 
data inputs) were excluded. Data extraction and analysis was performed based on the pre-
defined key areas of methods, which were informed by my research in Chapter 2 and the 
CHEERS checklist (38). It critically reviewed how existing evaluations had considered the 
characteristics of companion biomarker tests in their cost-effectiveness assessments of co-
dependent therapeutics.  
I then applied the findings from these two reviews to the modelling of a novel candidate 
companion biomarker test, Heat Shock Protein 27 (HSP27) expression and evaluated the 
cost-effectiveness of HSP27 testing prior to the administration of bevacizumab. This 
research article (Chapter 4) is titled “HSP27 Expression as a Novel Predictive Biomarker 





construction of this cost-effectiveness model was specifically informed by the previous SLR 
studies regarding the methods to incorporate the characteristics of companion biomarker 
tests in economic evaluations of the corresponding targeted therapies. HSP27 expression 
was chosen as a case study of modelling a companion biomarker test for a targeted therapy 
for three reasons. First, HSP27 expression was a novel candidate companion biomarker 
test discovered by my PhD research funder and it was of my funder’s interest to be 
informed of the health economic value of this potential companion test for bevacizumab. 
Thus, the analysis was done from the perspective of Norwegian health system. Second, I 
had access to clinical data in relation to HSP27 expression and bevacizumab beyond the 
trial period reported in the published paper. Third, this biomarker allowed me to closely 
collaborate with oncologists/clinicians in assessing the cost-effectiveness of HSP27 
expression.  
Building upon the review findings and modelling practice acquired from previous research 
activities (Chapters 2-4), Chapter 5 provides a practical guide to modelling companion 
biomarker tests when assessing the cost-effectiveness of biomarker-guided co-dependent 
health technologies. This final research article (Chapter 5) is titled “A Practical Guide to 
Conducting a Cost-Effectiveness Analysis of Companion Biomarkers for Targeted 
Therapies: Tutorial”, which is prepared for publication. This guide demonstrated in a 
practical manner how to construct the structure of alternative strategy arms including all 
relevant scenarios (e.g. test-treat strategy, treat-all with SOC without testing, treat-all with 
biomarker-guided therapy without testing). A core model was constructed and provided 
in R codes as a worked example for readers to follow. Readers (co-dependent technology 
developers, health economists, or modelers) can use this core model for local adaptations 
with appropriate adjustments according to their country-specific data requirements and 





requirements specifically relevant to companion biomarker tests as part of evaluating the 
value for money of biomarker-guided therapies. The R software was chosen to build this 
global model because it is open source (available free of charge), easily reproducible, and 
flexible compared to the other frequently used ones such as Excel®. The findings from all 
studies performed at the earlier stages of research activities in Chapters 2 to 4 assisted and 
informed the development of this core model. 
My final chapter, Chapter 6 provides an overview of the main findings and discusses the 
limitations of this thesis, as well as the implications for further research, along with policy 
implications and evaluation recommendations in the assessment of companion cancer 
biomarkers in an economic evaluation of targeted therapies.   
 
1.6. Contribution of the candidate to the thesis  
 
I undertook two systematic reviews (Chapter 2-3) and took the lead in the planning of the 
study design, data extraction, data analysis and synthesis. I performed electronic literature 
searches and hand searches to identify relevant published publications. I screened all 
identified literature and reviewed full-text papers.  
With regard to economic models (Chapter 4-5) included in this thesis, I designed and 
constructed both models and performed all cost-effectiveness analyses including survival 
analysis, value of information, and uncertainty analysis.  
Overall, I was the primary investigator of all studies included in this thesis and wrote all 
manuscripts as the first author while my supervisors, John Cairns and Alec Miners, 





More detailed descriptions of my contribution to each paper are provided in the title page 
of respective papers in the subsequent chapters.  
 
1.7. Funding and ethics approval  
 
This PhD was funded by the Centre for Cancer Biomarkers (CCBIO), University of Bergen, 
Norway and included tuition fees and an annual stipend over a period of 4 years.  
Ethics approval was given by the London School of Hygiene and Tropical Medicine (LSHTM) 
ethics committee (LSHTM Ethics Ref: 11886). As part of my LSHTM ethical approval 
applications, the ethical approval letters confirmed for the clinical trial of the effect of 
bevacizumab monotherapy in the treatment of metastatic melanoma and predictive value 
of markers were submitted as the evidence of local ethics approval. Furthermore, the 
completed Data Management Plan for Research Students was submitted to LSHTM as part 









2. DO CANCER BIOMARKERS MAKE TARGETED THERAPIES COST- 





















2.1. Research paper I 
 
Title: Do Cancer Biomarkers Make Targeted Therapies Cost-effective? A Systematic Review 
in Metastatic Colorectal Cancer   
Authors: Mikyung Kelly Seo1,2, John Cairns1,2 
Affiliations: 1 Department of Health Services Research and Policy, Faculty of Public Health 
and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom. 2 
Centre for Cancer Biomarkers (CCBIO), University of Bergen, Bergen, Norway. 
Publication status: Published.  
Citation: Seo MK, Cairns J. Do cancer biomarkers make targeted therapies cost-effective? 
A systematic review in metastatic colorectal cancer. PloS one. 2018 Sep 26;13(9):e0204496. 
Contribution of the candidate to this paper: I conceptualised this study together with John 
Cairns. I designed the literature search and review protocol based on the PICOS framework. 
I developed the search strategy per database where relevant studies were searched. I 
performed the literature search and identified studies fit with the purpose of this research. 
I performed the first and second screenings of title/abstract and full-text literature review. 
I developed and processed the data extraction for all studies identified relevant for the 
objective of this literature review study. I performed the data synthesis and analysis. I 








Recent advances in targeted therapies have raised expectations that the clinical 
application of biomarkers would improve patient’s health outcomes and potentially save 
costs. However, the cost-effectiveness of biomarkers remains unclear irrespective of the 
cost-effectiveness of corresponding therapies. It is thus important to determine whether 
biomarkers for targeted therapies provide good value for money. This study systematically 
reviews economic evaluations of biomarkers for targeted therapies in metastatic 




A literature search was performed using Medline, Embase, EconLit, NHSEED. Papers 
published from 2000 until June 2018 were searched. All economic evaluations assessing 
biomarker-guided therapies with companion diagnostics in mCRC were searched. To make 
studies more comparable, cost-effectiveness results were synthesized as per biomarker 
tests and corresponding therapies. Methodological quality was assessed using the Quality 
of Health Economic Studies (QHES) instrument.  
 
Results  
Forty-six studies were included in this review. Of these, 17 studies evaluated the intrinsic 





effectiveness of corresponding drugs. Most studies indicated favourable cost-effectiveness 
of biomarkers for targeted therapies in mCRC. Some studies reported that biomarkers 
were cost-effective, while their corresponding therapies were not cost-effective. A 
considerable number of economic evaluations were conducted in pre-defined genetic 
populations and thus, often failed to fully capture the biomarker’s clinical and economic 
values. The average QHES score was 73.6.  
 
Conclusion  
Cancer biomarkers for targeted therapies in mCRC were mostly found to be cost-effective; 
otherwise, they at least improved the cost-effectiveness of targeted therapies by saving 
some costs. However, this did not necessarily make their corresponding therapies cost-
effective. While companion biomarkers reduced therapy costs, the savings were not 
sufficient to make the corresponding agents cost-effective. Evaluation of biomarkers was 
often restricted to the cost of tests and did not consider their clinical values or biomarker 




Colorectal cancer (CRC) is the third most common cancer and the third leading cause of 
cancer deaths worldwide (40). In Europe, it is the most common cause of cancer death 
after lung cancer. In 2012, 241,600 men and 205,200 women were diagnosed with CRC [2], 
and 113,200 men and 101,500 women died from CRC (41). In the USA, 136,830 cases newly 





Despite recent developments in targeted therapies, gene sequencing and molecular 
diagnostics, promising optimized and personalized treatment regimens tailored for 
individual patients, CRC remains one of the less treatable cancers. Most cases of CRC are 
sporadic and develop slowly over several years, progressing through a series of clinical and 
histopathological stages from single crypt lesions through benign adenomas to malignant 
carcinomas, as a result of an accumulation of mutations in tumour suppressor genes and 
oncogenes or a genetic instability (43, 44). The 5-year survival rate for early-stage CRC is 
about 90% but it falls to 10% for late-stage CRC metastasized to distant sites (45) and  
cancer mortality is mainly due to metastasis (46, 47).  
There are multiple treatments available for patients with metastatic colorectal cancer 
(mCRC), including targeted therapies guided by biomarkers (48-50). Recent advances in 
targeted therapies have raised expectations that clinical application of biomarkers might 
improve health benefits while avoiding unnecessary toxicity and adverse events. It can 
potentially reduce health care system costs by containing unnecessary costs without 
hurting patient health outcomes (51).  
These therapies comprise epidermal growth factor receptor (EGFR), vascular endothelial 
growth factor (VEGF), and tyrosine kinase (TK) inhibitors. VEGF-targeted therapies include 
bevacizumab, aflibercept, and ramucirumab. EGFR inhibitors are cetuximab and 
panitumumab. Regorafenib is a TK inhibitor. Of these, only anti-EGFR therapies have a 
predictive biomarker clearly established for guiding treatment options as an integral part 
of the clinical pathways (52, 53). Current guidelines in Europe and the USA recommend 
that all mCRC patients receive Kirsten rat sarcoma (KRAS) testing prior to treatment with 
EGFR inhibitors since KRAS mutation status – wild type (WT) or mutant (MT) – predicts the 





testing (both KRAS and NRAS) (56). KRAS and NRAS mutations serve as predictive 
biomarkers for anti-EGFR therapies, only patients with RAS wild-type tumours benefit from 
these therapies. No positive predictive biomarkers exist yet, that identify eligible patients 
rather than exclude ineligible patients. No other molecular marker is part of routine clinical 
practice when deciding optimized and tailored treatment regimens for mCRC patients. 
However, irinotecan is a biomarker-directed chemotherapy for treating mCRC, which 
unlike molecularly targeted therapies, is a cytotoxic drug given to get rid of or control 
cancer cells. UGT1A1 testing showed clinical benefits for the administration of irinotecan 
(57). All these predictive biomarkers are currently used in clinical settings to make 
treatment decisions for the safe and effective use of targeted therapies in treating mCRC.  
Third-party payers often prioritize competing interventions by assessing cost-effectiveness 
using cost-effectiveness (CEA) and cost-utility analysis (CUA) (3). The former is often 
assessed per additional life-years gained (LYs), and the latter per additional quality-
adjusted life-year (QALY). Incremental differences in costs and benefits between 
alternative interventions are the main focus of economic evaluations and thus, the primary 
study outcome is usually to estimate the incremental cost-effectiveness ratio (ICER) per 
LYs or QALYs (3). The comparison of alternative courses of action for cancer biomarkers for 
targeted therapies can be broadly categorised into two forms: ‘test-treat’ strategy 
(patients are treated with new intervention guided by biomarker status) and ‘treat-all’ 
strategy (all patients are treated without biomarker testing) (58).  
To sum up, the use of biomarkers may permit optimising regimens without compromising 
health outcomes. This has significant implications for healthcare payers in containing 
expenditures that provide no or minimal benefits to patients. Despite such high 





are often co-assessed as part of high cost targeted therapy. This study systematically 
reviews economic evaluations of biomarker-guided therapies and aims to determine the 
impact of companion biomarkers on the cost-effectiveness of the corresponding therapies 
in mCRC.  
 
 MATERIALS AND METHODS 
 
Literature search  
A systematic literature search on the cost-effectiveness of cancer biomarkers for targeted 
therapies in mCRC was performed using Medline (Ovid), Embase (Ovid), EconLit, and the 
National Health Service Economic Evaluation Database (NHSEED) in June 2018. The search 
terms (Error! Reference source not found. 2-1) were validated by an information specialist. 
The reference lists of relevant articles were scrutinized, and the grey literature was hand-
searched.  
The electronic search was performed using Medical subject heading (MeSH) terms and 
keywords that were developed based on patients (mCRC), intervention (cancer biomarkers 
for targeted therapies), and outcome (ICERs). These were combined with free-word texts 
using relevant economic terms (e.g. “cost-effectiveness”) and the drug names of targeted 
therapies both in brand and generic terms. Targeted therapies granted a marketing 
authorization with companion biomarkers by the European Medicines Agency (EMA) or US 
Food and Drug Administration (FDA) were included in the literature search strategy (52). 







The study selection was based on the inclusion and exclusion criteria formulated by the 
PICOS framework i.e., population, intervention, comparator, outcome, study type 
(Appendix 2-2). Given the companion nature of predictive biomarkers for targeted 
therapies, their cost-effectiveness is interconnected with clinical effectiveness and costs of 
corresponding therapies as well as biomarker tests. Hence, the cost-effectiveness of 
biomarker testing as well as corresponding agents were included in this review. Selection 
of papers followed the eligibility criteria below:  
▪ Population: the intervention is being applied to adult patients with a diagnosis of 
mCRC.    
▪ Intervention: cancer biomarkers for targeted therapies (predictive/companion 
biomarkers). These biomarkers are used as diagnostic tools to guide treatment or 
select patients responsive to subsequent corresponding therapies. Cancer 
biomarkers without market authorizations co-licensed with targeted therapies 
were excluded.   
▪ Comparator: conventional treatments or targeted therapies with or without use of 
biomarker tests.  
▪ Outcome: ICERs for LYs, ICERs for QALYs. Studies merely reporting costs or 
effectiveness were excluded.  
▪ Study type: economic evaluations including model or trial-based analyses. Studies 
merely reporting on methodological issues, reviews, comments, letters or 
editorials were excluded.  
The study selection had three main stages. Firstly, search hits from the electronic 





the titles and abstracts of the identified articles were screened independently by two 
reviewers. Studies clearly indicated as irrelevant were excluded. Thirdly, the full articles 
retrieved that met the inclusion criteria were screened by two reviewers, with any 
disagreements between reviewers resolved by discussion.  
 
Data extraction 
A data extraction form was created based on the Cochrane Handbook of Systematic 
Reviews of Interventions and the CHEERS statement (38, 59). The following items were 
extracted: publication details, target patients, interventions, comparators, outcomes 
(ICERs), study designs. Data extraction was performed by the first assessor (MKS) using 
Microsoft Excel® and any ambiguities were resolved by discussion with the second 
reviewer (JC).   
 
Quality assessment  
The methodological quality of the included studies was assessed using the Quality of 
Health Economic Studies (QHES) scales (60). The QHES has been validated and shown to 
be useful in discriminating higher quality economic evaluation studies from poorer ones 
(61). The quality assessment was conducted by two assessors (MKS, JC). Since no 
standardized interpretation of QHES scores exist, we assigned QHES scores to three quality 
groups; above 70 scores as high quality, between 50 and 70 as fair quality, and below 50 







The cost-effectiveness results of included studies divided into two groups: 1) the cost-
effectiveness of cancer biomarkers for targeted therapies (predictive/companion 
biomarkers), 2) the cost-effectiveness of targeted therapies licensed with companion 
biomarkers. ICERs for companion biomarkers are the primary outcome of this study and 
those for targeted therapies are a secondary outcome.  
To enhance the comparability of heterogeneous cost-effectiveness studies especially for 
the primary outcome of this review, the cost-effectiveness results for companion 
biomarkers were qualitatively synthesized by the strategies compared in economic 
evaluations as described below.  
1) ‘Test-treat’ strategy: Biomarker test performed, and therapy guided by the 
biomarker results; for example, RAS wild-type patients receive new intervention 
(i.e. targeted therapies) and RAS mutant patients receive standard care (i.e. 
existing therapies/best supportive care (BSC)/chemotherapy). 
2) ‘Treat-all’ with new therapy strategy: No biomarker test performed, and all 
patients treated with new intervention.  
3) ‘Treat-all’ with standard care strategy: No biomarker test performed, all patients 









The electronic search located 2893 publications, and reference tracking identified two 
additional articles. Duplicates (228 papers) were removed, resulting in 2667 unique studies. 
The titles and abstracts were then assessed according to the pre-determined eligibility 
criteria, and 2489 papers were excluded. A total of 178 papers were selected for full-text 
assessment. Main reasons for exclusion were the type of intervention studied (i.e. not 
related to cancer biomarkers for targeted therapies) and the study type (i.e. not economic 
evaluations or cost-effectiveness analyses). Fifteen papers were excluded because the 
results were reported in another paper or insufficient information was reported in abstract 
only. Fourteen papers were excluded as they did not report ICERs as their study outcome. 
Eight papers were additionally excluded because they did not target patients with mCRC. 
Altogether, 46 publications were included in the review, consisting of 30 studies reported 
in full text and 16 reported in abstract only. Study selection is presented in a PRISMA flow 





FIGURE 2-1 :  PRISMA FLOW DIAGRAM OF STUDY SELECTION  
 
 
Overview of included studies 
The modelling designs, the intervention strategies, and the comparator strategies of the 
included cost-effectiveness studies were heterogeneous. The majority of studies were 
model-based economic evaluations except for three trial-based studies. Analyses involved 
comparisons between two and seven strategy arms. Most studies employed the 
perspective of third-party payers (79%), while only a small proportion of studies adopted 



























Records identified through 
database searching (n = 2893) 
Additional records identified 
through other sources (n = 2) 
Records after duplicates removed 
                         (n = 228) 
Records screened 
               (n = 2667) 
Records excluded (n =2489) 
Full-text articles assessed 
for eligibility (n = 178) 
Full-text articles excluded (n = 132) 
 
Reasons for exclusion: 
Population criteria not met (n=8) 
Treatment of interest not met (n=56) 
Outcome criteria not met (n=14) 
Study type criteria not met (n=30) 
Reported in another paper (n=3) 
Insufficient information reported in 
abstract (n=12) 
Duplicate (n=7) 
Not found (n=2) 
Studies included (n = 46) 





was not disclosed in three studies (62-64). Most of the included studies were modelled for 
lifetime or more than 10-year time horizons (66%), while trial-based analyses were 
modelled only for their trial periods, i.e. 1.5 or 2 years. Most of the studies were set in 
Europe (40%) and North America (35%), except for six in Latin America, five in Asia, and 
one in the Middle East. Manufacturer sponsorship was declared by 13 studies, while most 
studies were either funded by public or academic resources (nine studies from public 
resources, eight studies from either academic resources or no external funding). Most 
abstracts did not declare funding source for their projects. Moreover, three full papers did 
not declare their source of funding. Study characteristics are synthesized in Figure 2-2 and 
detailed characteristics for each study are provided in Appendix 2-3. No economic 
evaluations of cancer biomarkers for targeted therapies in mCRC were published before 
2005. Many studies were published in recent years, 60% after 2012. Four studies appeared 
between 2005-08, 14 studies in 2009-12, and 28 studies in 2013-18. Likewise, recent years 
were used in costing years of assessments; the years of 2005-08 in five studies, 2009-12 in 
nine studies, and 2013-18 in sixteen studies. However, a considerable number of 





FIGURE 2-2 :  OVERVIEW OF STUDY CHARACTERISTICS  
 
 
Primary synthesis   
• Cost-effectiveness of predictive biomarkers in mCRC  
Seventeen studies investigated the cost-effectiveness of cancer biomarkers for targeted 
therapies (Tables 2-1, 2-2, 2-3) (detailed results of ICERs per study are provided in Appendix 
2-4. These studies assessed the cost-effectiveness of predictive (companion) biomarkers 
aside from that of the corresponding therapies. Overall, all studies showed favourable 
results toward predictive biomarkers. Thirteen studies found biomarker testing to be cost-
effective (30, 65-76), of which four studies reported biomarker testing to be dominant (30, 
70-72). Five studies showed cost-saving (77-81) compared to that of ‘no-testing’. Wen et 
al. (69) evaluated cost-effectiveness of RAS screening prior to monoclonal antibodies and 
found that RAS testing before cetuximab is more cost-effective compared to KRAS-testing 





were well beyond the acceptable willingness to pay thresholds in China, but RAS testing 
appeared to be more favourable than KRAS testing for patients with mCRC. Some studies 
reported conflicting results of cost-effectiveness between predictive biomarkers and 
corresponding therapies; the biomarkers were cost-effective, but their corresponding 
therapies were not (71, 77-79). Existing predictive biomarkers (or companion diagnostics) 
co-licensed with targeted therapies in mCRC included KRAS and RAS approved for the use 
of panitumumab and cetuximab, and UGT1A1 genotyping approved for the administration 
of irinotecan. KRAS and RAS testing was the most frequently evaluated in economic 
evaluations (KRAS testing in eight studies; RAS testing in seven studies) and UGT1A1 testing 
in four studies.  
 
• Cost-effectiveness of KRAS testing  
All studies reported favourable cost-effectiveness for KRAS testing prior to the 
administration of the corresponding targeted therapies, while four corresponding 
therapies were not cost-effective (Table 2-1). KRAS testing for targeted therapies was 
assessed mostly to pre-select eligible patients before administering EGFR therapies such 
as cetuximab or panitumumab. As shown in Table 7, all studies suggested favourable cost-
effectiveness for the use of KRAS testing in administering EGFR therapies. Although 50% of 
these studies reported the corresponding targeted therapies as not cost-effective (71, 77-
79), they found that KRAS testing was cost-effective (n=4) or at least cost-saving (n=4) prior 





TABLE 2-1 :  COST-EFFECTIVENESS FINDING OF KRAS TESTING FOR CORRESPONDING TARGETED THERAPIES  














Conclusion based on outcome 
‘Test-treat’ strategy compared to ‘treat-all’ patients with standard care without testing 
Behl et al. 
2012 (77) 
KRAS testing plus Cmab vs. Treat all with BSC  
Markov model,  
10-year 
672,216*   NA  US$, 2010 
The use of KRAS testing was cost-saving prior to 
Cmab however, Cmab plus KRAS testing was not 
cost-effective. 
Blank et al. 
2011 (65) 
KRAS testing plus Cmab vs. Treat all with BSC  
Markov model,  
Lifetime 
NA 63,647*  Euro, NR  
KRAS testing prior to Cmab is clinically appropriate 
and economically favorable.  
Carlson J.J. 
2010 (78) 




NA 264,644  US$, NR  
KRAS testing was cost-saving but Cmab plus KRAS 





KRAS testing plus Cmab vs. Treat all with BSC  
Markov model,  
Lifetime 
NA 54,802  CA$, 2009 
KRAS testing was cost-effective for all strategies 
considered.  
KRAS testing plus Pmab vs. Treat all with BSC  NA 47,795  CA$, 2009 
KRAS testing plus Cmab + Irinotecan vs. Treat 
all with BSC  
NA 42,710  CA$, 2009 
Shiroiwa et 
al. 2010 (71) 
KRAS testing plus Cmab vs. No-KRAS testing 
(Treat all with BSC) 
Markov model,  
2.5- years 
120,000 180,000  US$, 2010 
KRAS testing strategy was dominant compared to 
no-KRAS testing strategy. However, Cmab (with or 
without KRAS testing) was not cost-effective.  





*ICERs were re-calculated using total costs and effects provided in the pertinent paper.  
AB; abstract, NA; not available, NR; not reported. 
Niedersuess-
Beke D. et al. 
2015 (80) 
KRAS testing + Pmab or Cmab vs. No predictive 
biomarker testing (Cmab/Pmab all) 
NR,  NR 26,276  NA 
EU€, 
2013 
Testing predictive biomarkers is cost-saving.  
‘Treat-all’ patients with new treatment without testing compared to ‘test-treat’ strategy 
Behl et al. 
2012 (77) 
Treat all with Cmab vs. KRAS testing plus Cmab 
Markov model,  
10-years 
2,932,767 NA US$, 2010 
Treating all patients with Cmab without testing 
was not cost-effective; no-testing is not cost-
effective.  
Blank et al. 
2011 (65) 
Treat all with Cmab vs. KRAS testing plus Cmab 
Markov model,  
Lifetime 
NA 314,588 Euro, NR  
Treating all patients with Cmab without testing 





Treat all with Cmab vs. KRAS testing plus Cmab  
Markov model,  
Lifetime 
NA Dominated CA$, 2009 
No-testing was not cost-effective. 
Treat all with Cmab vs. KRAS testing plus Pmab  NA 308,236 CA$, 2009 
Treat all with Cmab vs. KRAS testing plus Cmab 
+ Irinotecan  
NA 163,396 CA$, 2009 
Vijayaraghav
an et al. 
2012 (30) 
Treat all with Cmab/Pmab/Combination 
therapy vs. KRAS testing plus 
Cmab/Pmab/Combination therapy  









No-testing was not cost-effective (dominated). 
Pre-defined genetic population (KRAS WT patients) 
Harty et al. 
2015 (79) 
Cmab + FOLFIRI vs. FOLFIRI; strategies 
compared between different cohorts of 
patients stratified by different biomarker 
status including  KRAS WT group 
NR, NR NA 72,053 GB£, NR  
Cmab plus chemotherapy was not cost-effective 
in a subgroup of patients with KRAS WT. However, 
the stratification of patients by genetic biomarker 






Although all studies suggested favourable cost-effectiveness of KRAS testing before 
providing EGFR therapies, the inclusion of KRAS biomarker testing did not necessarily 
ensure the cost-effectiveness of the costly corresponding targeted therapies. For example, 
Behl et al. (77)  evaluated the cost-effectiveness of KRAS testing to select patients 
responsive to cetuximab compared to administering cetuximab to all patients without 
testing. We re-calculated their ICERs in order to evaluate cost-effectiveness using an 
appropriate strategy comparison such as ‘test-treat’ strategy against ‘treating all patients 
with BSC without testing’ strategy. KRAS testing plus administering cetuximab had a lower 
ICER ($672,216) than treating all patients with cetuximab with no KRAS testing ($827,913), 
when both strategies were compared against the reference strategy of not providing 
cetuximab at all. It confirms that KRAS testing saved some costs by restricting cetuximab 
to particular patients, however cetuximab is yet far beyond the acceptable cost-
effectiveness thresholds of USA.  
Carlson (78) compared two intervention strategies (1. Cetuximab for all patients, 2. 
Cetuximab for KRAS wild-type and BSC for KRAS mutant patients based on biomarker 
testing) compared to BSC for all patients without biomarker testing. Neither intervention 
strategy was cost-effective. However, the KRAS testing strategy saved $10,037 with a 
negligible decrease in QALYs compared to the cetuximab for all-patients strategy. Likewise, 
Shiroiwa and colleagues (71) conducted a comparative analysis using the same strategies; 
1) KRAS-testing strategy, 2) No KRAS-testing strategy (cetuximab for all), 3) No cetuximab 
strategy (BSC for all). They found the KRAS-testing strategy dominated the no-KRAS-testing 
(cetuximab for all) strategy, however, the ICER for cetuximab (with or without KRAS testing) 
was too high even if treatments were limited to KRAS wild-type patients. Meanwhile, Harty 
and colleagues (79) investigated the cost-effectiveness of cetuximab in combination with 





suggested that the use of a biomarker improved the cost-effectiveness of cetuximab but 
its ICER was beyond acceptable thresholds for UK. 
To sum up, targeted therapies were never cost-effective when a ‘no-testing strategy 
(treating all patients with new therapy)’ was compared to a ‘test-treat’ strategy. This 
confirms that KRAS testing is a better use of resources than ‘no-testing’ prior to the 
administration of targeted therapies. However, when a ‘test-treat’ strategy was compared 
to ‘treat all with BSC/SOC’, there were conflicting results; three studies not cost-effective 
(71, 77, 78) and two studies favourable (65, 66). This implies a positive impact of KRAS 
testing in improving the cost-effectiveness of its companion therapies however; it does not 
necessarily mean that KRAS testing can ensure the cost-effectiveness of subsequent 
targeted therapy.  
 
• Cost-effectiveness of RAS testing  
Seven studies evaluated the cost-effectiveness of RAS testing and most of them found 
favourable results for RAS biomarker testing (Table 2-2). Of these, two studies assessed 
the cost-effectiveness of RAS screening compared with that of KRAS testing with targeted 
therapies (69, 72). Both studies were performed from a Chinese health care system 
perspective and found that RAS testing was cost-effective compared to KRAS testing with 
cetuximab. However, Wu et al. (76) found that RAS testing with cetuximab is only cost-
effective when a patient assistance programme is available in China. However, Wen et al. 
(69) found that bevacizumab with RAS testing was not cost-effective compared to 
bevacizumab with KRAS testing. They reported $74,600 which is far more than three times 





















 Conclusion based on outcome 
‘Test-treat’ strategy compared to ‘treat-all’ patients with standard care without testing 




12,107 $14,049 US$, 2016 
RAS testing with Cmab is cost-effective when patient 
assistance program is available in China.  
‘Test-treat’ strategy compared to ‘treat-all’ patients with new treatment without testing 
Niedersuess-
Beke D. et al. 
2015 (80) 
RAS testing + Pmab or Cmab vs. 
No predictive biomarker 
testing (Cmab/Pmab all) 
NR, NR  9,686  NA 
EU€, 
2013 
Predictive biomarker testing was cost-saving; RAS testing 
scenario showed lower ICERs than KRAS testing scenario. 
Saito et al. 2017 
(68) 
RAS testing vs. No testing 




2,574,111 3,049,132 JP¥, NR  
RAS testing was cost-effective compared to no-testing; 
however, comprehensive profiling is more cost-effective than 
RAS testing only. 
Pre-defined genetic population (RAS WT patients) 
Harty et al. 2015 
(79) 
Cmab + FOLFIRI vs. FOFIRI for 
patients stratified into RAS WT 
group  
NR, NR NA 44,184  GB£, NR  
Stratification of patients by genetic biomarker status 
improved cost-effectiveness of Cmab; however, its ICERs was 
yet beyond the £20,000-£30,000 thresholds for UK.  
Recently however, NICE committees accepted that it was a 
life-extending end-of-life treatment and approved under the 
exceptional thresholds of £50,000 in UK(83). 
Souza et al. 2017 
(75) 





NA 56,750 BRL$, NR 
The addition of Cmab to the standard chemotherapy is a cost-














Patients treated with Cmab and RAS-testing was more cost-
effective against the strategy of KRAS-testing and treated with 
Cmab.  
RAS-Bmab vs. KRAS-Bmab NA 71079* 
Patients with RAS-testing and treated with Bmab was not 
cost-effective compared to KRAS testing and treated with 
Bmab.  
Zhou et al. 2016 
(72) 
RAS-Cmab vs. KRAS-Cmab Markov 
model, 
Lifetime 
NA (22450)* US$, NR 
(2016 
assumed) 
RAS screening was dominant over KRAS testing. 
 RAS-Bmab vs. KRAS-Bmab NA (3966)* 
*ICERs were re-calculated using total costs and effects provided in the pertinent paper.  





However, most of these studies did not use an appropriate strategy comparison such as 
evaluating a ‘test-treat’ strategy in comparison to a ‘treat all with existing standard 
therapy’. Two studies were compared against ‘treat all with new therapy’, and four studies 
were performed in a pre-defined genetic population. Only one recent study employed a 
comparative strategy of chemotherapy alone without mutation testing (76), however, this 
economic evaluation was of relatively low quality. Thus, the evidence on cost-effectiveness 
of RAS testing is still inconclusive. Further evaluation is required using an appropriate 
comparator strategy of ‘treat all patients with standard care without testing’ instead of 
‘treating all with new therapy without testing’.     
 
• Cost-effectiveness of UGT1A1 testing  
The four studies assessing UGT1A1 genotyping for the administration of irinotecan found 
that the genotyping was either cost-saving or cost-effective (Table 2-3). However, 
Obradovic et al. (81) reported that UGT1A1 genotyping in combination with a reduced 
dose of irinotecan was not cost-effective for Asian population groups, reporting very high 
ICERs at $6,818,000. Since all studies were conducted for populations in Europe or USA, 
further research on Asian populations to confirm this difference in cost-effectiveness of 





















Conclusion based on outcome 
‘Test-treat’ strategy versus ‘treat all’ patients with standard care without testing 
Butzke 2016 
(70) 
UGT1A1 genotyping and dose 
reduction vs. the current 






UGT1A1 testing dominates the strategy of no-testing strategy 
in treating patients with irinotecan-based chemotherapy. 
Gold et al. 
2009 (73) 
UGT1A1 testing and dose 
reduction of irinotecan vs. 







UGT1A1 testing could be cost-effective if irinotecan dose 
reduction does not reduce efficacy.  
Obradovic 
et al. 2008 
(81) 
UGT1A1 testing and dose 
reduction of irinotecan vs. No 
UGT1A1 testing and standard 
care of irinotecan 
Decision analytic 







Genotyping with dose reduction of irinotecan was cost-saving 
for the population of African/Caucasian however, not cost-





et al. 2010 
(67) 
UGT1A1 genotyping before 









Genotyping strategy was cost-effective compared to no-
testing strategy.  





All studies compared alternative strategies correctly, between ‘test-treat’ with new 
intervention and ‘treat all’ patients with standard care without testing. For example, Gold 
and colleagues (73) assessed the comparative analysis of UGT1A1 testing and no testing 
prior to irinotecan administration, using different scenarios of dose reduction efficacy of 
irinotecan. They reported that, assuming no reduction in treatment efficacy, the average 
cost savings of the genotyping test were $272.34 with 0.073 quality-adjusted days saved. 
Most recently, Butzke et al. (70) evaluated the UGT1A1 genotyping from a German 
statutory health insurance perspective and found that genotyping prior to irinotecan-
based chemotherapy dominates non-guided colon cancer care in Germany. However, this 
study also reported that there is substantial structural uncertainty in relation to the degree 
of dose-reduction in heterozygotic patients and suggested to validate it in clinical practice 
whether physicians indeed chose to reduce dosing in both heterozygote and homozygote 
patients.  
Overall, UGT1A1 testing appears to be cost-effective prior to the administration of 
irinotecan, especially in relation to dose reduction and prevention of adverse events. 
However, two studies used narrow health outcome measures such as neutropenia avoided 
(67, 81) and one study suggested a conditional cost-effectiveness of UGT1A1 testing 
depending on the treatment efficacy of irinotecan dose reduction.  
 
Secondary synthesis 
• Cost-effectiveness of targeted therapies licensed with companion biomarkers 
In 29 studies, the cost-effectiveness of targeted therapies was evaluated (62-64, 84-96).  





not explicitly analyse the value of predictive biomarkers as part of assessing the cost-
effectiveness of biomarker-guided therapies. Fifty-nine percent of these economic 
evaluations reported favourable cost-effectiveness findings for targeted therapies licensed 
with companion biomarkers in treating mCRC (n=17). 41% reported that targeted 
therapies were not cost-effective (n=12).  
76% of these studies (n=22) performed their comparative analyses in a pre-defined genetic 
population such as biomarker-positive patients and often, no differences in the value of 
predictive biomarkers were modelled. These studies frequently assumed that the study 
population (in all strategy arms) was tested before entering the economic models. 
However, all studies related to UGT1A1 testing considered the intrinsic value of UGT1A1 
testing as an integral part of their comparative analysis in administering irinotecan-based 
chemotherapies. Among the remaining seven studies, treatment decisions in four studies 
(62, 84, 97, 98) depended on biomarker mutational status, but in three studies (99-101) 
the comparative strategies employed were not clear.   
Overall, this secondary synthesis found that the inclusion of predictive biomarkers 
improved the cost-effectiveness of targeted therapies, but the improvement was 
insufficient to make the corresponding targeted therapies cost-effective. It may imply that 
the impact of their high drug costs on the cost-effectiveness of targeted therapies is much 
greater than that of the health benefits gained from pre-selection of responsive patients 
guided by biomarkers.  
Table 2-4 presents the cost-effectiveness results for targeted therapies labelled with 
predictive biomarkers (the ICERs are reported in). In the case of bevacizumab, which has 
not yet an established biomarker in clinical settings, it was often assessed as a comparator 





three therapies (cetuximab, panitumumab and bevacizumab) and found bevacizumab to 
be cost-effective (102, 103). Both studies were conducted in a pre-defined group of 
patients with KRAS wild-type status. All 29 studies included either cetuximab or 













Conclusion based on outcome 
Annemans et al. 
2007 (84) 
1. Cmab + Irinotecan (6 week rule, 12 
week rule) 
2. Current treatment 
Trial-based 
model, NR 
NS LYs Cmab + Irinotecan is cost-effective in Belgium. 
Asseburg et al. 
2011 (85) 
1. Cmab + FOLIFIRI  





First line treatment with Cmab plus FOLFIRI offers a cost-effective 
treatment option versus Bmab plus FOLFOX for KRAS WT genotype 
patients in Germany. Thus, KRAS testing should be performed on 
all presenting cases of mCRC to ensure access to this treatment 
option. 





Markov model,  
Lifetime 
RAS LYs 
Both Pmab and Cmab are not cost-effective in patients with RAS 
WT mCRC.  
Chaugule et al. 
2012 (105) 
1. Cmab + BSC 
2. BSC alone 
Markov model,  
Lifetime 
KRAS QALYs Cmab is not cost-effective in KRAS WT patients with mCRC.    
Davari et al. 2015 
(99) 
1. FOLFIRI, FOLFOX, CAPOX without the 
addition of Cmab 
2. FOLFIRI, FOLFOX, CAPOX with the 
addition of Cmab 
Unclear, NR KRAS 
LYs, 
QALYs 
Addition of Cmab to FOLFIRI, FOLFOX, CAPOX 
(Capecitabin+oxaliplati) is not cost effective. 
Dos Santos et al. 
2015 (86)  
1. Pmab + mFOLFOX6 






Pmab is clearly cost-effective compared to Bmab for treatment of 
wild-type RAS mCRC in Brazil. 
Ewara et al. 2014 
(102) 
1. Bmab + FOLFIRI 
2. Cmab + FOLFIRI 
3. Pmab + FOLFIRI 
Markov model,  
Lifetime 
KRAS QALYs 
Bmab+FOLFIRI is cost-effective. Bmab + FOLFIRI found to be 
dominant over the other two strategies. The other two strategies 





showed that Cmab + FOLIFIRI is being cost-effective under certain 
range of parameter values - thus, further investigation needed for 
Cmab. 










Pmab plus mFOLFOX represents good value for money compared 
to a current SOC Bmab plus mFOLFOX6. 
Graham et al. 
2016 (88) 
1. Panitumumab in pts with KRAS WT 
status 
2. Cetuximab in pts with KRAS WT status 
Semi-Markov 




Compared to Cmab, the study suggested that Pmab is favorable. 
Hnoosh et al. 
2015 (AWMSG) 
(89) 








Cmab is cost-effective and a good use of NHS Wales resource 
through stratification of RAS WT patients. 
Hnoosh et al. 
2015 (NICE) (106) 








Cost-effectiveness of Cmab could be deemed favorable when 
considering it as end-of-life medicine. 
Hoyle et al. 2013 
(97) 
1. Cmab 










All three strategies (Cmab, Cmab+Irinotecan, Pmab) are not cost-
effective. 
Huxley et al. 2017 
(98) 
1. FOLFOX (reference strategy) 
2. Cmab + FOLFOX 
3. Pmab + FOLFOX 
Semi-Markov 
model, 30 years 
(lifetime) 
RAS QALYs 
Cmab and Pmab in combination with chemotherapy are likely to 





Junqueira et al. 
2015 (RAS 
subgroup) (90) 




RAS LYs   
Cmab+FOLIFIRI is cost-effective for a subgroup of patients with 
RAS wild-type. 
Junqueira et al. 







The use of Cmab shown significant and meaningful benefits while 
being cost-saving to HCS in Brazil. 
Kourlaba et al. 
2014 (92) 
1. Pmab + FOLFOX6 
2. Bmab + FOLFOX6 
Markov model, 
NR 
RAS QALYs    Pmab + mFOLFOX6 is cost-effective. 
Krol et al. 2015 
(107) 
1. Cmab + FOLFIRI 
2. FOLFIRI 





ICUR results were close to CET. ICURs strongly differed from the 
Netherlands and Belgium. It is mainly due to lower drug costs in 
Belgium. 
Lawrence et al. 
2013 (103) 
1. FBC (reference) 
2. Bmab + FBC 
3. Cmab + FBC 
4. Pmab + FBC 
Markov model,  
Lifetime (to 
maximum of 10 
years) 
KRAS QALYs 














ICER of Cmab over BSC alone for unselected mCRC pts was high 
and sensitive to drug costs. ICER was lower when the analysis was 
limited to pts with KRAS WT. 
Moreno et al. 
2012 (62) 
1. Scenario A: KRAS WT pts receive 
weekly Cmab + FOLFOX 
2. Scenario B. Pmab + FOLFOX 






1st line oxaplatin combinations of biweekly Cmab for WT and 
Bmab for MT optimize cost per additional response rate rather 





AB; abstract, ASC/BSC; active/best supportive care, Bmab; bevacizumab, Cmab; cetuximab, Pmab; panitumumab and NR; not reported 
Norum J. 2006 
(100) 
1. 3rd line chemotherapy (Cmab + 
Irinotecan) 
2. No 3rd line chemotherapy 
Decision tree,  
Unclear 
EGFR LYs 
Cmab + Irinotecan as 3rd line therapy in mCRC is promising, but a 
very expensive antibody. Reduced drug cost and/or improved 
overall survival may alter this conclusion. 
Ortendahl et al. 
2014 (63) 
1. FOLFIRI + Cmab 







Cmab + FOLFIRI improve health outcomes and use financial 
resource more efficiently compared to Bmab + FOLFIRI. 
Riesco-Martinez 
2016 (109) 
Strategy 1 (reference strategy: EGFRI 
monotherapy in 3rd line).  
Strategy 2 (EGFRI and Irinotecan in 3L).  






1st line of EGFRI is not cost-effective at its current pricing relative 
to Bmab. 
Rivera et al. 2017 
(93) 
1. Pmab + mFOLFOX6   
2. Bmab + mFOLFOX6   
Semi-Markov 




Pmab+mFOLFOX6 is more cost-effective than Bmab+mFOLFOX6 
for the first line treatment of RAS WT mCRC.   
Samyshkin et al. 
2011 (94) 
1. Bmab + Chemotherapy 
2. Cmab + Chemotherapy 
3. Pmab + Chemotherapy 
semi-Markov 
model,  Lifetime 
KRAS QALYs 
Cmab plus FOLFIRI is the most cost-effective for patients with 
KRAS WT tumors. ICERs of Cmab + Chemotherapy (CT), Bmab + CT, 
and Pmab + CT are within the commonly accepted threshold of CE 
in UK. 
Shankaran et al. 
2015 (95) 
1. FOLFIRI plus Cmab in treatment-naïve 
patients with KRAS wt type in mCRC 
2. FOLFIRI plus Bmab treatment-naïve 
patients with KRAS wt type in mCRC   







Results were more favorable for Cmab in RAS-WT patients. 
Starling et al. 
2007 (101) 
1. Cmab + Irinotecan 
2. Active/best supportive care (ASC/BSC) 
Trial-based 




ICERs for Cmab+Irinotecan is relatively high compared to other 
healthcare interventions. 
Vargas-Valencia 
et al. 2015 (64) 
1. Pmab + FOLFOX 
2. Cmab + FOLFIRI 
Markov model,  
Lifetime 
RAS LYs 
Pmab showed treatment outcomes improvement vs. Cmab for RAS 
WT patients at a lower cost per life year. 















Cetuximab was assessed in the most studies (n=24). More studies found cetuximab not to 
be cost-effective (14 versus 10 studies finding it cost-effective). Among the studies 
reporting cetuximab as cost-effective, seven studies (78%) were conducted in a pre-
defined genetic population either KRAS wild-type or RAS wild-type, and two not (62, 84). 
Moreno and colleagues (62) evaluated weekly and biweekly administration of cetuximab 
compared to panitumumab, where patients in both arms receive biomarker-guided 
therapies (either cetuximab or panitumumab) when KRAS wild-type and receive 
bevacizumab when KRAS mutant. They found that biweekly cetuximab for KRAS wild-type 
and bevacizumab for patients with KRAS mutant status more cost-effective compared to 
panitumumab-based schedules. Annemans et al. (84) assessed the cost-effectiveness of 
cetuximab in combination with irinotecan-based chemotherapy compared to current care 
in Belgium and found that the cetuximab strategy is cost-effective with ICERs between 
€17000 (6-week treatment scenario) and €40000 (12-week treatment scenario) per LY 
gained. In this study, all patients in the intervention arm were treated with cetuximab plus 
irinotecan-based chemotherapy, while patients in the comparator arm were all treated 
with the current treatment. Nevertheless, none of these studies considered the clinical 
utility of predictive biomarkers in guiding the optimization of treatments depending on 
biomarker status in patients.  
Among fourteen studies reporting cetuximab as not cost-effective, ten studies were in a 
pre-defined genetic group and often, this population scoping was used to justify not 
considering the intrinsic value of predictive biomarkers in the evaluation. Only two studies 
made the appropriate comparison of a ‘test-treat’ strategy and a ‘treat all with standard 
of care’. Both were conducted from a perspective of the English NHS and both found 
cetuximab not cost-effective (97, 98). Hoyle et al. (97) assessed the cost-effectiveness of 





the perspective of the English National Health Service (NHS) and found that all three 
strategies were not cost-effective compared to BSC. They modelled that 54% of patients 
were KRAS wild-type and thus, costing £296 per person for KRAS testing (£160 per test).  
Most recently, Huxley et al. (98) evaluated cetuximab and panitumumab for patients with 
RAS wild-type mCRC, using a similar comparison structure with Hoyle et al., and they also 
found that cetuximab and panitumumab in combination of chemotherapy were poor value 
for money in the English NHS.  
Panitumumab assessed in 14 studies, was found to be cost-effective in eight studies (64, 
86-88, 92-94, 96) and not cost-effective in six. All studies finding panitumumab to be cost-
effective were conducted in a pre-defined genetic group and therefore, further research is 
required comparing an alternative strategy where all patients receive standard of care 
without testing rather than that patients in comparator arm are all provided of 
panitumumab without biomarker testing. For example, two studies reported 
panitumumab as not cost-effective when compared with treating all patients with best 
supportive care without prior testing (97, 98).   
Bevacizumab was evaluated only in three studies (94, 102, 103), two found it to be cost-
effective and one not cost-effective. All three studies were in pre-defined patient groups. 
Ewara et al. (102) assessed first-line treatment strategies for mCRC patients with KRAS 
wild-type and compared three strategies of bevacizumab, cetuximab, panitumumab 
respectively combined with FOLFIRI and found that bevacizumab is dominant over both 
cetuximab and panitumumab. Similarly, Samyshkin et al. (94) also assessed three 
strategies of cetuximab, bevacizumab, and panitumumab for the first-line treatments for 
mCRC patients with KRAS wild-type, however, they found cetuximab plus FOLFIRI is the 





within the acceptable thresholds in UK. On the other hand, Lawrence et al. (103) found 
bevacizumab was not cost-effective with ICERs of $131,600 per QALYs, compared to 
fluoropyrimidine-based chemotherapy (FBC) alone.   
 
Quality assessment 
The quality of the included studies was assessed by the Quality of Health Economic Studies 
(QHES) instrument (Appendix 2-5). The QHES scale consists of 16 weighted questions, with 
a range of scores from 0 (worst quality) to 100 (best quality). The QHES tool was used by 
two independent assessors to rate the quality of the studies. QHES score per study is 
provided in. Economic evaluations reported in full articles were scored using the QHES 
instrument (n=30) and studies reported only in abstract (n=16) were excluded from quality 
assessment due to their limited information.  
In total, 60% of the studies scored above 70 (good quality) and 33% scored between 50 
and 70 (fair quality), and only two papers scored below 50 (low quality). These scores were 
generated based on 16 ‘yes or no’ questions. The quality elements most commonly 
omitted from economic evaluations of cancer biomarkers for targeted therapies were the 
direction and magnitude of potential biases, the methodology for data abstraction, reliable 
use or justifications of health outcomes measures and scales. For the question “Did the 
author(s) explicitly discuss direction and magnitude of potential biases?” (Question 14), 
only 13% of articles were positively rated. With regard to health outcome measures 
(Question 11), only eight studies got positive scores. As for the question, “Was the 
methodology of data abstraction (including the value of health states and other benefits) 





The study objectives were clearly presented by all studies (Question 1). The perspective of 
the analysis was not stated by Behl et al. (77) (Question 2). However, it seems plausible 
that Behl et al. might have used the perspective of US payer since, they briefly discussed 
the potential cost savings for the payer, chose the mCRC interventions most commonly 
used in USA and the analysis was commissioned by US National Institutes of Health. We 
found eleven papers (67-69, 72, 73, 76, 81, 84, 100, 101, 109) unlikely to have used data 
from best available source (Question 3).  We interpreted this question as meaning that 
they provided insufficient justification of their choice of data sources. Applying data from 
another modelling paper or simply using RCT trial data without justifications (i.e. 
systematic literature review or meta-analysis) was considered insufficient. If estimates 
came from a subgroup analysis, were the groups pre-specified (Question 4). This item was 
not applicable for most of the studies since their estimates were not from a subgroup 
analysis. As for Question 5 on handling uncertainty, we awarded ‘yes’ to studies which 
performed at least one type of sensitivity analyses. We found that all studies performed 
one sensitivity analysis or more. However, five studies (30, 67, 68, 72, 104) only performed 
one-way sensitivity analysis which may be considered insufficient, for example, the NICE 
HTA guideline requires probabilistic sensitivity analysis (24). Two studies did not perform 
incremental analysis between alternatives (Question 6) (30, 69). Many studies did not 
clearly state the methodology for data abstraction of the values of health states and other 
benefits (n=17) (Question 7). Four studies did not state the time horizon and discount rates 
applied in their studies (Question 8) (81, 84, 99, 100).  However, some studies justified that 
they did not discount their costs and benefits because of short time horizon of trial periods 
(18-19 months or 2 years) (95, 108), however this is not sufficient reason for not 
discounting and, to be appropriate methodologically, all costs and benefits beyond 1 year 





costs appropriately and the methodology for cost estimation was not clearly described 
(Question 9). Seven studies (69, 72, 77, 85, 95, 99, 100) did not clearly state primary 
outcome measures or did not provide clear descriptions of how they were measured 
(Question 10). Only eight studies (66, 70, 87, 88, 93, 98, 101, 108) used valid health 
outcomes and provided sufficient justifications for the measures and scales used (Question 
11). Most other studies did not provide sufficient information on the health utility 
measures used or simply borrowed utility values from previous literature without 
justifications on validity of their measures and scales. Meanwhile, another eight studies 
did not include health outcomes at all and they estimated ICERs per LYs (30, 67, 77, 81, 84, 
85, 100, 104). Four studies were not transparent on their model structure and study 
methods including how they estimated monetary outcomes of cost-effectiveness 
(Question 12) (81, 99, 101, 108). For example, Davari et al.(99) provided almost no 
information about their study methods and modelling structure. Most studies stated the 
choice of model and assumptions (n=22) (Question 13). However, only four studies 
discussed potential biases in relation to their study results (70, 98, 100, 102) (Question 14). 
We found three studies did not come to a reasonable conclusion based on their study 
results (Question 15) but the conclusions of all other studies appear to be reasonable 
following their study results. However, three papers implied or suggested the intervention 
was cost-effective, while it was not cost-effective given the cost-effectiveness thresholds 
of the respective countries (69, 84, 103). For example, Wen et al. calculated monthly 
estimations and thus, it should conclude that it is not cost-effective given the yearly WTP 
in China. All but three studies explicitly disclosed their funding source (66, 68, 84) 
(Question 16), although the Health Quality Ontario report is likely to be commissioned by 





Finally, we also examined if there is any influence of commercial sponsorships in terms of 
the quality of economic evaluations and found that there is no influence. Among all 
eighteen studies rated as good quality (>=70), ten studies were in fact funded by 
commercial sources mainly from manufacturers. However, all studies performed by public 
sources such as HTA bodies, i.e. NICE or Ontario HTA were very highly rated, above 85 
scores (66, 70, 97, 98). Overall, we found that most of the studies were of good or fair 




Altogether, 46 papers were included in this systematic review. We identified three 
systematic reviews previously conducted for targeted therapies in mCRC (110-112), 
although they are different from ours in terms of the interventions focused. We focused 
on predictive biomarkers (or, companion biomarkers) and thus, targeted therapies with no 
licensed companion diagnostics were not included.  
Our review is more comprehensive than previous studies. We identified and screened a 
much higher number of papers (n=2893) and conducted longer periods of literature search 
(17.5 years between 2000 and June 2018). And finally, we included the highest number of 
studies in the review (n=46) despite the narrower focus on predictive biomarkers with 
targeted therapies, while excluding cost-effectiveness analyses of targeted therapies with 
no licenced companion biomarkers.  
Lange et al. (113) which focused on assessing the cost-effectiveness of monoclonal 
antibodies rather than that of biomarkers, is not directly comparable to our review. 





testing. They found that treatment with bevacizumab, cetuximab, and panitumumab was 
generally not cost-effective. They assessed the quality of identified papers but did not 
synthesize the results even qualitatively. Frank and Mittendorf (114) focused on 
pharmacogenomic profiling prior to the administration of pharmaceuticals in mCRC. They 
observed that the application of predictive biomarkers prior to EGFR antibodies was cost-
effective but the cost-effectiveness of biomarkers for irinotecan-based chemotherapy 
remained unclear. They provided qualitative synthesis on key drivers and areas of 
uncertainty in the included studies. First, they found that biomarker costs were a driver of 
cost-effectiveness. Second, the characteristics of biomarkers such as performance 
accuracy and time of testing influence cost-effectiveness. Third, limited availability of 
clinical data is a source of uncertainty, especially because the efficacy of biomarkers is 
determined by the effects of subsequent therapies. Both reviews (113, 114) suggested that 
the addition of KRAS testing prior to treatment could be more cost-effective than a no-
testing strategy. The most recent systematic literature review was done by Guglielmo et. 
al (112), focusing on genetic tests of Lynch syndrome (LS) and KRAS mutation tests. But 
their search covers a very short period and search strategies were not performed step by 
step. Overall, none of the studies synthesized the cost-effectiveness results of predictive 
biomarkers for corresponding therapies even qualitatively, although they assessed the 
quality of identified studies. To the best of our knowledge, this is the first paper that 
analysed the cost-effectiveness of predictive biomarkers and corresponding therapies 
separately and analysed the interactions between them in terms of the influence of 
predictive biomarkers on the cost-effectiveness of subsequent therapies.  
We found that most studies used a third-party payer perspective such as health care 
systems or national health insurances, often taking account of only direct costs in their 





perspective (72, 105, 107). Zhou et al. (72) stated that they evaluated from a perspective 
of Chinese health care system, however, we categorised their study as having a societal 
perspective since they considered indirect costs as well i.e., travel fees and absenteeism 
fees. Although a general view is that it is appropriate to include both direct and indirect 
costs in cost-effectiveness analyses (3), it is not commonly practised in performing 
economic evaluations for pharmaceutical products especially when aimed to get 
reimbursed. Consequently, few economic evaluations have taken a societal perspective 
(n=3) as seen in Appendix 2-3Error! Reference source not found.. Without the changes to 
the HTA guidelines for reimbursement in respective countries, this trend won’t be reversed. 
For example, Krol et al. (107) conducted their study from two perspectives, a HCS 
perspective for Belgium and societal perspective for Netherlands, following the respective 
country’s HTA guidelines.  
When conducting a comparative analysis such as cost-effectiveness analyses, it is 
methodologically and ethically important to use the most appropriate alternative therapy 
as a comparator strategy. Standard of care (SOC) is the most widely accepted comparator 
in economic evaluations according to cost-effectiveness analysis guidelines in many 
countries. However, we found that a majority of economic evaluations of biomarker-
guided therapies were performed in a pre-defined genetic group (n=23) and by doing so, 
most studies failed to explicitly consider the values of predictive biomarkers in their 
comparative analyses.  
Our finding that whether the use of biomarkers makes corresponding therapies more cost-
effective is largely driven by the expected impact on health outcomes rather than on costs 
contrasts with that of Frank and Mittendorf (114). This finding also highlights that the cost-





of biomarker testing. Our review showed that only six studies included the clinical 
characteristics of the biomarker such as performance accuracy (30, 65, 70, 73, 74, 80). A 
considerable number of studies did not include this in their evaluations. For example, low 
sensitivity may lead to not giving targeted therapies to KRAS WT patients, whereas low 
specificity may lead to treating patients unresponsive to the therapy. Then, some of these 
patients may experience poorer outcomes owing to adverse events, compared to the 
comparator strategy of receiving BSC. Or, false negative test results may lead to not 
treating the responsive patients, which causes an accumulated loss of health benefits 
compared to the strategy of having all patients treated with the intervention without 
biomarker testing. Biomarker prevalence (proportion of patients with a biomarker status) 
was often not considered in evaluations.  
Some limitations need to be acknowledged with regard to the present review. Systematic 
reviews are transparent, rigorous and reproducible and thus, are widely used to identify 
existing literature in many fields including health economics. However, literature searches 
using an electronic database may be limited by the performance of database filtering 
algorithms and indexers. Therefore, our review was supplemented by hand-searches using 
snowballing methods and references from other reviews as well as conference abstracts. 
Our review relies on published evidence in the public domain and consequently is 
vulnerable to publication bias. Given that quantitative synthesis of the study results of 
economic evaluations is not possible owing to heterogeneity across different countries and 
clinical settings, we performed the data synthesis qualitatively in order to provide a 
comprehensive view on the cost-effectiveness of predictive biomarkers for targeted 
therapies. As a typical example, economic evaluations of low-income countries such as 
Chinese studies are not comparable to that of high-income countries in terms of 





In conclusion, companion biomarkers for targeted therapies in mCRC were mostly found 
to be cost-effective; otherwise, they improved the cost-effectiveness of corresponding 
therapies by saving some costs. However, they did not necessarily make the corresponding 
targeted therapies cost-effective. Biomarker’s clinical and economic inputs captured in 
economic evaluations of targeted therapies were often limited to the cost of tests and 
these values were frequently omitted especially when the scope of comparative analysis 
was limited to a pre-defined genetic population. In addition, we observed that there is no 
consensus on the best practice of strategy comparisons and no consistency in how to 
compare alternative strategies to estimate the ICERs of cancer biomarkers for targeted 
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Despite the increasing economic assessment of companion biomarkers, no agreement 
exists whether existing methods are sufficient or whether different methods might 
produce different cost-effectiveness results.  
Objectives 
This study reviews economic evaluations of companion biomarkers for targeted therapies 
and synthesizes the current practices and issues. It highlights the challenges to be 
overcome to reach a consensus on methods and data requirements for economic 
evaluations of cancer biomarkers.    
Methods  
A literature search was performed using Medline, Embase, EconLit, Cochrane library. 
Articles published from 2014 to 2018 were searched. Economic evaluations on biomarker-
guided therapies with companion diagnostics in cancer were searched. To make studies 
more comparable, data extraction and analysis was performed based on ten key areas of 
methods where consensus is lacking when modeling companion biomarkers in the 
assessments of co-dependent targeted therapies.  
Results  
Eighteen papers were included in this review. All studies modelled the costs of companion 
biomarker testing in economic evaluations. Three out of eighteen studies found to be of 
good quality in incorporating model inputs relevant to companion biomarkers in economic 





utility, resource use, and the timing of the test. No consistent approaches were found to 
be existent in the current practices of assessing and reflecting the value of companion 
biomarkers as part of the economic assessment of targeted therapies in oncology.  
Conclusion  
Although no consistency exists in the current practices of evaluating companion 
biomarkers, some common patterns found to be useful to provide possible solutions in 
evaluating and capturing the full value of companion biomarkers beyond 




Economic evaluations (EEs) are increasingly used to inform market access, reimbursement 
and coverage of new medical technologies including biomarker diagnostics for targeted 
therapies. Companion biomarkers are used to select and guide the best treatment options 
for patients prior to the administration of a corresponding therapy. However, no 
agreement exists whether existing methods are sufficient to evaluate the health economic 
impact of biomarkers, or whether different methodological approaches might produce 
conflicting results with regard to the cost-effectiveness of biomarkers or biomarker-guided 
therapies. 
This study focuses on companion biomarkers for targeted cancer therapies. Specific 
biomarkers, known as companion diagnostics (CDx) are the focus of this review. CDx can 
be defined as a medical device (often in vitro) providing information for the safe and 
effective use of a corresponding intervention (1). CDx is the diagnostic test labelled to be 





treatment decision is made based on the biomarker testing result. That is, the use of a 
specific test is obligatorily proceeded by the provision of corresponding therapy (e.g. HER2 
testing prior to trastuzumab). If test accuracy is not satisfactory, the treatment decision 
may detrimental to the patient outcomes when treated with the biomarker-guided 
therapy.  
This study reviews current methodological approaches and challenges in EEs of cancer 
biomarkers. It highlights the complexity of evidence generation faced by test developers 
without clear guidance on evidentiary standards and data requirements. It aims to analyze 
the approaches currently adopted in EEs of biomarkers and to identify current practices 
and address policy implications. This review focuses on biomarkers co-licensed with 
therapeutic products, namely CDx. Also, the methodological issues commonly relevant to 
the classical therapeutic interventions are not of interest in this review. It only considers 
methodological challenges and issues faced in the evaluation of biomarker tests which do 




A systematic review of model-based health economic evaluations of companion 
diagnostics for targeted cancer therapies was undertaken. This review was conducted 
followed by recommendations of the Preferred Reporting Items of Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines (116, 117).  
Literature search  
A systematic literature search was conducted for EEs of cancer biomarkers co-licensed for 





Embase (Ovid), EconLit, Cochrane library were used. Hand search was done by reviewing 
article citations and review articles. Four articles were then identified(68, 118-120).    
The electronic search was performed using Medical subject heading (MeSH) terms and 
keywords that were developed for disease (cancer), intervention (companion biomarkers 
for targeted therapies), and study design (economic evaluations). These were combined 
with free-word texts using relevant economic terms (e.g. “cost-effectiveness”) and the 
names of biomarker-guided therapeutic products both in brand and generic terms. The list 
of CDx approved by the US Food and Drug Administration (FDA) (37) was targeted in the 
literature search. Studies published in English were searched from 2014 to 2018. The 5-
year search period was chosen given that this literature review aimed to explore current 
EE practice and to critically appraise them in depth. Five years was considered to be long 
enough to capture a sufficient number of recently published EEs and also to exclude any 
out-of-date approaches not applicable to current practice.  Search terms are provided in 
Appendix 3-１.  
 
Study selection  
Studies were selected using pre-specified inclusion and exclusion criteria based on the 
PICOS framework. Details are provided in Appendix 3-２. Given the aims of this literature 
review, studies failing to report important information relevant to EEs of a companion 
biomarker (e.g. biomarker characteristics, biomarker-related modeling inputs) were 
excluded.  
The study selection had three stages. First, identified articles from electronic databases 





abstracts of the identified articles were screened to assess suitability by the first reviewer 
(MKS) and the studies clearly indicated as irrelevant were excluded but any studies with 
ambiguity were discussed with the second reviewer (JC). Third, remaining articles that met 
the inclusion criteria were read in full text by the first reviewer (MKS) and cross-checked 
by the second reviewer (JC). Any disagreements in all stages were resolved by discussion 
between two reviewers (MKS, JC) (Figure 3-1Error! Reference source not found.).  
 








































Records identified through 
database searching (n = 796) 
Additional records identified 
through other sources (n = 4) 
Duplicates removed (n = 29) 
Records screened 
(n = 771) 
Records excluded (n = 685) 
Full-text articles 
assessed for 
eligibility (n =86) 
Full-text articles excluded (n = 68) 
Reasons for exclusion: 
Biomarker not modelled (n= 18) 
Costing study (n= 1) 
Letter (n= 1) 
Not in English (n= 1) 
Not intervention of interest (n= 2) 
Not study type (n= 10) 
Poster (n= 1) 
Pre-specified population (n= 11) 
Not in full text (i.e. abstract) (n = 22) 
Duplicate publication (n=1) 
 
Studies included  





Data analysis and synthesis  
Ten methodological areas were selected to focus on in reviewing the current practices of 
methodological approaches of EEs for companion biomarkers. These key areas were 
formulated based on previous studies (51, 121-123), and partly on the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) checklist (124) and from our 
experience working in health technology assessments of cancer biomarkers for targeted 
therapies. The ten areas are as follows: (i) target population; (ii) viewpoint of analysis; (iii) 
the choice of alternative strategy arm(s); (iv) structure of comparative analysis (or 
structure of strategy comparisons); (v) measurement of clinical value of companion 
biomarkers; (vi) measurement and valuation of preference-based outcomes of companion 
biomarker tests; (vii) estimating resource use and costs; (viii) timing of the test use; (ix) 
uncertainty analysis; (x) data sources for biomarker-related data inputs. The narrative 
syntheses and analyses were performed for these ten methodological areas. To be more 
specific, a list of questions was developed based on these items (Error! Reference source 
not found.).  
TABLE 3-1 :  A LIST OF KEY METHODOLOGICAL ITEMS IN REVIEWING THE EES OF BIOMARKER-GUIDED 
THERAPIES  
Question items Yes No 
Q1. Did the EE target all patient groups regardless of biomarker status of test positive, 
negative, unknown?  
  
Q2. Did the EE justify the viewpoint of analysis? (I.e. Analysis perspective; third-party 
payer, society, hospital, etc.)  
  
Q3. Was the standard of care chosen as a comparator strategy?   
Q4. Was the test-treat strategy compared to the comparator strategy arm(s)?    
Q5. Was the clinical effectiveness of the companion biomarker test considered in the 
economic models? If not considered, justification/assumption provided? 
  
Q6. Were preference-based outcomes of companion biomarker tests were considered in 
the economic models? If not considered, has the assumption been provided with 
justifications? 
  
Q7-1. Were the details of the resource consequences of the use of companion biomarker 






Q7-2. Were the costs of companion biomarker test(s) considered and reported?    
Q8. Different timing of the test(s) was considered and reported? (i.e. at the time of 
diagnosis, at the time point of progression to metastasis, etc.) 
  
Q9. Was uncertainty with respect to the characteristics of the companion biomarker 
test(s) explored? (i.e. at least one component of the characteristics of biomarker test was 
tested; such as cost, cut-off threshold, sensitivity/specificity) 
  
Q10. Were the data sources for the model inputs clearly reported and justified? (i.e. 
meta-analysis, clinical trials, published papers, etc.) 
  
Q11. Was the name/type of biomarker test specified? (e.g. Cobas® BRAF V600 mutation 
test) 
  
Q12. Was the frequency/prevalence of biomarker status considered in the economic 





Overall, eleven papers assessed the cost-effectiveness of the corresponding drugs (87, 102, 
125-134), while seven papers evaluated the cost-effectiveness of companion biomarkers 
per se (68, 69, 72, 118, 135-137). The most frequently used modeling type was a Markov 
model (eleven papers), followed by partitioned survival model (two papers) and semi-
Markov model (two papers). All economic evaluations were performed from a third-party 
payer perspective except for one study which took a societal perspective. All studies were 
performed for high income countries except for four studies of China.  
The overview of the included studies analyzed by the list of questions is provided in 
Appendix 3-3. Study characteristics are synthesised by key items in Figure 3-2 and detailed 
in Table 3-2. The most frequently ignored model inputs related to companion biomarkers 





































Q1 Q2 Q3 Q4 Q5 Q6 Q7.1 Q7.2 Q8 Q9 Q10 Q11 Q12
Whether key items were addressed or not, followed by 































Rx To assess cost-
effectiveness of immune 
checkpoint inhibitor with 
and without the use of 








3 strategies compared: 
Treat-all with docetaxel.  
Treat-all with immunotherapy.  
Test-treat (if PD-L1 expressed with 1% or more, 
patients were treated with immunotherapy; if 































Rx To assess the cost-
effectiveness of afatinib 




mutation.   
Afatinib, 
Gefitinib.  
2 strategies compared on pre-specified 
patients:  
Treated with afatinib. 





















ipilimumab) for patients 








3 strategies compared on pre-specified 
patients: 
Treated with dacarbazine.  
Treated with vemurafenib.  

















Rx To assess the cost-
effectiveness of three 
strategies (bevacizumab 
plus FOLFIRI, cetuximab 
plus FOLFIRI, 
panitumumab plus 
FOLFIRI) for mCRC 






3 strategies compared on pre-specified 
patients: 
Treated with bevacizumab plus FOLFIRI.  
Treated with cetuximab plus FOLFIRI. 




















with bevacizumab plus 
mFOLFOX6. 
RAS mutation. Panitumumab, 
Bevacizumab.  
2 strategies compared on pre-specified 
patients:  
Treated with panitumumab plus mFOLFOX6.  
Treated with bevacizumab pus mFOLFOX6. 
KRAS and RAS 
testing cost. 


















panitumumab in patients 





2 strategies compared on pre-specified 
patients: 
Treated with cetuximab.  




















chemotherapy for rat 
scarcoma (RAS) wild-type 
(WT) patients for the 
KRAS/RAS 
mutation.  
Cetuximab. 2 strategies compared: 
Treated with FOLFIRI alone.  






























chemotherapy for rat 
scarcoma (RAS) wild-type 
(WT) patients for the 
first-line treatment of 
mCRC. 
RAS mutation. Cetuximab, 
Panitumumab. 
5 strategies compared on pre-specified 
patients:  
Treated with FOLFOX/FOLFIRI.  
Treated with cetuximab plus FOLFOX/FOLFIRI.  




(50% of patients 
assumed to be 














Rx To determine the ICER of 
adding cetuximab to 
first-line 
chemotherapeutic 
treatment of patients 
with advanced 
esophageal squamous 
cell carcinoma (ESCC), 




Cetuximab. 2 strategies compared on pre-specified 
patients: 
Treated with cetuximab plus cisplatin-5-
fluorouracil.  







assumed to be 




















Dx To evaluate the cost-
effectiveness of treating 
patients guided by EGFR 
testing compared to no-
testing (which is current 
practice in South Korea). 
EGFR 
expression.  
Erlotinib. 2 strategies compared: 
Test-treat (if EGFR positive, treated with 
erlotinib; if EGFR wild-type, treated with 
conventional chemotherapy; if unknown, re-
biopsy required). 
No-testing (Treat all with conventional 



























Dx To examine the 
economic outcome of 
three techniques for 
testing ALK gene 
rearrangement 
combining with crizotinib 
(first-line), compared 




Crizotinib.  3 ALK rearrangement testing techniques prior 
to crizotinib were compared (4 strategies 
compared): 
No gene screening - all treated with standard 
chemotherapy.  
Ventana IHC - if ALK rearrangement positive, 
treated with crizotinib; if ALK rearrangement 
negative, treated with standard chemotherapy.  
qRT-PCR - if ALK rearrangement positive, 
treated with crizotinib; if ALK rearrangement 
negative, treated with standard chemotherapy  
Conventional IHC - if IHC ALK rearrangement 
negative, treated with standard chemotherapy; 
if IHC ALK rearrangement positive, FISH testing 
(to confirm) to be performed and then, if FISH 
ALK rearrangement negative, treated with 
standard chemotherapy, if FISH ALK 
rearrangement positive, treated with crizotinib. 










IHC; qRT-PCR).  













Rx To assess the cost-
effectiveness of crizotinib 




cancer (NSCLC).  
ALK 
expression.  
Crizotinib  2 strategies compared on pre-specified 
patients: 
Treat all with crizotinib.  
Treat all with pemetrexed chemotherapy in 
combination with cisplatin or carboplatin.  

























Dx To explore the costs and 
effectiveness of RAS 
screening before 
RAS mutation.  Cetuximab, 
Bevacizumab.  
Four strategies compared:  
 
KRAS/RAS 














monoclonal antibodies in 
mCRC based on FIRE-3 
study. 
KRAS tested - treated with cetuximab and 
FOLFIRI.  
RAS tested - treated with cetuximab and 
FOLFIRI.  
KRAS tested - treated with bevacizumab and 
FOLFIRI.  






Dx To compare the 
performance and cost-
effectiveness of KRAS 
mutation tests in 
differentiating adults 
with mCRC who may 
benefit from first-line 
treatment of cetuximab 
in combination with 
standard chemotherapy 
from those who should 
receive standard 
chemotherapy alone.  
KRAS 
mutation.  
Cetuximab.  10 different tests for KRAS mutation status. No 
comparator approach taken.  
Cobas KRAS Mutation Test Kit (Roche 
Molecular Systems). 
Therascreen KRAS RGQ PCR Kit (QIAGEN). 
Therascreen KRAS Pyro Kit (QIAGEN).  
KRAS LightMix Kit (TIB MOLBIOL).  
KRAS StripAssay (ViennaLab).  
HRM analysis.  
Pyrosequencing.  
MALDI-TOF mass spectrometry.  
Next-generation sequencing.  












test result).  

















Rx To evaluate the 
economic outcome of 
adding cetuximab to the 
standard chemotherapy. 
RAS mutation. Cetuximab. 2 strategies compared: 
No testing – treat all with FLOFIRI.  
Test-treat (if RAS wild-type, treated with 
cetuximab plus FOLFIRI, if RAS mutant, treated 
with FOLFIRI).  
RAS testing 
cost. 














Dx To evaluate the cost-
effectiveness of 
predictive testing for 
extended RAS WT status 
in the context of 
targeting the use of 
cetuximab/bevacizumab. 
RAS mutation.  Cetuximab, 
Bevacizumab.  
4 strategies compared: 
KRAS WT tested-treated with cetuximab plus 
chemotherapy.  
KRAS WT tested-treated with bevacizumab plus 
chemotherapy.  
RAS WT tested-treated with cetuximab plus 
chemotherapy.  
RAS WT tested-treated with bevacizumab plus 
chemotherapy.  
KRAS/RAS 
testing cost.  
China Societal 
perspect
ive.   
Markov 
model. 









EGFR therapies in mCRC. 






+ SRC, and 































Dx To evaluate the cost-
effectiveness of UGT1A1 
genotyping in patients 






Irinotecan 3 strategies compared:  
No testing-treat all with standard dose of 
irinotecan. 
Test-treat (if tested wild-type, standard dose of 
irinotecan treated; if hetero-and homozygotes, 
treated with a dose reduction of irinotecan by 
25%). 
Test-treat (all patients receive standard dose, 
and hetero-and homozygotes additionally 











Lifetime QALY No 
funding. 









Target population  
The patient population targeted in EEs of biomarker-guided therapies was varied but it can 
be broadly classified into two categories; one is a subgroup of patients with a specific 
biomarker status confirmed and the other is a group of patients with disease conditions 
regardless of biomarker status. Eight studies were performed on a pre-defined group of 
patients with a particular biomarker status (87, 102, 126-128, 130-132) however, they 
considered at least one characteristic of companion biomarkers in their evaluations. Many 
EEs were conducted using a pre-specified patient group with a particular confirmed 
biomarker status, and authors used this to justify excluding some of the key characteristics 
of companion biomarkers from their evaluations. In addition, two studies were conducted 
on all patients regardless of biomarker status, while additional analyses were done for a 
subgroup of patients with a specific biomarker status (68, 129).  
 
Analysis viewpoint  
The analysis viewpoint defines the scope of costs and health benefits to be assessed in EEs; 
often referred to as study perspective. All included studies clearly reported the perspective 
of EEs conducted. A majority of studies showed that EEs were performed applying the 
third-party payer perspective. Only two studies stated that they employed a societal 
perspective (72, 127); one from China and the other from the US. However, the US study 
(127) was found to be more appropriately described as a third-party payer perspective (e.g. 
Medicare).  
Given the nature of multiple purposes of biomarker testing application or use, and the 





perspective of third party payers might not be sufficient to capture all costs and benefits 
relevant to companion biomarkers in the clinical context of selecting patients suitable for 
the corresponding therapy. However, only one study considered indirect costs such as 
travel fees and absenteeism costs together with the cost of adverse events (72). However, 
this study did not consider any biomarker-related indirect costs either. For example, 
Schnell-Inderst and colleagues conducted a targeted review and highlighted measuring the 
potential effect modifiers such as the dependency of treatment effects on contextual 
factors and learning curve (138).  
 
Choice of treatment alternatives (comparators)  
It is widely accepted that the alternative strategy to be compared in EEs should be based 
on the current practice with respect to the target population (139, 140). Several different 
types of comparator strategies were employed in the EEs of companion biomarkers for 
targeted therapies. These different strategies can be categorized in five forms as below. 
Some papers used more than one comparator strategy arm (102, 125, 136).  
First, all patients were tested prior to the administration of the corresponding biomarker-
guided therapy and treated depending on the test result. For example, if the patients 
tested positive for a particular biomarker, they received the guided therapy; however, they 
were treated with the non-guided therapy if they tested negative. This ‘test-treat strategy’ 
strategy was often employed as an intervention strategy rather than as a comparator in 
EEs of companion biomarker therapies. Five studies employed this strategy type as a 
comparator (68, 69, 72, 136, 137) however, these studies focused on comparing the 
analysis among different biomarker types or testing kits rather than comparing biomarker-





Second, patients were not tested but were treated with the biomarker-guided therapy; so-
called ‘no-testing-treat-all with the guided therapy’. Only one study fell into this category 
(125). This study aimed to assess the cost-effectiveness of a new guided-therapy with and 
without the use of biomarker testing.  
Third, no patients were tested but all patients were treated with the non-guided therapy; 
so-called ‘no-testing treat-all with the non-guided therapy’.  Six studies used this strategy 
as their comparator (118, 125, 129, 133, 135, 136), and mostly a standard chemotherapy 
was chosen as the non-guided therapy.  
Fourth, all patients modelled in EEs were already pre-specified like biomarker positive or 
negative, and all treated with the guided therapy; called ‘biomarker-specified group 
treating all with the guided therapy’. This type of comparator strategy is also commonly 
observed in EEs of biomarker-guided therapies in addition to the test-treat strategy. Two 
studies used this as their comparator strategy (102, 126). Both studies focused on assessing 
different guided therapies for the group of patients confirmed with a particular biomarker 
status. Only a handful of model parameters of companion biomarker tests were considered 
in their EEs and thus, they often failed to provide a full spectrum of decision-making 
information relevant to the use of companion biomarker medicines.  
Fifth, all patients were biomarker positive or negative and treated with the non-guided 
therapy; called ‘biomarker-specified group treating all with the non-guided therapy’. Seven 
studies employed this as their comparator strategy (87, 102, 127, 128, 130-132). This 
strategy is the most frequently employed comparator arm in EEs of companion biomarker 







Structure of strategy comparisons 
We found a wide range of inconsistencies in structuring the strategies to be compared in 
EEs of companion biomarker therapies. Structuring the comparative strategy arms can be 
determined by various factors such as eligible patient populations, decision-making bodies’ 
EE guidelines, and local clinical settings. For example, an EE study aiming to compare a 
guided therapy against a standard of care applied the structure of comparing the test-treat 
therapy against treat-all with the guided therapy or with the non-guided therapy. Or, a 
similar study aiming to assess the cost-effectiveness of a new therapy with or without 
biomarker testing could employ the comparative structure of a testing strategy against a 
no-testing strategy on a particular group of patients with known biomarker status. The 
structure of comparing strategies in comparative analysis can be classified into five types 
as described in Figure 3-3.   
The comparative structure of applying strategy arms in EEs of companion biomarkers was 
so varied, it would likely lead to a different or even conflicting conclusion in terms of cost-











FIGURE 3-3 :  STRUCTURE OF COMPARING STRATEGIES IN EES OF COMPANION BIOMARKER THERAPIES 
       









1. Test-treat strategy compared with test-treat strategy (69, 72, 137). 
2. Test-treat strategy compared with no-testing-treat-all with the guided therapy (68, 125).  
3. Test-treat strategy compared with no-testing-treat-all with the non-guided therapy [15, 19, 21, 22, 
27] 
  





4. Biomarker-specified group treated with a specific guided therapy compared with the strategy of 
biomarker pre-defined group treated with another guided therapy (102, 126, 128, 130).  
5. Biomarker-specified group treated with the guided therapy compared with the strategy of treating 
the same patient group with the non-guided therapy (87, 127, 131, 132).  
 
Measuring the clinical value of companion biomarkers 
No consensus currently exists on data requirements when incorporating the clinical value 
of biomarkers into the modeling of EEs of biomarker-guided therapies. For example, the 
Diagnostic Assessment Program requires testing accuracy in appraisal of diagnostic tests 
(25), although it is not always feasible in practice especially when assessors are faced with 
no data on test accuracy at all . On the other hand, NICE methods guide of technology 
appraisal does not necessarily require the testing accuracy but requires the incorporation 
of the associated costs of biomarker testing (139). Furthermore, none of the EEs reviewed 











guided therapy  
Treat-all: non-







by testing different cut-off thresholds including false positive and false negative results as 
part of uncertainty analysis. The cut-off threshold is the cut-off point defining the presence 
of the biomarker, determining biomarker-positive and biomarker-negative patients for the 
administration of corresponding co-dependent therapeutic agents (141-143). Varying 
levels of accuracy may lead to different patient subgroups being eligible for the 
corresponding drugs. According to previous studies (51, 122), the clinical value of 
biomarker tests could be assessed in three ways; analytic validity, clinical validity, and 
clinical utility. Analytic validity is about how well a test detects the presence or absence of 
a particular marker (140). Clinical validity refers to the performance of a test (diagnostic 
accuracy) in detecting the presence of a specific disorder; so-called sensitivity and 
specificity (122). Clinical utility is defined in the ACCE (analytical validity, clinical validity, 
clinical utility, and ethical/legal/social implications) model project as “how likely the test is 
to significantly improve patient outcomes”, which goes beyond sensitivity and specificity 
and then which may change treatment options for the patient (144).  In other words, 
clinical utility (effectiveness) of companion testing technology is based on the ability to 
improve patient health outcomes by altering treatment decisions (145, 146).  
Relatively few EEs considered the diagnostic accuracy of biomarker testing using data on 
sensitivity and specificity (135-137). Many EEs did not consider the performance of 
biomarker testing or often did not mention this at all (68, 72, 87, 102, 118, 125-128, 131). 
Otherwise, some studies provided some assumptions or justifications why they did not 
consider the clinical value of a companion diagnostic test (69, 129, 130, 132, 133). It is 
often assumed that the technical accuracy of patient stratification by biomarker testing is 
perfect and thus, the sensitivity and specificity were either not considered or assumed to 
be 100%. However, no studies explicitly considered or assumed the clinical utility of 





of companion biomarker testing was supposedly incorporated into the clinical 
effectiveness of the corresponding drug based on the clinical trial of the sub-population 
delineated by the diagnostic.  
Meanwhile, a handful of studies considered the frequency or prevalence of a particular 
biomarker status among their target patient populations (68, 87, 131, 135-137). Among 
them, only one study considered the probability of unknown test result in the analysis 
(137).   
 
Measurement and valuation of preference-based outcomes  
The quality-adjusted life-year (QALY) is a preference-based health outcomes widely used 
in EEs of therapeutic products(3, 24). It is widely accepted because it allows comparisons 
of health benefits and costs across different disease areas and therapeutic interventions. 
However, challenges emerge with the economic assessment of companion biomarkers 
given the nature of targeted therapies guided by companion biomarker testing and indirect 
impact of companion biomarker testing on patient outcomes. The current metrics for 
measuring preference-based outcomes using population-based preferences cannot fully 
capture patient preferences for biomarker tests (147).  There seems to be more aspects of 
individual patient preference when valuing biomarker tests compared to the valuation of 
conventional drugs. For example, patients could be informed in advance of the likelihood 
of therapeutic response or unresponsiveness prior to the provision of treatment.  
Or, patients can have an improved sense of controlling their own choices of therapeutic 
options informed by their biomarker status. Shared decision making (SDM) and 





decisions guided by companion biomarker test results. Patients may feel empowered to 
make informed decisions about their own treatment and care (148-150). Although the 
provision of biomarker-guided therapy is dictated by the patient’s biomarker status, being 
informed of the biomarker status can support the SDM of both clinicians and patients to 
explore more fully the potential benefits and risks. It can then potentially improve patient 
satisfaction with health services.   
Or, companion diagnostics for cancer patients usually require collecting a bio-sample for 
analysis, and this gives rise to the existence of process utility (including reassurance or 
information) (151-153). Brennan and Dixon’s study (154) supported the existence of 
process utility and found that different approaches were being used to detect and measure 
process utility such as gamble techniques, time trade-off, conjoint analysis. Some 
biomarker tests involve relatively invasive methods to collect the bio-sample, such as 
tissue biopsy, needle biopsy, skin biopsy in diagnosing cancer (155, 156), that can be 
measured and incorporated into QALY estimates. Yet, how to measure and incorporate 
process utility into cost-utility analyses needs to be further researched with more empirical 
studies in HTA.  Or, if companion biomarker tests were already integrated into the clinical 
study of measuring patient reported outcomes (PROs) for co-dependent therapeutic 
agents, it can be assumed that the disutility or utility value of companion biomarker testing 
is already embedded or indirectly expressed in PROs of the corresponding therapy.  Yet, 
this aspect should be transparently reported in health economic models of companion 
biomarkers or biomarker-guided therapies. Nevertheless, none of the EEs included in this 
systematic review discussed these aspects of companion biomarker testing or indicated 
how preference-based outcomes of companion biomarker devices were measured and 
valued. For example, no studies explicitly included utility or disutility values for biomarker 





argued that patient preferences do not need to be considered in the economic modeling. 
However, none of the EEs mentioned this aspect or attempted to justify the omission of 
preference-based outcomes of biomarker testing. As an example, patients might need to 
undergo another biopsy for the purpose of biomarker testing after the cancer has 
progressed to metastasis. Or, a second biopsy might be needed to confirm the biomarker 
status when the testing accuracy was unsatisfactory. Or, turnaround time of biomarker 
testing may lead to additional waiting time for patients to access the treatment. Or, 
patients might experience anxiety or hopelessness when they are informed that the test 
predicts non-response to the targeted therapy and no alternative therapy options are 
available.  
 
Estimating resource use and costs  
All included EE studies considered the costs of biomarker testing however, some details 
were  ignored. Some papers did not report the cost of biomarker testing devices (125) and 
often a total lump sum cost was modelled without providing details on how the total cost 
calculated  (69, 72, 102, 126, 127, 131). Several studies reported at least some details 
regarding data source or the names/types of biomarker testing kits (68, 87, 118, 128-130, 
132, 133, 135, 136), but many EEs did not consider or report the resource use parameters 
relevant to the testing of companion biomarkers. None of the studies considered the 
capital cost related to the initial purchase of a biomarker test kit or diagnostic equipment 
as well as other costs such as training staff, relevant consumables, or lab reporting tools. 
Even in the situation where laboratories can re-purpose existing testing platforms to 
deliver the new test, relevant costs of consumables and staff with appropriate skills need 





be not carried out in this specific clinical setting if crizotinib was not available (157), and 
therefore it is highly likely that the hospitals will need to purchase the testing equipment 
(i.e. capital costing items) however, it was not considered in their EE.  
 
Timing of the test use 
Details of where in the clinical pathway testing was undertaken were often not reported. 
Only two studies (68, 137) provided some explanation on this aspect, however, it was not 
clear how the timing of the test use was considered in the analysis of the Westwood study 
(158). Whereas, Saito and colleagues (68) provided and justified their assumptions. Given 
the nature of companion biomarkers, the health benefit to the patient arises from the 
corresponding therapy guided by the testing result, which is best understood as it being 
part of the clinical pathway in relation to its indirect impact on patient outcomes. 
Therefore, the value of companion biomarkers is best assessed while considering the 
timing of the test use; for example, whether the testing was done at diagnosis or following 
progression to metastasis. Westwood and colleagues (137) noted that the timing of KRAS 
testing may vary; some clinicians might undertake routine testing for all patients at 
diagnosis or some might wait until metastases have been detected. Yet, they did not 
specify how their evaluation was done in this respect.  
 
Uncertainty analysis  
Six studies (125, 129-131, 135, 136) explored the impact of cost-effectiveness of varying at 
least one component of the characteristics of companion biomarker tests being evaluated 





prevalence. However, many studies did not examine the characteristics of a test separately 
from that of the corresponding therapy. According to HTA guideline, “if a diagnostic test 
to establish the presence or absence of the biomarker is carried out solely to support the 
treatment decision… a sensitivity analysis should be provided without the cost of the 
diagnostic test” (139). However, out of three UK studies, two studies performed a 
sensitivity analysis on biomarker testing cost (129, 130).  
 
Data sources for biomarker-related data inputs  
All papers except for three studies (102, 125, 131) provided data sources used for the 
characteristics of biomarker tests. However, several studies did not provide a specific name 
of companion biomarker testing kits, although some of them reported a general biomarker 
testing type (e.g. RAS testing) and therefore, several studies were not transparent and 
reproducible. The most frequently used data sources were previous published literature. 
However, testing cost inputs were mostly sourced from reimbursement schedules (127-
129, 131, 133), manufactures or laboratories (72, 87, 137), and if such information was 




Altogether, eighteen papers were included in this review. One existing systematic review 
found to be similar to this study in terms of study scope and objective (121). However, it 
mainly focused on reviewing the sensitivity and specificity of companion diagnostics and 
the cost of testing. It did not provide a comprehensive review of methodological 





context of precision medicine. To the best of our knowledge, this is the first review 
providing a comprehensive report on current practices and possible solutions in terms of 
methodological approaches and evidence requirements in assessing the value for money 
of companion biomarkers.  Table 3-3 summaries possible solutions and suggestions to 







TABLE 3-2 :  SUMMARY OF CURRENT PRACTICES AND SOLUTIONS IN ECONOMIC EVALUATIONS OF COMPANION BIOMARKERS  
Methodological areas 
Issues identified in the current 
practice of economic evaluations  
Possible solutions/suggestions  
Methodological approaches  Data requirements  
Target population 
Pre-selected population group with 
known biomarker status was 
targeted in EEs.  
Target the entire patient group including 
biomarker positive, negative, and 
unknown.  
Clinical data on all patients including false positive, false negative, 
unknown biomarker status.  
Perspective 
Payer perspective was mostly used 
following the HTA guidelines by the 
reimbursement authority.  
Holistic viewpoint desired (e.g. societal 
perspective). However, if infeasible, 
biomarker testing related cost items 
should be included in evaluations.  
- 
Comparator  
With versus without the use of 
biomarker testing compared in 
evaluations yet in the context of the 
same targeted therapy.  
SOC in current routine clinical practice 
should be employed as a comparator in the 
context of treating the disease condition of 
interest and the target patient population.  
Evidence on standard of care being routinely practiced for the 
target patient population with the disease condition in a country-
specific setting.   
Comparison structure 
No consistency in structuring 
strategies to be compared in 
comparative analysis of companion 
biomarkers for targeted therapies.  
Test-treat versus treat-all with SOC is 
suggested as a base-case comparison 
structure.  
 
Clinical data on patients treated all with SOC without biomarker 
tested.  
Clinical data on patients tested negative.  
Clinical effectiveness 
Clinical value of companion 
biomarkers was limited to 
sensitivity/specificity. Often, 
biomarker prevalence data was 
ignored. Sensitivity /specificity was 
often assumed to be 100% or 
excluded completely from the 
economic model inputs.  
Clinical value of companion biomarkers 
beyond sensitivity 
/specificity should be incorporated in 
economic evaluations of biomarker-guided 
therapies.  
Clinical evidence generated from clinical trials on both the drug 
and the diagnostic. If possible, separate RCTs in test positive and 
test negative patients respectively treated with guided therapy 
and non-guided therapy. In addition, the clinical utility values 
including the change of clinician’s behavior in choosing this 







Utility and/or disutility values 
related to biomarker testing were 
not considered.  
Biomarker related patient preferences 
should be incorporated in economic 
evaluations of biomarker-guided 
therapies.  
Individual patient utility (or disutility) values on the use of a 
companion biomarker test prior to the administration of targeted 
therapy. Patient preference data can be acquired along the 
clinical trials, reflecting all biomarker relevant preference items.  
Timing of the test use 
The timing of the use of companion 
biomarker testing is often not 
incorporated and not reported in 
economic evaluations.  
The value of companion biomarkers should 
be understood throughout the clinical 
pathways applicable to the decision-
making of clinicians.  
The timing of the test use in clinical routine settings is preferred 
over the RCT setting.  
Uncertainty analysis 
Many economic evaluations did not 
examine the characteristics of a test 
separately from that of the 
corresponding therapy.   
The characteristic components relevant to 
a companion biomarker diagnostic should 
be tested separately as part of uncertainty 
analysis of biomarker-guided therapy.   
- 
Information and model 
inputs to be 
incorporated in 
economic evaluations of 
companion biomarkers  
Limited number of model 
parameters pertinent to biomarker 
testing was incorporated into the 
economic assessment of 
companion biomarkers.  
Model inputs relevant to companion 
biomarker testing should all be captured 
and incorporated in economic evaluations 
of biomarker-guided therapies.  
Name/type of biomarker testing diagnostic/kit.  
Resource use of testing. 
Unit cost of testing. 
Capital cost if the testing device is not currently available in 
current clinical settings.  
Prevalence of biomarker status in patient population.  
Sensitivity/specificity.  
Utility and/or disutility values of performing the test in relation to 
preference-based outcomes.   
Clinical pathways including the test (for example, when the test is 





Many of the EEs of biomarker-guided therapies target a pre-selected patient group with a 
specific biomarker status instead of including all patients with a disease regardless of their 
biomarker status. This is then often used as a justification for excluding companion 
biomarker testing from EE, leading to a lack of robust economic evidence for the entire 
patient group with the disease. It is important to consider all patients regardless of 
biomarker status and then, to perform the economic assessment of companion biomarker 
therapies for all populations of interest with the condition or disease.  
Also, EEs need to be consistent with the decision problem being addressed for targeted 
patient populations using a payer perspective.  EEs usually adopt a perspective proposed 
in country-specific health technology assessment guidelines and then, the third-party 
payer perspective is the most frequently employed viewpoint of analysis. However, 
considering the multiple purposes of biomarker tests and the indirect health impact of 
companion biomarkers on patient outcomes of corresponding therapies, it might be better 
to adopt a holistic viewpoint and capture the full spectrum of health economic 
consequences of biomarkers. This would then permit the inclusion of non-health related 
costs and benefits such as early information or reassurance on treatment option.  
Applying comparator strategy of relevance in specific clinical settings is crucial and may 
change the cost-effectiveness outcomes of the intervention being assessed. Economic 
evaluation of biomarker-guided therapies often requires more than one comparator arm 
such as biomarker-guided therapy without biomarker testing and standard of care without 
biomarker testing (13). A previous study (123) sometimes found conflicting cost-
effectiveness results depending on the comparator strategy chosen such as test-treat 
versus treat-all with standard of care (SOC) and test-treat versus treat-all with new therapy. 





strategies to be compared. Biomarker-guided therapies are often evaluated by comparing 
biomarker testing and no-testing strategies in administering the new intervention being 
evaluated. Such comparative analyses often ignore the standard of care being provided in 
current clinical practice.  
There are challenges in determining the clinical value of companion biomarkers. If the 
companion biomarkers were integrated as an integral part of the clinical trials of their 
corresponding therapies, determining the clinical utility of companion biomarkers can be 
assumed or justified that it is already reflected in the clinical effectiveness of corresponding 
therapies (159). Otherwise, it is difficult to show the clinical utility of companion 
biomarkers in clinical practice. Often, biomarker tests are developed independently from 
the drug and the common practice of biomarker test developers in terms of evidence 
generation is only limited to provide clinical validity (i.e. sensitivity and specificity). 
Reflecting this common practice in the generation of clinical evidence for biomarkers, we 
found that the assessment of the clinical value of companion biomarkers in EEs is limited 
to a consideration of the sensitivity and specificity of the test.  
Most studies considered and included the cost of companion biomarker testing in their EEs. 
However, they often did not provide sufficient details on how they calculated the cost of 
testing and what data sources were used. This posed challenges in terms of transparency 
and reproducibility of EEs of companion biomarkers. This may be because testing cost is 
not standardized (e.g. no coding systems exist for biomarker testing in medical records) or 
not publicly available (e.g. secret pricing or individually negotiated price at a 
hospital/laboratory level) in many countries. Given that no standardized cost information 
such as unit costs is publicly available, most economic evaluations might need to rely on 





It is said in the field of precision medicine that we need to introduce more flexible 
reimbursement systems in order to reward innovation, reflecting the added value of 
diagnostics or biomarker tests (32). Otherwise, the value of biomarkers will not be fully 
captured and reflected in EEs. This also leads to an issue of understanding the entire clinical 
pathways in relation to the biomarker test and capture the right place of the added value 
of biomarkers in the continuum course of disease management and cure. Our study 
showed that many evaluations failed to reflect this aspect by not even reporting the timing 
of the test use. Furthermore, the patient preference utility of companion biomarkers in 




It is in the public interest to ensure timely integration of new technologies into clinical use 
through adequate levels of reimbursement and coverage. However, it requires that test 
developers demonstrate robust evidence of the health economic impact of biomarker 
tests. Companion biomarker characteristics captured in EEs are often limited to the cost or 
the accuracy of the test. Often, only the costs of biomarker testing are modelled. Clinical 
outcomes or utilities are often difficult to include due to the limited data generated by 
clinical trials.  
We found that there was no consistent approach applied in assessing the value of 
biomarkers and including the characteristics of biomarkers in an economic evaluation of 
targeted oncology therapies. Currently, many EEs fail to capture the full value of 
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Despite the extensive use of bevacizumab in a range of oncology indications, the US FDA 
revoked its approval for breast cancers, and multiple negative trials in several solid 
malignancies have been reported, so the need for predictive biomarkers has increased. 
The development of predictive biomarkers for anti-angiogenic bevacizumab therapy has 
long been pursued but without success. 
 
Introduction  
Heat shock protein 27 (HSP27) expression has recently been identified as a predictive 
biomarker for bevacizumab in treating metastatic melanoma. This study aims to evaluate 
the cost-effectiveness of HSP27 biomarker testing prior to the administration of 
bevacizumab compared to two comparator arms of treating all patients with bevacizumab 
and dacarbazine respectively without HSP27 testing.  
 
Methods 
A partitioned survival analysis model with three mutually exclusive health states 
(progression-free survival, progressed disease, and death) was developed using a 
Norwegian health system perspective. The proportion of patients in each state was 
calculated using the area under the Kaplan-Meier curve for progression-free and overall 
survival derived from trials of bevacizumab and dacarbazine. Three strategies were 





dacarbazine without HSP27 testing, 3) treat-all with bevacizumab without HSP27 testing. 
Quality-adjusted life-years (QALYs) and costs (Norwegian Krone (NOK), year 2019 values) 
were calculated for each strategy and discounted at 4%. A life-time horizon was applied. 
Uncertainty analyses were performed. Expected value of perfect information (EVPI) was 
estimated to assess the potential value of further research to generate more evidence.  
 
Results 
Although the test-treat strategy was cost-effective compared with treat-all with 
dacarbazine (ICER per QALY at 21,069 NOK), it was not cost-effective compared to treat-
all with bevacizumab without HSP27 testing (fewer QALYs was not justified). EVPI results 
showed a very minimal value (NOK 5,910 per case) or no value in conducting further 
research efforts to reduce uncertainties around current information.  
 
Conclusion 
This study indicates that HSP27 expression is not cost-effective as a potential predictive 
biomarker for bevacizumab. This may not necessarily mean that HSP27 is a bad biomarker 
for bevacizumab, but it may mean that bevacizumab is in any case much better than 
dacarbazine regardless of HSP27 expression. Or, indeed it may imply that HSP27 is not 










Cutaneous malignant melanoma is common in fair-skinned populations in many countries 
(160-163). Worldwide, 132,000 melanoma skin cancers occur each year (164). Incidence 
and mortality continue to rise across the world (163, 165-167). Norway has among the 
highest incidence of melanoma in the world (168). In Norway, the five-year relative survival 
is 90% for patients with localized melanoma but only 16% for those with distant melanoma 
(169). The target population of this evaluation followed the patient population included in 
a clinical trial (ClinicalTrials.gov NCT00139360); patients with metastatic melanoma. The 
American Joint Committee on Cancer (AJCC) staging system is internationally accepted 
classification system in staging patients with melanoma in stage I, II, III, IV, aligned with 
TNM classifications (tumor thickness, nodes, and metastasis) (170). Patients are 
categorized as having localized disease (stage I-II), regional disease (stage III), or metastatic 
disease (stage IV). Detailed classification of TNM of melanoma is provided in Appendix 4-
6, followed by Schuster’s PhD thesis (171).    
The routinely available treatment options for metastatic melanoma were high dose 
interleukin-2 and dacarbazine with a low response rate of around 10% (172-174). 
Chemotherapy has for a long time been the main treatment option for metastatic tumours 
although marginally effective, with dacarbazine as the standard drug for most melanoma 
cases (168), being the only FDA-approved drug. However, dacarbazine has shown low 
response rates with no life-extending effect (168). Recently, new targeted drugs have been 
developed, and especially the introduction of BRAF (B-Raf proto-oncogene, 
serine/threonine kinase) and MEK (Mitogen-activated protein kinase) inhibitors has 
improved progression-free and overall survival of advanced melanoma (175-181). 





metastatic melanoma (182, 183). Currently, the presence of a specific BRAF mutation is 
the biomarker recommended for routine clinical practice to administer the corresponding 
targeted therapies (BRAF inhibitors: vemurafenib, dabrafenib; MEK inhibitors: trametinib, 
cobimetinib) in advanced melanoma (182, 184-186). In addition, immune checkpoint 
inhibition for metastatic melanoma has created significant optimism in later years (187, 
188), but no predictive biomarkers have been validated for immunotherapy.  Norway has 
its own regulatory approval agency for medicines, called Norwegian Medicines Agency 
(NoMA). Norway has universal health coverage funded by general taxes and NoMA 
evaluates whether or not to cover the expenses of certain treatment in the national health 
insurance scheme (23). The reimbursement application must contain cost-effectiveness 
analysis data performed by the applicant (except for the application of generic products 
no more costly than relevant reimbursed ones) which reflects the resource use in relation 
to health benefit (23, 189). NoMA can make a recommendation to the Norwegian Ministry 
of Health concerning reimbursement of applicant’s product based on an overall 
assessment of medical, social, and health economic information. Overall, the government 
plays a major role in governing the health system in Norway (190).  
Given bevacizumab’s mechanism of action as a vascular endothelial growth factor (VEGF) 
inhibitor, certain patient populations might be less likely to benefit from the drug as 
indicated by measured VEGF levels. Thus, a development of predictive biomarkers for 
bevacizumab has long been pursued but without success. Recently however, a study 
identified Heat Shock Protein 27 (HSP27) as a potential predictive biomarker for 
bevacizumab in treating metastatic melanoma (clinical trial information: NCT00139360), 
which is still at the early stage of a novel companion biomarker development (191). HSP27 
is known to be associated with poor prognosis and treatment resistance in many cancers 





metastasis can predict response to bevacizumab. Staining intensity was defined as absent 
(no positive tumour cells), weak (less than 10% positive tumour cells), moderate (10-50% 
positive tumour cells), or strong (more than 50% positive tumour cells). The staining index 
(SI) is a product of intensity and area (ranging from zero to nine) (193). Based on this recent 
study, this cost-effectiveness analysis aims to assess the cost-effectiveness of HSP27 
testing prior to the administration of bevacizumab in treating patients with metastatic 
melanoma. Given the early stage of companion biomarker discovery, we also aim to inform 
decisions to invest in further research to generate more evidence. To the best of our 
knowledge, there are no economic evaluations of biomarker testing prior to the 





A partitioned survival analysis model (PSM), similar to previous economic evaluations of 
treatments of advanced or metastatic cancers, including the cost-effectiveness of a BRAF 
inhibitor (dabrafenib) and bevacizumab (192, 194), was developed using Microsoft® Excel® 
(16.0.12730.20144). Our analysis performed and reported following the Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS) (38). Model structure was 
conceptualized based on the decision problem of assessing the cost-effectiveness of HSP27 
testing prior to the administration of bevacizumab, followed by a report from Roberts et 
al. (195). Provided that the disease of metastatic melanoma can be broken into mutually 
exclusive health states and the presence or absence of HSP27 expression can be broken 





modelling type of PSM was driven by the form of available data; for example, clinical data 
on the comparator strategies was obtained by published Kaplan-Meier (KM) curves, which 
allowed to construct the model by calculating area under the KM curves. 
A hypothetical cohort of 10,000 patients with metastatic melanoma was modelled. The 
model has three mutually exclusive health states: alive with no progression (progress-free 
survival, PFS), alive with progression (progressed disease, PD), or dead (Figure 4-1). The 
proportion of patients in each health state over time was calculated using the Kaplan-
Meier (KM) survival curves for PFS and overall survival (OS).  Partitioned survival analysis 
assumes that, at any discrete time point, the difference between the proportion of patients 
in OS and the proportion of patients in PFS determines the proportion of patients who are 
alive with PD. This PSM do not need to consider the cause of mortality and thus, all-cause 
mortality was not included in the dead state. Bevacizumab is not licensed for metastatic 
melanoma, although HSP27 expression is identified as a companion biomarker test for 
bevacizumab in treating bevacizumab. However, this is an early economic evaluation 
performed on a candidate biomarker test which is at the early stage of technology 
development, thereby, using clinical data from a Phase II trial for the intervention strategy 
(196) from the perspective of Norwegian health system considering the clinical trial was 
conducted on Norwegian patient population and the research interest of Norwegian 
funder (Centre for Cancer Biomarkers, Norway).  
A Norwegian health system perspective was employed, which considered direct costs in 
treating metastatic melanoma. No studies have reported the prevalence of HSP27 
expression for patients with metastatic melanoma in Norway. Therefore, 70% was 
assumed and tested in the uncertainty analysis.  The model has a monthly cycle and a 





outcomes were discounted at 4% annually as recommended by the Norwegian Ministry of 
Finance and guidelines for health economic evaluation in the health sector (197). The 
primary measure of cost-effectiveness was the incremental cost per quality-adjusted life 











PFS; Progression-Free Survival, PD; Progressed Disease 
 
Strategies compared  
Three strategies were compared and assessed in this study, in treating patients either with 
bevacizumab or dacarbazine in the first line of MM. The intervention technology of interest 
in this study was testing the HSP27 biomarker status of patients prior to the administration 
of bevacizumab (hereafter, referred to as the test-treat strategy). This intervention 
strategy of interest was compared against two comparator strategies; first, treating all 
patients with dacarbazine without HSP27 biomarker testing (hereafter, treat-all with 
dacarbazine strategy), second, treating all patients with bevacizumab without HSP27 
biomarker testing (hereafter, treat-all with bevacizumab strategy). This model structure 
follows what I found in previous chapters. Previous literature reviews found that several 
economic evaluations employed the modeling structure of assessing the value of 
biomarker-guided therapy with and without the biomarker testing. Thus, the standard of 
care was not considered in the economic model. It can then potentially lead to different or 
conflicting conclusion in terms of cost-effectiveness of a new guided therapy. Therefore, I 







testing prior to the administration of bevacizumab can be respectively compared against 
all applicable comparator strategies such as treating all patients with dacarbazine without 
HSP27 testing (standard of care) and treating all patients with new therapy without 
biomarker testing.  
Under the test-treat strategy, patients truly tested positive for HSP27 expression received 
bevacizumab while HSP27 negative patients received dacarbazine. However, for patients 
who falsely-tested positive, the health effect of dacarbazine was assumed for them even 
though they were treated with bevacizumab. Also, patients truly or falsely tested negative 
were assumed to be efficacious of dacarbazine because they were not treated with 
bevacizumab. Based on the findings of Schuster et al.(191), patients with HSP27 tissue 
expression with a staining index 4 or above were considered to be HSP27 biomarker 
positive and those below index 4 were considered HSP27 negative.  
 
Survival estimates for partitioned survival analysis modelling  
The survival analysis for bevacizumab used PFS and OS KM data from the phase II study (35 
patients) (198), which identified a potential predictive biomarker to guiding administration 
of bevacizumab in treating patients with metastatic melanoma (MM) (191). This phase II 
trial is a single arm, non-randomised, non-blinded single centre study. This trial reported 
median OS was 9 months (mean: 13, range: 1.1-49) and the median number of cycles was 
4 (mean: 14, range: 1.1-64). One treatment cycle is two weeks. This trial reported that no 
patients died of causes other than MM. We obtained the individual patient dataset (IPD) 
from the clinical research group, which reported the clinical data beyond the published 
trial period.  We then performed non-parametric survival analysis to calculate the KM 





bevacizumab. Extrapolation was required in order to incorporate non-observed survival 
(e.g. the event may have not occurred by the end of trial follow-up) in health economic 
models (199). Different distributions (exponential, Weibull, gompertz, log-logistic and log-
normal) were fitted to the KM. The log-normal distribution found to be the best fit to PFS 
curve and the gompertz distribution for OS curve. Parameters used in fitting the parametric 
models were provided in Appendix 4-3. Also, KM curves and model fits were provided in 
Appendix 4-3 together with the Akaike Information Criterion (AIC) and the Bayesian 
Information Criterion (BIC).  
Dacarbazine survival was based on the PFS and OS KM curves from the dacarbazine arm of 
a phase III randomized study (675 patients) (200, 201). This trial was selected based on 
patient characteristics such as age, ECOG performance status, and sex being broadly 
similar to those in the bevacizumab study (Appendix 4-1). No head-to-head trial as well as 
no pooled analysis (i.e. meta-analysis) provide a treatment effect for bevacizumab 
compared to dacarbazine for patients with metastatic melanoma. The OS and PFS data 
values were read off from the published KM survival curves using Digitizelt® (202), and the  
KM dataset was reconstructed using an algorithm developed in R by Guyot et al. (203); the 
full R code used in this study is provided in the appendix of the same paper. This process 
of data transformation was needed because the time-to-event data were not available. 
We used R version 3.5.0; R is a programming language and free software for statistical 
computing (204). Parametric survival distributions were fitted to the KM data 
reconstructed from the published KM curves using Stata (StataCorp. 2015. Stata Statistical 
Software: Release 14. College Station, TX: StataCorp LP). To determine which model best fits 
the data, different distributions were fitted against the data. Various distributions of 
exponential, Weibull, gompertz, log-logistic and log-normal were fitted and tested using AIC 





by looking at the shape of the distribution to see whether any of the models fitted appeared 
clearly inappropriate. To sum up, the model selection was based primarily on information 
criteria, supplemented by visual inspection (205). The log-normal distribution was selected 
for OS and the generalized gamma distribution was selected for PFS based on visual 
inspection, AIC and BIC. The pertinent parameters used in extrapolating survival are 
provided in Appendix 4-2. The log-normal distribution provided the lowest AIC and BIC 
values for OS and the generalised gamma distribution for PFS. AIC and BIC results are 
provided in Appendix 4-3.  
 
HSP27 expression characteristics and ROC analysis  
Since the HSP27 expression is still at the early stage of technology development, its 
performance data (e.g. diagnostic accuracy – sensitivity and specificity) was not yet 
estimated and thus, the receiver operating characteristic (ROC) analysis was needed in 
order to estimate sensitivity and specificity of HSP 27 biomarker testing. The ROC analysis 
was conducted, using the clinical trial data (191) in order to estimate the optimal threshold 
of true positive fraction and false positive fraction of HSP27 biomarker testing (206). ROC 
analysis is a simple but useful tool to evaluate the accuracy of a diagnostic test (207). The 
ROC curve shows the trade-off between sensitivity and specificity; any increase in 
sensitivity will lead to a decrease in specificity. The closer the curve follows the left-hand 
border of the ROC curve, the more accurate is the test. Meanwhile, the closer the curve 
comes to the 45-degree diagonal of the ROC curve, the less accurate the test is. ROC curve 
analysis was used to test the performance of a test in identifying eligible patients for the 
treatment of interest. As shown in Figure 4-2, the true positive rate (sensitivity) was plotted 





predicted the optimal cut-off threshold of HSP27 biomarker testing performance at the 
sensitivity of 81.8%. Following this ROC analysis, a sensitivity of 81.8% and specificity of 
41.7% have been incorporated in the cost-effectiveness model. Given the low specificity, 
we also considered a higher index however, when a HSP27 staining index higher than four 
was applied (which is staining index 6 or 9 in this case), it was worse than the random 
selection (45-degree diagonal of the ROC space). For example, under the HSP27 index 6, 
both sensitivity and specificity improved over 90%, however, it was located below the 45-
degree diagonal of the ROC curve (Figure 4-2). The estimated cut-off thresholds according 
to different levels of the HSP27 staining indices are reported in Appendix 4-4. Thus, based 
on the ROC analysis results (Figure 4-2), the best cut-off threshold for determining HSP27 
biomarker positivity or negativity was at the staining index 4. In other words, HSP27 
expression is positive when the staining index is 4 or higher, while HSP27 negative when 
the staining index is lower than 4.  
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Costs were calculated from the perspective of the Norwegian healthcare system. Direct 
costs included drug costs (drug acquisition and administration), HSP27 biomarker testing 
costs, and monitoring costs during and after the administration of drugs(197, 198, 208-
211). Costs other than health care costs were not included. For the costs of testing HSP27 
biomarker status, the list price of this test was used assuming 200µg/ml of HSP27 antibody 
and converted from USD to NOK using the exchange rate of 1USD=7.72NOK and year 2019 
values used (208). The drug costs depended on the acquisition price, the dosage, and the 
treatment duration. The estimated cost of dacarbazine assumed that 850mg/m2 body 
surface is administered on day 1 and then once every 3 weeks by intravenous infusion. 
Dacarbazine could be administered for up to 24 months while in the PFS state and then no 
dacarbazine given afterwards. After the 24 months of treatment with dacarbazine, 
monitoring costs were included for patients continuing in PFS and PD states.   
Patients received 10mg/kg of bevacizumab as an intravenous infusion on day 1 of a two-
week cycle until progression or for up to 12 cycles (24 weeks). Only monitoring costs were 
included for patients in PFS who had finished treatment after 6 months. Monitoring costs 
were the considered in PFS and PD states. Treatment was assumed to cease on progression. 
Cost calculations were made with respect to a monthly cycle length of 30.42 days. An 
average body weight of 80kg was assumed. The dosages used in this model follow the 
information in the summary of product characteristics (SPC) or trial protocol. Details of the 
costs are shown in Table 4-1.  
TABLE 4-1 :  COST INPUTS USED IN THE MODEL 











    Drug acquisition cost per cycle (NOK) 1259 881 1637 Gamma (210) 
    Administration cost per treatment (NOK) 1312 918 1706 Gamma (210) 
    Number of doses per cycle  1.33 - - - (209) 
Bevacizumab 
    Drug cost per mg (NOK) 415.49 291 540 Gamma (211) 
    Number of doses per cycle 2 - - - (198) 
    Average body weight(kg) 80 56 104 Normal Assumption 
Monitoring cost per cycle (NOK) 2858  2001 3715 Gamma (210) 
HSP27 testing kit (NOK) 1583 1108 2057 Gamma (208) 
Discount rate 4% - - - (197) 
 
Health outcome (QALYs)  
Quality Adjusted Life-Years (QALYs) gained were the primary health outcome of interest in 
this analysis. However, utility data on bevacizumab for patients in MM was not available 
and therefore, health state-based utility values were used in the model with the data 
sourced from a study which at least collected utility data on dacarbazine. The health state 
utility values were based on EQ-5D data collected in the BREAK-3 trial of dabrafenib vs. 
dacarbazine using the EuroQoL-5 Dimensions, 3 Levels instrument (212). The health state 
utility of patients receiving dacarbazine was 0.750. Patients treated with bevacizumab 
were assumed to have the same health state utility (0.767) as those receiving dabrafenib. 
The health state utility of all patients following progression was 0.677.  
 
Cost-effectiveness threshold (CET)  
Whether the test-treat strategy is cost-effective or not depends on how much a payer is 
willing to pay for additional health outcomes (QALYs or LYs) gained (213). When the 





a dominant strategy and clearly recommended to be the optimal strategy to implement 
(3). However, if the intervention strategy is more effective and more expensive than 
comparator strategies, decision-making should be made according to the cost-
effectiveness threshold (CET) set by healthcare payers.  Norway does not have a specific 
CET however, the Ministry of Health have argued that 275,000 NOK per additional QALY 
gained is the best estimate of the opportunity cost of health care in Norway (214). While 
it is suggested that a higher CET per QALY should be accepted for more serious conditions 
(214), and NOK 500,000 per QALY has been  used for some disease conditions, NOK 
275,000 per QALY was used in this study in the absence of an explicit definition what 
constitutes a serious condition.  
 
Uncertainty analysis  
Sensitivity analysis: handling parameter uncertainty 
We conducted deterministic sensitivity analysis (DSA) to identify key drivers in the model, 
whilst holding all other variables at their baseline values (213). We also performed 
probabilistic sensitivity analysis (PSA) to assess the uncertainty around the base case ICER 
by varying all relevant parameters simultaneously (215). When available, we used the 
bounds of 95% confidence intervals (CIs) as high and low estimates in the sensitivity 
analysis. When the bounds of 95% CIs were unavailable, we used a range of ±30%. Survival 
estimates were based on a beta distribution. Distributions of cost inputs used for PSA are 
detailed in Table 4-1. Monte Carlo simulation was used to assess the effect of simultaneous 
variation of all relevant parameters (216). Additionally, we performed scenario analyses 
for sensitivity and specificity of the HSP27 expression testing to examine their impact on 






Expected value of perfect information (EVPI): handing decision-making uncertainty with 
current evidence  
Healthcare decisions made based on existing information have the costs of uncertainty. If 
the wrong decision is made based on existing information, there will be opportunity costs 
in terms of healthcare resources and health benefits. The expected costs of uncertainty 
can be interpreted as expected value of perfect information (EVPI) because perfect 
information can remove the possibility of making wrong decisions (217). The opportunity 
costs of making wrong decisions can be estimated using the value of information 
techniques. The EVPI estimates the upper bound of the value of conducting further 
research, meaning that additional research cost is not justifiable if the expected cost of 
future research does not exceed the research cost (218).  
EVPI estimated the expected value of a decision made with current information against 
perfect information (Equation 1).  
Equation 1.  EVPI = E[maxtNB(t, )] - maxtE[NB(t, )] 
Where;  
 refers to unknown parameters, NB the net benefit, t the treatment, NB(t, ) the net benefit of treatment 
if parameters take the value .  
                                           
 
 







Deterministic cost-effectiveness results  
The base-case ICER per QALY for the test-treat strategy (Bevacizumab plus HSP27 testing) 
compared to treat-all patients with dacarbazine without HSP27 testing was NOK 21,069, 
being cost-effective. However, the test-treat strategy was not cost-effective when 
compared to treat-all with bevacizumab without HSP27 testing because it costed less and 
produced fewer QALYs (Table 4-2). To be cost-effective in this situation, the ICER needs to 
be above the CET. Otherwise, the cost saving is not compensating adequately for the loss 
of benefit. In other words, we should be able to save costs per QALY at a rate above the 
CET, otherwise, it is not worth giving up the QALYs and we would rather keep the QALYs. 
The base-case ICER results clearly showed lower than the Norwegian CET (NOK 275,000). 







































































































Bmab; bevacizumab, DTIC; dacarbazine, HSP27; heat shock protein 27, ICER; incremental cost-effectiveness 
ratio, Incr; Incremental, NOK; Norwegian Krone, QALY; quality-adjusted life years.  
 
Probabilistic cost-effectiveness results  
The probabilistic cost-effectiveness results showed that the total cost and QALYs gained 
for individuals tested for HSP27 and treated with bevacizumab were NOK 132,148 and 8.89 
QALYs, where those patients simply treated with dacarbazine were NOK 1,598 and 2.91 
QALYs, respectively (Table 4-2). Therefore, the ICER per QALY was NOK 21,847.  
However, the test-treat strategy was not cost-effective when compared with the treat-all 
with bevacizumab strategy. It saved costs but produced fewer QALYs as observed in base-
case results. Likewise, the cost savings per QALY needed to be at a rate above the CET in 
order for the intervention strategy to be cost-effective. However, the ICER per QALY is NOK 











Sensitivity analysis results 
Tornado diagram  
The DSA results are presented in a tornado diagram (Appendix 4-5). The key drivers in the 
model were the bevacizumab costs and the proportion of HSP27 positive patients. 
However, they did not ultimately change the cost-effectiveness decision. 
 
Probabilistic sensitivity analysis  
PSA was performed to assess the effect of parameter variation across all relevant 
parameters on the base-case ICER when all parameters simultaneously varied. One 
thousand simulations were run with QALYs gained as effectiveness measures.  
 
The scatterplot of the incremental costs and incremental QALYs from these simulations 
are presented in Figure 4-3 and Figure 4-4. All the iterations were contained in the north 
east quadrant of Figure 4-3 which means that the test-treat strategy of bevacizumab and 
HSP27 biomarker testing was costlier and more effective than the strategy of treating all 
patients with dacarbazine without HSP27 testing. However, when the test-treat strategy 
was compared to the strategy of treat-all with bevacizumab, a majority of the 1000 
simulations were located in the southwest quadrant of the scatterplot, suggesting that the 
intervention strategy was less costly but less effective as well (Figure 4-4). The PSA results 
confirmed that, although the test-treat strategy was cost-effective compared to treat-all 
with dacarbazine, it was not cost-effective compared to treat-all with bevacizumab 





FIGURE 4-3 :  PSA SCATTERPLOT FOR TEST-TREAT STRATEGY COMPARED TO TREAT-ALL WITH 
DACARBAZINE 
 
































































Scenario analysis on the sensitivity and specificity of HSP27 expression testing 
Scenario analysis was performed to examine the impact of the sensitivity and specificity of 
HSP27 testing on the cost-effectiveness results. It did not change the results in the different 
scenarios of the sensitivity and specificity of HSP27 testing under the different staining 
index of HSP27 expression. The cost-effectiveness results depending on different 
combination scenarios of sensitivity and specificity of HSP27 expression testing is provided 
in Figure 4-4.  
TABLE 4-3 :  SCENARIO ANALYSIS RESULTS  
HSP27 staining 
index* 
Sensitivity  Specificity  
ICER per QALY 
(NOK, year 2019) 
Test-treat strategy against 
treat-all with dacarbazine 
Test-treat strategy 
against treat-all with 
bevacizumab 
8 36.4% 12.5% 36737 11453 
6 72.7% 50.0% 22634 13989 
4 81.8% 58.3% 21069 15515 
3 90.9% 95.8% 19818 18234 
2 100% 100% 18794 24450 
*HSP27 expression is positive when the staining index ≥ 4 and HSP27 negative when the staining index < 4.  
 
EVPI analysis results  
A willingness-to-pay of NOK 275,000 was assumed in the EVPI analysis. The EVPI was 
estimated at NOK 5,910 for the test-treat strategy vs. treat-all with bevacizumab, while the 
EVPI was estimated at zero value for the comparison of the test-treat strategy and treat-
all with dacarbazine (Table 4-5). The EVPI for the test-treat strategy against the treat-all 
with dacarbazine implies that further research to reduce the uncertainties around current 
information would not be warranted. Likewise, the EVPI of NOK 5,910 for the test-treat 





worthwhile either, given the small number of new cases of metastatic melanoma in 
Norway (annual average of 173 cases (169)).  The upper bound of the population EVPI of 
the comparative analysis between the test-treat and the treat-all bevacizumab strategy 
was only NOK 1,022,430 per annum (EVPI per patient multiplied by the annual case of MM 
in Norway). In other words, in order to justify further investment in research efforts of data 
collection such as conducting a phase III trial for HSP27 testing and bevacizumab, the 
research costs need to be lower than this upper bound, which is very unlikely for Norway. 
However, a couple of data limitations should be considered when interpreting this EVPI 
result. First, we need to consider that this analysis is based on a single arm study with the 
small sample size (35 patients) for bevacizumab-related strategy arms. However, according 
to Schuster et al. (198), a statistical significance of their study results was met despite its 
small sample size. Second, considering the nature that this analysis was conducted using 
the clinical inputs from the Phase II trial, the interpretation of this EVPI result can be 
considered exploratory rather than definitive. EVPI results are provided in Table 4-5. The 
EVPI graph depicted in Figure 4-5: EVPI graph. Figure 4-5shows the change of EVPI 
depending on different thresholds. The spike is when we have maximum uncertainty 
where CET equals the ICER.  
TABLE 4-4 :  EVPI RESULTS  
ENMB for test-treat 
 Strategy (NOK) 








2474879 910986 2474879 2474879 0 
ENMB for test-treat 
strategy (NOK) 








2464076 3097583 3097583 3103493 5910 





FIGURE 4-5: EVPI GRAPH 
 




The cost-effectiveness of giving bevacizumab in treating MM to those testing positive for 
HSP27 was compared with two alternative strategies (treating all patients with 
bevacizumab without HSP27 testing and treating all patients with dacarbazine without 
HSP27 testing), using a partitioned survival model. From the Norwegian health system 
perspective, a strategy of HSP27 biomarker testing was not cost-effective. Treating all 
patients with bevacizumab was the best of the three strategies. EVPI results suggested that 
investing in further research of evidence generation, such as a Phase III trial, is not justified 
given the number of patients with metastatic melanoma in Norway.  This is the first study 
analysing the cost-effectiveness of HSP27 biomarker testing prior to the administration of 
bevacizumab. There are no cost-effectiveness analyses of potential biomarkers (newly 






















Previous studies have assessed the cost-effectiveness of BRAF and MEK inhibitors in 
metastatic melanoma. They employed a variety of different modelling approach, ranging 
from decision tree analysis, to PSA and Markov model. Delea et al. (194) employed a PSA 
similar to my study and evaluated the cost-effectiveness of BRAF inhibitors however, did 
not assess the impact of BRAF testing separately. Tarhini (219) used a discrete event 
simulation model and assessed the sequence of different targeted therapy options in 
melanoma but biomarker status was not considered. Curl and her colleagues (220) also 
estimated the cost-effectiveness of treatments for BRAF-mutated metastatic melanoma 
patients, using decision tree model. Likewise, Bohensky (221) conducted the cost-
effectiveness for the treatment of BRAF wild-type advanced melanoma in Australia based 
on a Markov model, but all patients entering the model were BRAF-wild-type. However, 
none of these studies analysed the cost-effectiveness of biomarker testing prior to the 
provision of corresponding targeted therapies. However, Oh and her colleagues (222) 
analysed the cost-effectiveness of targeted therapy depending on the biomarker status 
(PD-L1 positive and negative patients) and found that PD-L1 biomarker status contributed 
the most uncertainty to their model. However, none of these previous studies were 
performed from the perspective of Norwegian health system based on Norwegian 
populations.  
This study has several limitations. First, the survival data for dacarbazine is derived from 
one clinical study not through meta-analysis. No meta-analysis study on the effect of 
dacarbazine was found and thus, we chose a study based on the patient characteristics in 
clinical trial among other studies considered for dacarbazine monotherapy for patients 
with metastatic melanoma (223, 224). On the other hand,  the survival data for HSP27 
testing and bevacizumab was derived from a small-sized single arm non-randomised study 





evidence for health interventions. We thus need to consider that potential biases are likely 
to be greater for non-randomised trial (NRT) compared to RT such as selection bias and 
confounding. In other words, in NRT, the observed difference in treatment effects between 
intervention and control groups might be due to differences in baseline characteristics of 
patients and not necessarily the treatment (225). However, RT study is not always feasible 
for early stage health technology and is costly in money and time (226). Furthermore, this 
is the only clinical data available on HSP27 expression and bevacizumab for patients with 
metastatic melanoma. Second, bevacizumab does not have a marketing authorization for 
treating patients with metastatic melanoma. This might limit the usability of this study 
finding in informing decision-makers when reviewing the introduction of this new 
companion biomarker test prior to the administration of bevacizumab in MM. However, 
the objective of this study is to determine the value of HSP27 testing in terms of cost-
effectiveness and EVPI. Third, given the early stage of the development of HSP27 
biomarker for bevacizumab, it was necessary to make some assumptions with regard to 
HSP27 testing. Fourth, it is a naïve indirect comparison and we did not perform matching 
patients between dacarbazine and bevacizumab. This may lead to some potential bias in 
the results. For example, patients in dacarbazine trial were younger than those in 
bevacizumab trial; however, the eastern cooperative oncology performance (ECOG) status 
was better for patients in bevacizumab trial than for those in dacarbazine. Also, it is known 
that the prognosis of female patients with MM is better than that of male patients with 
MM. However, both trials showed the same proportion in male and female population. 
Fifth, the utility values were not available on patients with MM treated with bevacizumab 
for Norwegian populations. However, utility values on patients treated with dacarbazine 
were available and also, the model applied utility values for a targeted therapy for patients 





synthesise the utility data in order to complete this PhD research within the timeline. 
However, the objective of this work package is to apply the previous study findings 
(Chapter 2 and 3) in a case study of modelling a novel companion biomarker test for 
targeted cancer therapy. Sixth, all-cause mortality was not modelled in this analysis. It was 
assumed that no patients died of causes other than MM in this model given that patients 
entering the model are already at the metastatic stage of melanoma (short survival). 
Clinical data extracted from published KM curves did not differentiate all cause death from 
disease specific. Furthermore, Schuster and colleagues (198) in fact reported that no 




The cost-effectiveness results showed that testing HSP27 biomarker status prior to the 
administration of bevacizumab was not cost-effective. The finding may imply that this 
HSP27 biomarker is not good enough in identifying the right patients for treatment as 
shown in the results of ROC curve analysis, or that bevacizumab is in any case much better 
than dacarbazine in terms of health outcomes regardless of identifying eligible patients or 
not. The EVPI suggests that no further research is required to generate more evidence for 
assessing the test-treat strategy against the treat-all with dacarbazine; however, it 
suggests some health gains to reduce the uncertainties around the comparative analysis 
of test-treat strategy and treat-all with bevacizumab strategy. Depending on the budget 
required to conduct further studies such as clinical trials, the decisions regarding additional 





account of the expected gain in health and the upper bound of the monetary value of 
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Despite the increasing number of potential biomarkers identified in laboratories and 
reported in much literature, the number of biomarkers routinely adopted in clinical use is 
very limited. Reimbursement decisions for new health technologies are often informed by 
economic evaluations. It is argued that the lack of consensus in methodological approaches 
and data requirements in economic evaluations of biomarkers might be one of the key 
limiting factors on why there are yet only a small number of biomarker tests routinely 





economic evaluation of cancer biomarkers and how to model the characteristics of cancer 
biomarkers as part of the value for money of corresponding targeted therapies. This paper 
presents a brief introduction to the methods and data requirements, a step-by-step guide 
to constructing a health economic model of cancer biomarkers, and a discussion of issues 
that arise in their application to healthcare decision making. This practical guidance is 
provided in R, and worked examples are provided in this paper with R codes in 




This tutorial paper aims to guide the process of the development of cost-effectiveness 
models of cancer biomarkers for targeted therapies (specifically  specifically companion diagnostics, 
classifying patients into responders and non-responders for a specified therapeutic agent 
in treating patients with cancer). Although model conceptualization is the first key step in 
developing an appropriate model, it is beyond the scope of this tutorial paper. This paper 
is intended for those who chose a state-transition model as their appropriate model based 
on their decision problems to be represented in the model. For those who are not yet clear 
what model types are appropriate for their decision problems, there is a useful paper 
providing a series of consensus-based best practices for the process of model 
conceptualization (195). For example, when the decision problem requires modelling the 
effect of patient interaction (e.g. the treatment effect on disease spread), this core model 
is not applicable. As explained in Roberts et al.(195), this state-transition model is 





This core model can be applied in assessing cancer biomarkers for targeted therapies in 
terms of data requirements and methodological approaches for the purpose of local 
adaptation with appropriate adjustments required from the perspective of specific payers 
and country settings. The example used in this tutorial paper has three health states, 
progression-free survival (PFS), progressive disease (PD), and dead. This analysis is 
performed for a hypothetical cohort of cancer patients who are not eligible for tumor 
excision surgery.  
I chose to use R in building this practical model because of the advantages of using R (or 
script-based programming) for the development of economic models for health 
technology assessment although these are only beginning to be recognised (227). R is 
easily reproducible and flexible compared to Excel®.  
 
MODEL BACKGROUND AND DESCRIPTION 
 
Overall, several elements need to be defined in order to construct the health economic 
model for health technologies. The scope and scale of the relevant decision problems are 
presented in Table 5-1, using the PICOS framework. The decision problem is basically to 
assess the cost-effectiveness of testing patients with a companion biomarker test and 
treating them according to their biomarker status, in comparison with comparator 
strategies such as treat-all patients with the biomarker-guided therapy or treat-all patients 
with usual treatment regardless of biomarker status without testing. The study design is 
model-based cost-effectiveness analysis using a hypothetical cohort of patients and the 
study outcome to be calculated is ICER (cost per LY and cost per QALY gained). The 





2. This core model is developed based on the findings of Chapters 2-4. The process of 
building a health economic model involves defining the structure of the model and data 
inputs. Its detailed descriptions are provided in sub-sections as follows.  
 
Table 5-1 : Scope of decision problems  
Population  A hypothetical cohort of patient populations with cancer.  
Intervention  Companion cancer biomarker testing* for co-dependent therapeutics 
such as biomarker-guided therapies.  
Comparators Biomarker-guided therapies without biomarker testing.  
Usual therapies without biomarker testing.   
Outcome ICER, ICUR  
Study design Economic evaluation; model-based cost-effectiveness analysis.  
* Companion diagnostics licensed for the safe and effective use of specific drug or biological product.  
 
TABLE 5-2 :  SUMMARY OF THE REFERENCE CASE USED IN THIS GUIDE 
Element Reference case 
Intervention strategy  Test-treat patients according to biomarker status, using 
companion diagnostics for targeted therapies.  
Choice of treatment alternative 
(comparator strategies) 
The comparator strategy that the new biomarker-guided 
therapy will most likely to replace. Thus, in this core model, two 
comparator strategies employed: 1) Treat-all patients with 
biomarker-guided therapy regardless of biomarker status; 2) 
Treat-all patients with usual treatment regardless of biomarker 
status.  
Health state Three health states: Progression-free survival (PFS), Progressed 
disease (PD), Dead 
Viewpoint of the analysis Health system perspective  
Time horizon Lifetime 
Model of analysis Cost-utility analysis  





Method for the measurement and 
valuation of health effects 
Generic measures of health instruments 
Discounting rate 3.5% 
Uncertainty  Probabilistic sensitivity analysis; with an option of deterministic 
sensitivity analysis 
 
Strategy arms to be compared and assessed  
It is widely accepted that standard of care (SOC) is an appropriate comparator strategy in 
economic evaluations (3). However, my literature reviews (Chapters 2,3) found that the 
existing literature of economic evaluations demonstrates that the choice of comparator 
strategies and the comparison structure is not consistently applied in economic 
evaluations of biomarker-guided therapies. For example, SOC (e.g. usual therapy without 
biomarker testing) was not necessarily chosen as a comparator strategy but evaluated the 
cost-effectiveness of biomarker-guided therapy with testing against the guided therapy 
without biomarker testing. Therefore, based on the study findings from Chapters 2-4, it 
was found that assessing the biomarker-guided therapy against two comparator strategies 
was most commonly relevant. However, this core model allows readers to alter this 
structure of comparative analysis for their decision-specific problems and local 
requirements in economic evaluations.  In this core model, I constructed the model 
structure using  three strategies so that it can ensure the flexibility and applicability of this 
core model for readers to readily adapt. The three strategies constructed in this core model 
as default structure as follow: (1) patients being tested with a cancer biomarker and 
treated with the corresponding targeted therapy according to the biomarker testing result 
(hereinafter, test-treat strategy; “TT arm”), (2) a usual care strategy with patients being 
treated with standard of care without testing of their biomarker status (hereinafter, usual 





receive the biomarker-targeted therapy (hereinafter, targeted care strategy; “all-TC arm”). 
This construct of comparative strategy arms is also line with what has been suggested by 
previous studies (13, 122). The detailed schematic of comparative structure of strategy 
arms is depicted in Figure 5-1.   
FIGURE 5-1 :  MODEL SCHEMATIC. ‘M’ INDICATES A MOVE INTO THE MODEL IN FIGURE 5-2 
 
Model structure  
A discrete-time Markov cohort model is constructed to record the transition between 
health states experienced by a hypothetical cohort of patients eligible to be treated either 
with targeted care (biomarker-guided therapy) or usual care (non-guided therapy) in 
oncology treatments. Health-related quality of life weights and a cost pertinent to each of 
these health states are assigned. The model has three mutually exclusive health states: 
progression-free disease (PFS), progressed disease (PD), and dead. As depicted in Figure 
5-2, the arrows indicate the flow of individual patients in every model cycle. Transition 
from PD to PFS is assumed to be impossible. The transition probability can be calculated 





exclusive, the transition probabilities sum to one. A Markov model of disease progression 
is presented in Figure 5-2. The detailed model schematic of decision tree linking to the 
health state transitions is provided in Figure 5-1, and ‘M’ indicates a move into the Markov 
model. Once patients are allocated to their respective decision branch, they will enter a 
Markov model based on their assigned transition probabilities. Patients assigned to ‘treat-
all’ strategies (either with new therapy or with usual therapy) will enter the Markov model 
without being biomarker-tested and move to respective health states (PFS, PD, Dead) 
assigned by given transition probabilities. On the other hand, patients assigned to ‘test-
treat’ strategy arm will be either provided of new therapy or usual therapy according to 
biomarker status and then will enter a Markov model and assign to respective health state 
followed by transition probabilities. A lifetime horizon is applied.  





PFS; progression-free survival, PD; progressed disease.  
 
Data requirements and model inputs used in the practical/example model  
Model inputs are detailed in Table 5-3. These data inputs are just exemplary figures to 
guide the process of developing an economic model for biomarker-guided therapies, 
developed based on the previous study findings (Chapter 2 to 4). A third-party payer 







thus, any non-medical costs (e.g. lost productivity costs) are beyond the scope of this core 
modeling practice. Health state costs are defined per model cycle including drug costs and 
biomarker testing costs (Table 5-3). Health-related quality of life (HRQoL (e.g. EQ-5D)) data 
inputs are also provided in Table 5-3. In practice, HRQoL data is often obtained along with 
clinical trials or by separate literature reviews (e.g. systematic literature review and/or 
meta-analysis). However, for the development of this practical guide on core modeling for 
cancer biomarkers, HRQoL weights are given per model cycle for patients experiencing 
each health state. Biomarker-related parameters such as biomarker testing disutility value, 
performance accuracy (sensitivity and specificity), and biomarker prevalence are also 
shown in Table 5-3. Companion diagnostic technology for cancer patients ususually require 
collecting a bio-smaple for analysis, and this gives rise to the existence of process utility 
(such as reassurance or information) (151-153) Brennan and Dixon supported the 
existence of process utility and found that different approaches being used to detect and 
measure it (154). Given the existence of process utility, in this core model, testing disutility 
was used under the assumption that undergoing biomarker testing might cause some 
discomfort to patients. However, if this is not the case (e.g. testing bring not discomfort 
but convenience to patients), the utility value of testing should be considered when 
adapting this core model. In addition, transition probabilities, drug efficacy and discounting 
rate are also provided. All-cause mortality was not considered into this core model 
however, it should be considered when adapting this core model for local adaptations of 
country specific settings. In other words, modelers are advised to incorporate the country 
specific epidemiological data such as all-cause mortality into the core model for their local 
adaptations if applicable.  
TABLE 5-3 :  PARAMETER VALUES FOR THE MODEL DEVELOPMENT  






cPFS 500 State cost of one cycle in the progression-free disease state. 
cPD 3000 State cost of one cycle in the progressive disease state. 
cDrug 1000 State cost of drug for one cycle. 
cTest 100 State cost of biomarker testing for one cycle. 
cDead 0 State cost of one cycle in the death 
Quality of life adjustments 
uPFS.UC 0.75 
Quality-of-life weight for one cycle in PFS for patients treated with 
usual care.  
uPD.UC 0.65 
Quality-of-life weight for one cycle in PD for patients treated with 
usual care. 
uPFS.TC 0.80 
Quality-of-life weight for one cycle in PFS for patients treated with 
targeted care. 
uPD.TC 0.70 
Quality-of-life weight for one cycle in PD for patients treated with 
targeted care. 
Biomarker-related parameters 
disutility.Test 0.05 Disutility value of testing a biomarker status  
pSensitivity 0.95 Biomarker testing accuracy: Sensitivity  
pSpecificity 0.75 Biomarker testing accuracy: Specificity 
pPrevalence 0.35 Biomarker prevalence/frequency  
Transition probabilities 
pPFS2PD 0.2 Probability of entering the PD state. 
pPD2D 0.25 Probability of dying from the PD.  
pPFS2D 0.05 Probability of dying from the PFS. 
pPD2PFS 0 Recovery from PD to PFS is not permitted in the model. 
Other parameters 
eff 0.25 
Targeted drug reduces likelihood of being progressed by 25%. Relative 
risk of disease progression from using the drug.  
Targeted drug is discontinued upon progression.   
rDiscount 0.035 Discount rate for outcomes and costs 3.5% 
 
Uncertainty analysis 
Uncertainty analysis is a standard practice in modeling studies to assess the uncertainties 
around parameters and assumptions used in the model. Both deterministic sensitivity 
analysis (DSA) and probabilistic sensitivity analysis (PSA) are performed in this practical 
model in order to assess the impact of different variables on the cost-effectiveness results. 
DSA is performed to test the change of ICERs while individual parameters are changed from 





tested for uncertainty while randomly sampling the parameter values according to the 
assigned distribution data.  
 
STEP BY STEP GUIDE 
 
Figure 5-3 is an overall picture of the steps involved in order to perform cost-effectiveness 
analysis of cancer biomarkers for targeted therapies in R. Note that it is a general guidance 
and thus, some specific adjustments might be required depending on the country specific 
clinical settings or country specific HTA requirements. It should be also decision problem 
specific. An explanation of each step is provided. More detailed R codes are provided in 
Appendix 5-1 to 5-7. R codes can be self-explanatory with some notes written in italics with 
the symbol of # which can be useful when the codes are copied and pasted in R; however, 
basic understanding on R is required in order to follow this guide. This modeling guide is 
not intended for complete R beginners. For a basic note, the symbol of <- is to assign values 





FIGURE 5-3 :  ALGORITHM STEPS IN PERFORMING COST-EFFECTIVENESS ANALYSIS FOR CANCER 











Step 1. Create transition probability matrices  
The step is to prepare the transition probability matrix per strategy arm. Before this step, 
it is necessary to decide first what model is suitable such as a Markov or semi-Markov 
model, etc. as shown in Figure 5-3. This core model presented here is constructed based 
on a state-transition model. In order to construct the probability matrices, parameter 
values exampled in Table 5-3need to be assigned to R first. It can then create the transition 
matrix of each health state per strategy arm. Refer to  
 
Appendix 5-1 for the entire R code for this step 1. 
 
Step 2. Create cost and utility transition matrices 
Vectoring model inputs   
Constructing transition matrices (probability, costs, utility values) 
Building a Markov model for all UC strategy arm    
Adapting all-UC model for all-TC and Test-Treat arm respectively    
Computing epidemiological outcomes    
Estimating the basecase cost-effectiveness     
Performing sensitivity analyses     





Similarly, the transition matrices for cost and utility values can be prepared using the 
command of Matrix in R. This step is similar to step 2 in a sense that model inputs are 
defined and vectored into the R model.  The detailed R code for this step 2 is provided in 
Appendix 5-2.  
 
Step 3. Building a Markov model for all-UC arm  
Based on the transition matrices set up in the step 1, a Markov trace which a hypothetical 
cohort of patients summing up over time needs to be constructed. In this stage, all 
different scenarios of treatment pathways by different strategy and testing results should 
be respectively constructed as depicted in Figure 5-1 and 5-2. Thus, biomarker related data 
need to be defined and vectored into the R model including biomarker testing accuracy 
and biomarker prevalence. 1000 cycles were assigned to capture the lifetime horizon of all 
patients entered in the model and one cycle is a month in this core model. In other words, 
1000 cycles are equivalent to 83.33 years which is long enough to simulate the model in a 
lifetime horizon. Depending on the progression of disease of interest, the cycle can be 
shortened or lengthened. These model settings can be easily altered according to local 
adaptation requirements.  R code for this step 3 is detailed in Appendix 5-3.   
 
Step 4. Adapting the model for all-TC arm and Test-Treat arm respectively  
This stage is relatively simple. The R code used for all-UC arm in step 3 can be easily 
modified and adapted for both the all-TC and TT arms. This feature is one of the advantages 
of using a script-based program when building health economic models. It can be easily 





dedicated. The cohort trace of patients in the all-TC arm needs to be separated into two 
branches depending on their actual biomarker status because all patients will be treated 
with biomarker-guided therapy however, some of the patients might not be biomarker 
positive and thus the targeted therapy will not be effective for them. The cohort trace for 
the patients in the TT arm needs to be separately constructed for patients truly-tested 
positive, falsely-tested positive, truly-tested negative, falsely-tested negative. Cohort 
simulation commences with a hypothetical cohort of patients (in this core model, it is set 
at 1000; which means a hypothetical cohort of 1000 patients started the model) These 
patients then move or stay in the possible health state according to the transition 
probabilities defined by different treatment scenarios of strategy arms. The simulation 
tracks the cohort from one cycle to the next following the transition probabilities. Refer to 
Appendix 5-4 for the detailed R code of this step 4. 
 
Step 5. Computing epidemiological outcomes 
Epidemiological outcomes of different health states can be computed and plotted in a 
graph using the R code written in Appendix 5-5. Respective cohort trace per strategy arm 
can be plotted as survival curves. For all-TC arm and TT arm, the matrices of cohort 
transition need to be merged before plotting survival curves. Overall survival (OS) 
probability can be separately computed and plotted in OS curve according to different 
strategy arms. Life expectancy can be calculated by summing probability of OS over time.  
 





It is now ready to perform the analysis and estimate the expected values and cost-
effectiveness. In R, the expected values of each strategy can be calculated by processing 
the multiplication of the Markov trace produced in Step 3 and 4 and the transition matrices 
of cost and utility inputs produced in Step 2. The R code for this step 6 is provided in 
Appendix 5-6 with self-explanatory comments in italics. The example base-case ICER 
calculated for this exercise is also provided in Appendix 5-6.  
 
Step 7. Performing sensitivity analyses  
Given that there is uncertainty around parameter values used in the analysis, the base-
case ICER results are left with a question how much confidence can be placed on the results. 
Sensitivity analysis is used to investigate the impact of uncertainty. By testing the impact 
of parameter uncertainty for example on the base-case results, decision makers can 
determine the confidence to be placed on decisions based on the health economic 
modeling analysis. Uncertainty analysis is a standard practice in modeling studies in order 
to assess the uncertainties around parameters and assumptions used in the model. 
Traditionally, researchers reported a range of parameters to assess the impact by altering 
a single parameter value (one-way sensitivity analysis) or a combination of parameters 
(scenario sensitivity analysis) (228). These forms of sensitivity analysis are interchangeably 
called DSA. However, DSA is largely superseded by the use of PSA which tests a range of 
parameters simultaneously followed by the distribution of model parameters inputted 
(228). In Appendix 5-7, it explains how to perform PSA using R as an integral part of 
uncertainty analysis of cancer biomarkers for targeted therapies in addition to the detailed 
R code. In R, the model can be run by the function defined by the modeler (R is known to 





psa.model.run. DSA modeling is similar to that of PSA; refer to supplementary R code for 
DSA simulation (Appendix 5-7).  
In addition to this parameter uncertainty, an analysis of structural uncertainty can be 
performed by adapting this core model. For example, the structure of health states can be 
readily altered considering the natural course of disease progression of interest for local 
adaptation. Currently, three health states (PFS, PD, Dead) were designed as a default 
structure. The number of health states can be added or reduced. Example PSA output 




This paper has introduced a core model which can be adaptable for the user’s analysis to 
her or his specific datasets and requirements in assessing the value of cancer biomarkers. 
This guide demonstrated the model structure of strategy comparisons and data 
requirements relevant to the characteristics of cancer biomarker testing that require to be 
incorporated in the health economic modeling of cancer biomarkers for targeted therapies.  
This paper has also provided a step-by-step guide to carrying out cost-effectiveness 
analysis for biomarker-guided therapies in the state-transition modeling framework and 
has provided R codes in vectoring data inputs, running the simulations, performing survival 
analysis, calculating base-case mean life years/QALYs, and performing sensitivity analyses. 
The user can adapt this core model to develop their own local model applied to his or her 
specific cancer biomarker testing technology and specific jurisdiction of reimbursement 
decision-making. Or, test developers can assess the potential value for money of their 





pertinent model inputs with necessary adaptations and modifications to this core model. 
For example, the user can adapt the structure of health states, the strategy arms to be 
compared against one another, transition probabilities, biomarker specific characteristics, 
cost and utility values, etc. However, for those who need to reconstruct time-to-event data 
from published Kaplan-Meier survival curve as part of building health economic models in 
R, there are two useful tutorial papers providing algorithms for the user to use (229, 230). 
There are a couple of limitations that readers might wish to take into consideration when 
adapting this model for their local ones. First, this core model is constructed based on a 
state transition model and therefore, for those wishing to build a partitioned survival 
model (PSM) might require more time to adapt. However, PSM does not require many of 
modeling techniques as does with the state-transition model. Second, the user is required 
to have some understanding on the concepts of economic evaluations and HTA as well as 
programing in R. Therefore, there is still a programing language barrier for test developers 
to adapt or apply this core model to their data and requirements if the user (e.g. laboratory 
scientists) is not familiar with cost-effectiveness analysis and R coding. It requires some 
intermediate level of R programing/coding and conceptual understanding of economic 
evaluations of health technologies. Third, guiding on how to validate a model was not 
covered by this guide because this study intends to provide a step-by-step guide on how 
to build a model of co-dependent technologies rather than providing a guide to the 
validation of a specific model. Furthermore, this core model is built using ‘exemplary’ data 
inputs (not real dataset) and thus, as Eddy et al guided on the model validation(231), the 
concept of validity should apply to particular applications not to the model itself. Therefore, 
modelers wishing to adapt this core model to their local settings with specific dataset (e.g. 
‘real’ data inputs from clinical trials) and assumptions applied to their specific decision 





model. There are several guidance and checklist published on good practices of model 
validation (231-233).  
A couple of areas can be recommended for further development to this core model. First, 
although the R codes provided in this guide are verified by running the model in R, it was 
not tested, to what extent, this model can be applicable to actual datasets. By applying this 
core model to published economic evaluations of biomarker-guided therapies, the 
generalizability of this model can be further validated. By doing so, it might give more 
insights on what circumstances this core model is adaptable, difficult to adapt or 
unadaptable at all. Second, this core model can be further developed to make it easily 
accessible for those unfamiliar with R. For example, it can be further developed to user-
friendly interface web-based apps using Shiny R package as done by Strong et.al in 
assessing the value of information (234).  
 
6. DISCUSSION  
 
6.1. Research objective  
 
Overall, this thesis sought to explore good practice in economic evaluations (EEs) of cancer 
biomarkers for targeted therapies and to provide a practical guide to conducting the cost-
effectiveness analysis of companion cancer biomarkers. It reviewed modeling approaches 
and biomarker characteristics considered in previous model-based economic evaluations 
and conducted a cost-effectiveness analysis of a novel biomarker (HSP27 expression); 
these studies contributed to the development of a practical guide with a worked example 





First, it aimed to explore how the use of biomarkers affects the cost-effectiveness of the 
corresponding therapies in oncology. Whether or not the integration of biomarker tests 
improved the cost-effectiveness of the corresponding targeted therapies. (First 
objective/Chapter 2) 
Second, it aimed to highlight the current challenges and issues to be overcome to reach a 
consensus on methods and data requirements for EEs of cancer biomarkers. It investigated 
current practice of modeling and incorporating the characteristics of companion 
biomarkers when assessing the cost-effectiveness of biomarker-guided therapies. (Second 
objective/Chapter 3) 
Third, it aimed to apply the study findings to assessment of the cost-effectiveness of an 
actual novel biomarker (HSP27 expression) as part of the EEs of corresponding targeted 
therapy (bevacizumab). The economic model of HSP27 expression was constructed based 
on what I found in previous literature review studies. (Third objective/Chapter 4) 
Fourth, it aimed to provide a practical guide on how to model companion biomarkers when 
assessing the cost-effectiveness of co-dependent targeted therapies. I developed a core 
model with worked examples for readers to adapt. (Forth objective/Chapter 5) 
 
6.2. Key findings  
 
The first objective of this thesis was to explore the impact of companion cancer biomarkers 
on cost-effectiveness of co-dependent targeted therapies; whether the use of biomarker 
tests makes targeted therapies cost-effective or not. The aim was to synthesise and 
critically appraise the cost-effectiveness findings and identify key factors driving the cost-





companion biomarkers improved the cost-effectiveness of co-dependent targeted 
therapies; however, the improvement did not necessarily make targeted therapies cost-
effective. Although the use of companion biomarkers saved some costs by stratifying 
patient groups responsive and unresponsive to the associated drugs, it appeared that the 
saving was not large enough to make targeted therapies cost-effective. Given the indirect 
influence of companion biomarkers, the cost-effectiveness of biomarker-guided therapies 
seemed to be driven by the characteristics of corresponding drugs rather than those of 
companion cancer biomarkers. Especially, high costing drugs continue to struggle to be 
cost-effective despite the integration of companion biomarkers in a cost-effectiveness 
analysis of co-dependent targeted therapies.  
The second objective of this thesis was to review the current practice of modeling 
approaches and biomarker characteristics considered in EEs. This study found that there 
were no consistent modeling methods in assessing the value for money of biomarker-
guided therapies. As an example, the comparative structure of applying strategy arms in 
EEs of companion biomarkers were so varied that it may lead to a different or even 
conflicting conclusion in terms of cost-effectiveness of biomarker-guided therapies. I 
reviewed EEs focusing on ten methods areas deemed to be specific issues and challenges 
faced by test developers when generating evidence of the health economic impact of 
biomarker tests. I found that many studies were not relevant because they conducted EEs 
of companion cancer biomarkers for targeted therapies in specific groups of patients with 
known biomarker status.  
Among the studies included in the review (Chapter 3), all studies included the costs of 
biomarker testing. The most frequently ignored areas were preference-based outcomes, 





of studies considered the prevalence of a biomarker and unknown test result was also 
ignored. Furthermore, a significant challenge was observed in integrating patient 
preference values in EEs of biomarker-guided therapies given the indirect impact of cancer 
biomarkers on patient outcomes. Also, no studies explicitly considered the clinical utility 
of cancer biomarkers in their EEs. It is practically very difficult to generate the evidence of 
clinical value of cancer biomarkers especially when the biomarker is developed 
independently from the corresponding drug because of the indirect impact of biomarkers 
on clinical effectiveness of targeted therapies.  
The third objective of this thesis was to conduct the cost-effectiveness analysis of a novel 
biomarker and assess whether the use of a biomarker test makes the targeted therapy 
cost-effective or not. This analysis also aimed to apply the previous findings from Chapters 
2-3 in the health economic assessment of this novel biomarker, HSP27 expression. This 
study showed that the cost-effectiveness of testing HSP27 expression prior to the 
administration of bevacizumab produced conflicting results depending on the comparator 
strategy used in the analysis, which is in line with findings from previous literature reviews. 
When the intervention strategy was compared against the standard of care without testing, 
it was cost-effective. However, when it was compared against the new therapy without 
biomarker testing, it was not cost-effective. This indicates that HSP27 expression is not 
cost-effective as a predictive companion biomarker for bevacizumab in treating patients 
with metastatic melanoma. This may not necessarily mean that HSP27 expression is a bad 
biomarker for bevacizumab, but rather bevacizumab is in any case much better than 






The fourth objective of this thesis was to provide a practical guide to the methods of 
modeling companion biomarkers for targeted therapies in cancer. It showed solutions to 
resolve the modeling challenges and specific issues faced by test developers when 
assessing the cost-effectiveness of cancer biomarkers.  This practical guide provided a step-
by-step guide along with a core model for test developers to adapt for local requirements. 
This core model reflected the findings from previous literature reviews. For example, the 
previous literature review studies (Chapters 2 and 3) on modeling approaches of 
companion cancer biomarkers suggested some solutions to constructing the comparative 
analysis by employing the strategy of ‘treat-all with standard care’ as a baseline 
comparator arm rather than using the ‘treat-all with new therapy’. The entire patient 
population should be considered including biomarker positive, negative and even 
unknown patient groups rather than only focusing on a pre-selected group of patients with 
a specific confirmed biomarker status. Furthermore, model inputs relevant to cancer 
biomarker testing should be all captured and incorporated in EEs of biomarker-guided 
therapies. Based on the previous findings, a worked example of core model was developed 
with step-by-step guide for test developers to use.  
 
6.3. Study limitations  
 
There are of course some limitations that I would like my audience to take into 
consideration when interpreting the findings of my studies and adapting my core model 
developed as part of my PhD thesis. First, the literature review of current practice in 
economic evaluations of companion cancer biomarkers (Chapter 3) was restricted to 





However, given that it aimed to review current practice of EEs in terms of modeling 
methods and data requirements, 5 years considered to be long enough to capture all 
recent EEs of companion biomarkers for targeted cancer biomarkers. Furthermore, 5 years 
was chosen in order to exclude any out-of-date approaches not applicable to current 
practice.  
Second, the systematic literature review to see whether or not the use of companion 
biomarkers improves the cost-effectiveness of the corresponding targeted therapies 
(Chapter 2) was conducted for biomarker-guided therapies in metastatic colorectal cancer. 
It did not encompass all biomarker-guided therapies in cancer for the practical reason of 
conducting the study within the limited time of my PhD research. Therefore, the findings 
from this review might not necessarily be applicable to other cancer areas of biomarker-
guided therapies. For example, if the cancer drug costs are reasonably priced from the time 
of reimbursement and market access, the cost-effectiveness of biomarker-guided 
therapies would not be necessarily driven by the high drug cost.  
Third, the cost-effectiveness analysis of HSP27 expression prior to the administration of 
bevacizumab (Chapter 4) was conducted in order to explore the applicability of the findings 
from the two literature reviews on an actual candidate biomarker on top of the aiming to 
inform the cost-effectiveness of HSP27 expression testing. However, this analysis was 
challenged by the robustness of early stage clinical evidence. For example, the clinical data 
used in the analysis were based in a small-sized phase II single arm study and no head-to-
head trial existed generated from a large-scale phase III randomized clinical study. 
However, this study assisted in informing me of practical challenges and issues faced by 
test developers who would mostly experience similar challenges with candidate 





the early stage of technology development process so that their candidate biomarker tests 
can have better chance to be ensured of reimbursement and coverage by payers.  
Fourth, although the core model and the step-by-step guidance (Chapter 5) were 
developed in order to ease the process of developing a health economic model for cancer 
biomarkers for test developers who may not necessarily health economic modelers. 
However, it still requires a certain level of understanding in EEs of health technologies and 
the basic concepts of economic modeling in order for the user to follow the guide together 
with the operation of core model. Furthermore, the user is required to have at least 
intermediate level of R coding to adapt this core model to local models to their needs using 
their own data and following local HTA requirements. Given R is a script-based 
programming language, the user needs to be able to understand the R scripts. However, 
this limitation can be resolved by further developing this core model to user-friendly web-
based interface apps for example, using Shiny R.  
   
6.4. Policy implications and evaluation recommendations   
 
The thesis findings provide some policy implications and recommendations in assessing 
the value for money of companion biomarkers for targeted cancer therapies in the light of 
making reimbursement decisions of health technology assessment.  
▪ The results suggest that there is no consistency and/or consensus when it comes 
to the modeling approaches in the health economic assessment of cancer 
biomarkers as part of the evaluation of corresponding therapies. It is 
recommended to fully capture the clinical and economic value of biomarker testing 





▪ My literature review shows that cost-effectiveness analysis can produce conflicting 
results depending on the modeling approaches taken in the health economic 
assessments of biomarkers. For example, the review of mCRC therapies found that 
the use of different comparator arms led to conflicting cost-effectiveness results 
for the corresponding therapies. Therefore, it is recommended to reach a 
consensus on modeling methods and data requirements in assessing the value for 
money of companion biomarker tests as an integral part of that of co-dependent 
targeted therapies.  
▪ My cost-effectiveness analysis of HSP27 expression suggests that testing HSP27 
expression prior to the administration of bevacizumab in treating patients with 
metastatic melanoma is not cost-effective. It has saved some costs and contributed 
to improving the cost-effectiveness of bevacizumab, however, the saving was not 
sufficient to make a targeted bevacizumab strategy cost-effective. Furthermore, 
the EVPI analysis suggests further research costs  cannot be  justified to generate 
more evidence for assessing the test-treat strategy against the treat-all with 
dacarbazine; however some health gains might be possible by reducing the 
uncertainties around the comparative analysis of test-treat strategy against the 
treat-all with bevacizumab. Yet, the upper bound of research costs generated by 
EVPI analysis was too low for the Norwegian setting.  
▪ Given the nature of indirect impact of companion biomarkers on the clinical 
effectiveness and cost-effectiveness of biomarker-guided therapies, test 
developers face challenges in generating evidence for reimbursement decisions. 
Some clarity on methods and evidentiary standards of health economic 





on evidentiary requirements for incorporating the characteristics of companion 
biomarkers need to be established and guided.    
▪ National reference cost database for laboratory tests including companion 
biomarker tests needs to be established. The price of medical devices including 
biomarker testing kits/diagnostics is often set by negotiations between test 
developers and hospitals or set freely by individual laboratories.  Therefore, it is 
likely to exist large variations in costing biomarker tests in EEs of biomarker-guided 
therapies even within the same jurisdiction. Furthermore, biomarker-guided 
therapies would require EEs to include a much wider range of cost items and more 
frequently than that of non-guided therapies; for example, capital costs or upfront 
infrastructure costs related to biomarker testing. Reimbursement decision makers 
need to clearly guide test developers on specific cost items to be included when 
assessing the value for money of companion biomarkers for targeted cancer 
therapies.  
  
6.5. Contributions of this study to the field  
 
The thesis contributes to the field of health economic assessments of companion 
biomarkers for targeted cancer therapies in several ways.  
▪ First, it identifies current practice and describes inconsistent approaches to 
modeling companion biomarkers when evaluating the cost-effectiveness of 
biomarker-guided therapies in oncology.   
▪ Second, it recommends possible solutions to the modeling approaches and data 





targeted cancer therapies. The thesis findings can be a useful starting point to the 
development of methods guide in modeling companion biomarkers for co-
dependent targeted therapies or in health technology assessment for biomarker-
guided treatments.   
▪ Third, it guides test developers or modelers wishing to assess the value for money 
of companion cancer biomarkers at an early stage of technology development. The 
core model provided in this thesis can be adapted by the user to their specific 
decision problem and specific data requirements.  
▪ Fourth, it provides a step-by-step guide with example data and scenarios that have 
been developed based on the previous findings (Chapter 2-4). This thesis highlights 
good practice by constructing an economic model of companion cancer biomarkers 
which considers all biomarker-related parameters and scenarios.  
 
6.6. Areas for further research adding to previous studies 
 
A number of studies have previously addressed the challenges in evaluating co-dependent 
technologies, although some of these papers were not necessarily focusing on companion 
cancer biomarkers per se.  While the scope of these studies is broader than that of my own 
work with respect to modeling the characteristics of companion biomarkers in economic 
evaluations of guided cancer therapies, some of their findings have raised similar issues.  
Faulkner et al. (13) raised issues from payer and manufacturer perspectives. They 
identified five key areas to improve in evaluating personalised medicine. They suggested 
that health economic models should no longer compare a new medicine and an existing 





suggested that the rate of false positives and false negatives, as well as their respective 
consequences, should be considered in the model. They then highlighted evidence gaps, 
such as whether the QALY is the best metric for personalised medicine, and clinical 
evidence when the diagnostic was developed as a stand-alone test rather than being co-
developed with therapy. These aspects were similarly identified in my work however, my 
research suggested modeling three strategy arms instead of two, so that the ‘test-treat’ 
intervention strategy is  compared with ‘treat-all with existing care’ and ‘treat-all with new 
therapy’ options.  
Annemans et al. (122) presented ten methodological issues that arise when modeling 
personalised medicine. Similarly to my finding with respect to the current practice of 
modeling the characteristics of companion biomarkers, their paper also discussed the 
importance of capturing the clinical utility of the test. They argued that it is vital to evaluate 
the added value of a companion diagnostic test to its co-dependent therapy. They note 
that the correct reporting of sensitivity and specificity is a key element in modelling 
companion diagnostics however, information for patients with false negative and false 
positive test results is often lacking, which is in line with Faulker et al (13). In addition, 
combined use of different tests can lead to more complex models, which potentially causes 
a higher degree of uncertainty in the assessment. Also, as with my study, data gaps were 
found especially for key epidemiological data such as the prevalence of the biomarker or 
mutation in the population. They suggested performing early population-level simulations 
which can aid the identification and collection of critical data inputs. This early economic 
modeling can inform the manufacturer ‘go’ or ‘no-go’ or research priority setting decisions 
for co-dependent technologies such as companion biomarkers for targeted therapies in 





useful as a step-by-step guide for the test developers and manufactures to adapt for their 
specific decision problems and country-specific settings.  
Several studies performed systematic literature reviews to identify and analyse current 
methodological characteristics and approaches in evaluating genetic testing technologies. 
First, Assasi et al.(235) systematically reviewed HTA reports on genetic tests. The study 
scope investigated in this review was broader than my own research. They included 
diagnostic, preventive genetic tests, prognostic, predictive or genetic tests guiding 
treatment. Only three of the fifteen studies identified involved predictive testing of the 
response to treatment. However, similar methodological challenges were found in this 
review such as adopting a third-party payer perspective (rather than a social perspective) 
or failing to capture the full range of outcomes and costs of testing technologies. However, 
since this review included diagnostic and preventive screening, the need to consider long-
term psychological and social impacts were more pronounced in this study than mine and 
accordingly, more comprehensive frameworks were suggested for the evaluation of 
genetic testing technologies. 
Second, Shabaruddin et al.(6) identified six existing systematic reviews of economic 
evaluations of genetics-and genomics-targeted technologies as examples of personalised 
medicine. They discussed existing challenges and summarised the data requirements of 
health economic assessments of pharmacogenetic technologies. The key data required 
were clinical effectiveness and utility, changes in health status, and resource use and 
associated costs, and the uptake of the test. Regarding issues specific to companion 
diagnostics, this study suggested that evidence that the testing improves patient outcomes 
is needed. However, generating the evidence for improved health outcomes is not always 





of their co-dependent therapeutic agents, it can be assumed that their clinical utility is 
already reflected in the clinical evidence for the corresponding therapies. Otherwise, it is 
difficult to show the clinical utility of companion biomarkers in clinical practice given that 
the patient outcome of the combined test-therapy intervention is expressed in the clinical 
outcome of therapy. In other words, the clinical utility of companion biomarker tests is 
indirectly expressed in the patient outcome of their co-dependent therapies. Therefore, 
the clinical value of companion biomarker tests is often limited to the testing accuracy 
(clinical validity expressed in sensitivity and specificity) as I found in my research work.  
Oosterhoff et al. (147) also conducted a systematic review on recent economic evaluations 
of diagnostic biomarkers and examined whether these studies dealt with specific issues 
related to the characteristics of diagnostic biomarkers. This review suggested that the 
incorporation on non-health outcomes and patient preferences is crucial to fully capture 
the potential value of diagnostic biomarkers. However, this study covered a wide range of 
biomarker tests including diagnosing, staging diseases, and guiding treatment. Despite the 
broad scope of their search, the number of papers identified appears to be low. 
Interestingly, this review suggested incorporating personal utility assessed by non-health 
outcomes, for example, the utility of diagnostic information (‘value of knowledge’) in 
genetic testing of relatives, or the discomfort experienced by patients while undergoing 
the test (process utility). It appears that genetic testing technologies require a broader 
definition of health utility, such as potential benefits to family members and relatives, 
knowledge to be informed of heritable disease, or preventive treatment decision-making.  
However, Buchanan et al. (236) found that non-health outcomes have limited applicability 
as standard outcome measures to be considered in economic evaluations, and alternative 





data was weak, posing challenges to incorporating them in standard economic analyses. 
The authors continued with a similar argument about measuring the outcomes of genomic 
sequencing technologies in their recent publication (237). Similar to my research, they also 
raised the issue that the metrics currently recommended by HTA agencies (e.g. EQ-5D 
instrument) may not capture patient health outcomes, such as patient wellbeing before 
and after undergoing genomic sequencing technologies. Although the study scope of 
testing technologies investigated in this review was broader than my work, it also 
highlighted that the issue of not being able to capture the added value of testing needs to 
be further studied and a consensus needs to be reached in the field of health economics 
and HTA agencies.   Husereau et al. (238) reviewed current Canadian approaches in 
evaluating personalised medicine, employing the methods of literature review and 
informal interviews with ten experts. They identified specific issues using the framework 
of the Canadian evaluation guideline and discussed some solutions to the issues identified. 
Their solutions include improving guidance on accurate valuation of testing costs (fixed, 
variable and other costs), defining interventions/comparators aligned with the rapid 
evolution of clinical pathways (e.g. test sequences combined with treatment may lead to 
multiple strategies), and further research on population preference heterogeneity and 
standards for disutility from harm. This study also suggested improving current guidelines 
for the economic evaluation of personalised medicine interventions in Canada. The expert 
interviews reached a consensus that a new paradigm will not be required but that 
personalised medicine requires more complex analyses. Similarly, Rogowski et al. (239) 
found that the principles and methods of current economic evaluations are appropriate 
for personalised medicine especially in oncology. However, some methods are under-





assessing the health economic value of co-dependent technologies identified in this thesis 
has also been identified by other studies (13, 122).  
Adding to these previous studies, the studies presented in this thesis expand our 
understanding and knowledge of current practices and of the challenges faced by test 
developers in conducting economic evaluations of companion biomarkers for targeted 
cancer therapies in terms of modeling methods and data requirements. However, further 
efforts are required to make a consensus in the field of health economics, especially 
regarding how to measure and appraise preference-based utilities for biomarker testing. 
Further research is required to capture the full value of biomarkers particularly given the 
indirect impact of companion biomarker tests on patient benefits.  
First, the current metrics for the measurement and valuation of health outcomes do not 
necessarily allow capturing the full value of patient preferences of companion biomarkers 
given their indirect impact on patient benefits. Further research is required to develop the 
methods on how to capture the full spectrum of patient benefits derived from biomarker 
tests and measure them appropriately.  
Second, building on the findings of this thesis, further research is required to reach a 
consensus among experts and stakeholders including payers and patients with regard to 
best practice when evaluating the value for money of companion cancer biomarkers. We 
can then develop a methods guide on modeling approaches and data requirements when 
modeling companion biomarkers as part of economic evaluations of co-dependent 
targeted therapies based on the consensus reached among stakeholders.  Furthermore, 
there is the issue of how to deal with biomarkers that are not cost-effective at even a zero 






Third, it is required to revisit the current practice of HTAs of diagnostics/devices and 
pharmaceutical drugs which are currently being implemented in isolation from each other 
in many countries. With the advent of co-dependent health technologies such as 
biomarker-guided therapies, it gives rise to the need of integrating the HTA methods and 
procedures of the devices and the drugs rather than implementing them in isolation.  
Fourth, an urgent area of further research concerns the evidence generation of clinical 
outcomes or clinical utility of biomarker tests. Currently, the clinical evidence on biomarker 
testing is limited to the performance accuracy (e.g. sensitivity and specificity). There is no 
consensus on the good practice for measuring and generating the clinical effectiveness of 
biomarker tests. For example, an enrichment trial design could be one of the potential 
solutions to this challenge however, this study design has limitations in generating clinical 
evidence for biomarker negative patients.  
Lastly, from the practical point of view, extending my core model with an R package of 
Shiny would benefit decision-makers, health economists, or test developers who are not 
familiar with R coding. R Shiny would lower the barrier to using the core model even if 
users are not familiar with R coding.  
In addition, beyond what I have done, there are other types of studies that can be built 
upon and further investigated for future research. First, systematic literature review is 
recommended to search all available methods guide on co-dependent technologies or 
test-guided therapies. I have provided two example guides (Australia and Scotland); 
however it would be clearer to find out if there are more methods guide researched by 
conducting a systematic review. It can then provide a comprehensive body of literature 
with all available methods guide for co-dependent technologies. It can then provide a solid 





requirements were addressed, etc. Second, built upon what found in the systematic review 
(as mentioned above), a consensus among stakeholders and experts can be pursued. I have 
also provided a framework of key items to be addressed in incorporating the 
characteristics of companion biomarker tests in economic evaluations of their 
corresponding test-guided therapies. Thus, a group consensus in methodological 
approaches and evidentiary standards for assessing the value for money of test-guided 
therapies can be made using consensus methods such as Delphi and nominal group (240). 
These studies can be performed built upon what I have reached and found. The studies 
done in my PhD and the systematic literature review on existing methods guide on co-
dependent technologies can equip participants with the best available information and a 
structured environment for problem solving in reaching a consensus on methodological 
approaches and data requirements for health economic evaluations for companion 
biomarkers and test-guided therapies.  
 
6.7. Conclusion  
This thesis found that no consistency and consensus existed to the methods of existing 
economic evaluations of companion cancer biomarkers for targeted therapies. It was also 
shown that conflicting cost-effectiveness results were likely depending on what 
comparator arm was chosen and what comparison structure was designed in the model. 
My modelling study on a candidate companion biomarker test (HSP27 expression) for 
bevacizumab inferred the same; for example, the intervention strategy with new therapy 
(test-treat strategy) was cost-effective against treat-all with SOC however it was not cost-
effective against treat-all with new therapy. Furthermore, this thesis highlighted good 





tests as an integral part of cost-effectiveness analysis of biomarker-guided targeted 
therapies. Also, a core model was developed and provided with worked examples and 
step-by-step tutorials, applying best practice solutions and modelling practicality acquired 
throughout the entire research phases in this thesis.  
Based on the results of my PhD research, I want to see changes in the methods guide for 
the assessment of companion biomarkers for economic evaluation of targeted therapies 
in cancer. To be more specific, I would like to see the introduction of a methods guide for 
biomarker-guided therapies (e.g. companion biomarkers for targeted therapies) instead of 
applying different evaluation methods guide for drugs and diagnostics in isolation. As 
found in my research, there was inconsistency in incorporating the characteristics of 
companion biomarkers in the economic evaluation of targeted therapies and in structuring 
the comparative analysis between intervention and comparator arms. We need to reach a 
consensus on the methods of evaluating companion testing technologies as part of 
economic evaluations of their corresponding test-guided therapies. Built upon the 
consensus made, a methods guide for co-dependent technologies needs to be introduced, 
providing a coherent and unified guidance on good practices, reference case, evidentiary 
standards and data requirements for modelling the characteristics of companion 
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APPENDIX 2-1 :  SEARCH TERMS  
(SEARCHED JUNE 25, 2018) 
Database: EMBASE via Ovid 
1 exp biological marker/ 
2 biomark*.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading] 
3  (molecul* mark* or tumo?r mark* or biologic* mark* or signature molecule*).mp. [mp=title, 
abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword, floating subheading] 
4 (cetuximab or Erbitux* or panitumumab or Vectibix* or bevacizumab or avastin* or aflibercept or 
ziv-aflibercept or zaltrap* or regorafenib or stivarga* or ramucirumab or cyramza* or  irinotecan 
or campto*).mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading] 
5  (target therap* or targeted therap* or personali#ed medicine* or companion diagnostic* or 
precision medicine* or codependent technolog*).mp. [mp=title, abstract, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, 
floating subheading] 
6 exp economic evaluation/ 
7 ((cost* adj3 effective*) or (cost* adj3 benefit*) or (cost* adj3 utilit*) or willingness to pay or net 
benefit*).mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading] 
8  (econom* adj3 evaluation*).mp. [mp=title, abstract, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading] 
9  exp colon tumor/ 
10 1 or 2 or 3 or 4 or 5 
11 6 or 7 or 8 
12 9 and 10 and 11 
 
Database: MEDLINE via Ovid 
1 exp Biomarkers/ 
2 biomark* 
3 molecul* mark* OR tumo?r* mark* OR biologic* mark* OR signature molecule* 
4 exp Clinical Laboratory Techniques/ 
5 diagnos* 
6 cetuximab or Erbitux* or panitumumab or Vectibix* or bevacizumab or avastin* or aflibercept or 






7 target therap* or targeted therap* or personali#ed medicine* or companion diagnostic* or 
precision medicine* or codependent technolog* 
8 1 or 2 or 3 or 4 or 5 or 6 or 7 
9 exp Cost-Benefit Analysis/ 
10 econom* adj3 evaluation* 
11 (cost* adj3 effective*) or (cost* adj3 benefit*) or (cost* adj3 utilit*) or willingness to pay or net 
benefit* 
12 9 or 10 or 11 
13 exp Colorectal Neoplasms/ 
14 (colorectal or colon or colonic or bowel or rectum or rectal or intestin*) and (cancer* or tumo?r* or 
neoplasm* or carcinoma*) 
15 13 or 14 
16 8 and 12 and 15 
 
Database: EconLit via Ovid 
1 (biomark* or molecu* mark* or tumo?r mark* or biologic* mark* or signature molecule*).mp. 
[mp=heading words, abstract, title, country as subject] 
2 (target therap* or targeted therap* or personali#ed medicine* or companion diagnostic* or 
precision medicine* or codependent technolog*).mp. [mp=heading words, abstract, title, country 
as subject] 
3 ((colorectal or colon or colonic or bowel or rectum or rectal or intestin*) and (cancer* or tumo?r* 
or neoplasm* or carcinoma*)).mp. [mp=heading words, abstract, title, country as subject] 
4 1 or 2 or 3 
 
Database: NHSEED 
1 (biomarker*)  
2 MeSH DESCRIPTOR Biomarkers EXPLODE ALL TREES IN NHSEED 
3 MeSH DESCRIPTOR Clinical Laboratory Techniques EXPLODE ALL TREES IN NHSEED 
4 (diagnos*) IN NHSEED  
5 #1 OR #2 OR #3 OR #4 
6 MeSH DESCRIPTOR Colorectal Neoplasms EXPLODE ALL TREES IN NHSEED 





APPENDIX 2-2 :  PICOS INCLUSION AND EXCLUSION CRITERIA  
PICOS Inclusion Criteria Exclusion criteria 
Population Adult patients (>= 16 years) treated 
with metastatic CRC 
Patients < 16 years 
Diagnosed mild CRC 
No diagnosed CRC 
Intervention Cancer biomarkers for targeted 
therapies. Companion biomarkers 
licensed with corresponding 
targeted therapies  
No diagnostic biomarker  
Universal screening tools 
Triage procedures 
Severity or progression analyses 
Comparators Targeted therapies with or without 
biomarkers 
No comparative treatment 
Surgery 
Outcomes ICER, ICUR Only costs or effectiveness 
Study types Economic evaluations (model or trial 
based CEA, CUA, CBA) 
Cost-minimization analysis 
No economic evaluations. 
Published only as an abstract without 
reporting any outcomes. 
Publications reporting merely on 
methodological issues, reviews, comment 
letters and editorials. 
Abstracts reported elsewhere -  this 
criterion should only be applied if the 
numerical values are the same in the full 
publication.  





APPENDIX 2-3 :  OVERVIEW OF INCLUDED STUDIES  
Study Country Perspective Time horizon Type of 
modeling 






Belgium HCS not reported Trial-based 
model 
3 strategies NR Euro, NR NR FT 
Asseburg 
2011 
Germany HCS 10-year Patient-level 
simulation 
2 strategies 5% Euro, 2010 Commercial 
resource 
FT 





HCS Lifetime Markov model 4 strategies 3% Euro, NR Academic 
resource 
FT 
Butzke 2016 Germany HCS Lifetime Markov model 3 strategies 3% Euro, 2013 Public 
resource 
FT 
Carlson 2010 USA Payer perspective NR Unclear 3 strategies NR US$, NR NR AB 





USA Societal perspective Lifetime Markov model 2 strategies 3% US$, NR NR AB 
Davari 2015 Iran Iranian health care market Unclear/Not 
reported 
Unclear 6 strategies NR US$, NR NR FT 
Dos Santos 
2015 
Brazil Brazilian private healthcare 
system 
Lifetime Markov model 2 strategies 5% Brazil local 
currency, 2014 
NR AB 
Ewara 2014 Canada 
Ontario 
HCS Lifetime Markov model 3 strategies 5% CA$, 2012 Academic 
resource 
FT 


















Graham 2016 USA Third party payer Lifetime semi-Markov 
model 











NHS Wales 10-year horizon Markov model 6 strategies 3.5% GB£, NR NR AB 
Hnoosh 2015 
(NICE) 
UK NHS 10-year Markov model 4 strategies 3.5% GB£, NR NR AB 








Huxley 2017 UK NHS NICE 30 years (lifetime) Semi-Markov 
model  









Brazil Public healthcare system 10 years Markov model 2 strategies 5% BRL, 2014 NR AB 










Markov model 4 strategies 4% (NL), 3%(BL) for 
costs and 1.5% for 
effect 
Euro, NR NR AB 
Lawrence 
2013 
Canada Healthcare system Lifetime (to 
maximum of 10 
years) 














2 strategies Discounting not 
applied given the 
short time horison 
CA$, 2007 No external 
funding 
FT 
Moreno 2012 Spain not reported not reported Unclear 3 strategies NR Euro, NR NR AB 
Niedersuess-
Beke 2015 
Austria HCS Not reported Unclear 2 strategies NR Euro, 2013 NR AB 
Norum 2006 Norway third party payer Unclear Decision tree 2 strategies Not discounted 
because all 
benefits and costs 
occurred within a 
few months. 

















USA Not reported Lifetime Unclear 2 strategies NR US$, 2013 NR AB 
Pichereau 
2010 





Canada Canadian public health 
care system 
5-year Markov model 3 strategies 5% CA$, 2012 Commercial 
resource 
FT 




2 strategies 3% Euro, 2015 Commercial 
resource 
FT 
Saito 2017 Japan Japanese healthcare payer 5-year Markov model 3 strategies 2% JPY, NR NR FT 
Samyshkin 
2011 
UK UK NHS Lifetime semi-Markov 
model 







USA Payer perspective 2 years (trial 
period) 
Decision tree 2 strategies 0% US$, 2013 Commercial 
resource 
FT 
Shiroiwa 2010 Japan Healthcare payer 2.5 years Markov model 3 strategies 3% US$, 2010 Commercial 
resource 
FT 
Souza 2017 Brazil Public health system 
perspective 
20 years Markov model  2 strategies  5%  BRL, NR Commercial 
resource  
AB 
Starling 2007 UK NHS perspective  Lifetime Trial-based 
model 





Columbia Not reported Lifetime Markov model 2 strategies 
 












Wen 2015 China HCS 10 years (almost 
lifetime; all nearly 
dead) 
Markov model 4 strategies 3% US$, 2014  No funding FT 
Wu 2017 China Chinese medical insurance 
perspective 
10 years  Markov model 3 strategies  5% US$, 2016  Public 
resource  
FT 
Xu 2016  USA HCS (Medicare, Veteran) 3 years Markov model 2 strategies 3% US$, 2015 NR AB 
Zhou 2016 China Societal perspective 
(because travel fees and 
absenteeism fees 
constituted the indirect 
costs). However, the paper 
stated that it used Chinese 
HCS perspective 
Lifetime Markov model Two analyses 
performed. 
Analysis 1: 4 
strategies; 
Analysis 2: 4 
strategies 
3% US$, NR No funding FT 










ICER (/LYs) ICER (/QALYs) Conclusion based on outcome 
Anneman
s 2007 
1. Cmab + Irinotecan (6-week 
rule, 12 week rule) 
2. Current treatment 
NS LYs 1. Cmab + Irinotecan (6-week 
rule): £16766 
2. Cmab + Irinotecan (12-week 
rule): £40273 




1. Cmab + FOLIFIRI  
2. Bmab + FOLFOX 
KRAS LYs Cmab+FOLFIRI: €15,020 
compared to Bmab + FOLFOX 
- First line treatment with Cmab plus FOLFIRI 
offers a cost-effective treatment option 
versus Bmab plus FOLFOX for KRAS WT 
genotype pts in Germany. Thus, KRAS testing 
should be performed on all presenting cases 
of mCRC to ensure access to this treatment 
option. 
Behl 2012 1. No Cmab 
2. KRAS and BRAF testing + 
Cmab 
3. KRAS testing + Cmab 
4. Cmab without testing 
KRAS,  
BRAF 
LYs KRAS and BRAF testing + Cmab: 
US$648,396* 
KRAS testing + Cmab: 
US$672,216* 
Cmab without testing: 
US$827,913* 
- Screening for KRAS and BRAF improves the 
cost-effectiveness of Cmab. However, ICERs 
remain above the generally accepted 
threshold. Although we cannot confirm that 
Cmab is a cost-effective use of healthcare 




1. No test, no Cmab 
2. KRAS/BRAF testing  
3. KRAS testing 
4. No test, Cmab all 
KRAS,  
BRAF 
QALYs 1. no test, no Cmab (reference 
strategy): dominated 
2. KRAS/BRAF testing: euro 
62,653 compared to the 
reference strategy 
- Testing for KRAS and BRAF mutations prior 
to Cmab treatment of chemofractory mCRC 
patients is clinically appropriate and 
economically favorable, despite high costs 





3. KRAS testing: euro 313,537 
compared KRAS/BRAF testing  
4. No test, Cmab all: euro 




Strategy 1. dose reduction (WT 
receive standard dose of 
irinotecan, hetero-and 
homozygotes receive a dose 
reduction of irinotecan by 
25%) 
Strategy 2. prophylactic 
administration of bone marrow 
proective GCSF growth factor 
analogs (all pts receive 
standard dose of irinotecan, 
hetero-and homozygotes 
additionally receive the growth 
factor 'pegfilgrastim') 
Strategy 3. no genetic test (all 




QALYs - Genetic test + irinotecan (dose 
reduction): dominant over two 
other strategies. 
UGT1A1 testing and dose reduction is more 
effective, and cost-saving compared to the 
current standard of no-testing. UGT1A1 
testing prior to irinotecan-based 
chemotherapy dominates non-personalized 




1. Cmab alone 
2. BSC 
3. KRAS testing plus Cmab for 
KRAS WT pts and BSC for KRAS 
MT pts 
KRAS QALYs Cmab for all : $357,224 compared 
to BSC 
KRAS testing + Cmab : $264,644 
- Use of KRAS testing to select pts for Cmab 
can reduce costs with a negligible impact on 
QALYs as compared to using Cmab for all 
pts. However, the CE of KRAS testing vs. BSC 











RAS LYs 1. Pmab: US$52772 
2. Cmab: US$58240 
- Both Pmab and Cmab are not cost-effective 
in patients with RAS WT mCRC  
Chaugule 
2012 
1. Cmab + BSC 
2. BSC alone 
KRAS QALYs - Cmab + BSC: US$ 313,113 
compared to BSC 
Cmab is not cost-effective in KRAS WT pts 
with mCRC    
Davari 
2015 
1. FOLFIRI, FOLFOX, CAPOX 
without the addition of Cmab 
2. FOLFIRI, FOLFOX, CAPOX 
with the addition of Cmab 
KRAS LYs, QALYs 1. FOLFIRI vs. FOLFIRI+Cmab 
$654846 
2. FOLFOX vs. FOLFOX+Cmab 
$458113 
3. CAPOX vs. CAPOX+Cmab 
$461989 
1. FOLFIRI vs. FOLFIRI+Cmab 
$859756 
2. FOLFOX vs. FOLFOX+Cmab 
$1588143 
3. CAPOX vs. CAPOX+Cmab 
$1567786 
Addition of Cmab to FOLFIRI, FOLFOX, 






1. Pmab + mFOLFOX6 
2. Bmab + mFOLFOX6 
RAS LYs, QALYs 1. Pmab + mFOLFOX6 vs. Bmab + 
mFOLFOX6 : 25,798 BRL per LYs 
gained 
1. Pmab + mFOLFOX6 vs. Bmab + 
mFOLFOX6 : 34,960 BRL per QALYs 
gained 
Pmab is clearly cost-effective compared to 




1. Bmab + FOLFIRI 
2. Cmab + FOLFIRI 
3. Pmab + FOLFIRI 
KRAS QALYs - 1. Bmab + FOLFIRI : Dominant 
2. Cmab + FOLFIRI : Dominated 
3. Pmab + FOLFIRI : Dominated 
Bmab+FOLFIRI is cost-effective. Bmab + 
FOLFIRI found to be dominant over the other 
two strategies. The other two strategies are 
dominated by Bmab + FOLFIRI. However, 
sensivitiy analysis showed that Cmab + 
FOLIFIRI is being cost-effective under certain 
range of parameter values - thus, further 
investigation needed for Cmab. 
Gold 2009 1. Usual care: all pts receive a 
standard intermediate dose of 
irinotecan. 




QALYs - Genetic testing + Irinotecan : 
Dominant compared to no testing 
strategy 
Pharmacogenetic testing for UGT1A1*28 
variant homozygosity may be cost-effective, 
but only if irinotecan dose reduction in 
homozygotes does not reduce efficacy. 













LYs, QALYs Pmab : €26,918 Pmab : €36,577 Pmab plus mFOLFOX represents good value 




1. Panitumumab in pts with 
KRAS WT status 
2. Cetuximab in pts with KRAS 
WT status 




Compared to Cmab, the study suggested 








QALYs - 3 cohorts compared 
ITT (intention-to-treat) group: 
£130,929 
KRAS WT group: £72,053 
RAS WT group: £44,185 
RAS WT group showed the lowest ICER and 











RAS QALYs - Cmab + FOLFOX £29,512 
compared to FOLFOX alone. 
Cmab + FOLFIRI £35,731 compared 
to FOLFIRI alone. 
Cmab is cost-effective and a good use of 
NHS Wales resource through stratification of 










RAS QALYs - Cmab+FOLFOX: £46503 compared 
to FOLFOX alone 
Cmab+FOLFIRI: £55971 compared 
to FOLFIRI alone 
Cost-effectiveness of Cmab could be 





2. Cmab + Irinotecan  
3. Pmab 
4. BSC 
KRAS LYs, QALYs 1. Cmab £72,000 compared to 
BSC 
2. Cmab + Irinotecan £64,000 
compared to BSC 
1. Cmab £95,000 compared to BSC 
2. Cmab + Irinotecan £88,000 
compared to BSC 
All three strategies (Cmab, Cmab+Irinotecan, 





3. Pmab £153,000 compared to 
BSC 




1. FOLFOX (reference strategy) 
2. Cmab + FOLFOX 
3. Pmab + FOLFOX 
RAS QALYs - Cmab+FOLFOX vs. FOLFOX : 
£104205 per QALYs gained 
Pmab + FOLFOX vs. FOLFOX : 
£204103 per QALY gained 
Cmab and Pmab in combination with 






1. Cmab + FOLIFIRI 
2. FOLFIRI 
RAS LYs   BRL 66090.91 - Cmab+FOLIFIRI is cost-effective for a 









RAS LYs Cmab+FOLFIRI: dominant, cost-
saving  
- The use of Cmab shown significant and 
meaningful benefits while being cost-saving 




1. Pmab + FOLFOX6 
2. Bmab + FOLFOX6 
RAS QALYs    - 1. Pmab + FOLFOX6 : €34,644 
compared to Bmab + FOLFOX6 
Pmab + mFOLFOX6 is cost-effective. 
Krol 2015 
(Abstract) 
1. Cmab + FOLFIRI 
2. FOLFIRI 
3. Cmab + FOLFOX  
4. FOLFOX 
RAS QALYs - 1. 86180euro (NL) and €55430(BL) 
for Cmab + FOLFIRI vs. FOLFIRI 
ICUR results were close to CET. ICURs 
strongly differed from NL and BL. It is mainly 




2. Bmab + FBC 
3. Cmab + FBC 
4. Pmab + FBC 
KRAS QALYs - FBC     - 
Bmab + FBC : CA$131,600  
Pmab + FBC : Dominated 
Cmab + FBC : CA$3,844,571 
Bmab + FBC offers the best value for money 







1. Cmab + BSC 
2. BSC 
KRAS LYs, QALYs 1. For unselected mCRC pts, 
Cmab+BSC: CA$199,742 
compared to BSC.  
2. For KRAS WT pts, Cmab + BSC: 
CA$120,061 compared to BSC. 
1. For unselected mCRC pts, Cmab 
+ BSC : CA$299,613 compared to 
BSC.  
2. For KRAS WT pts, Cmab+BSC: 
CA$186,761 compared to BSC. 
ICER of Cmab over BSC alone for unselected 
mCRC pts was high and sensitive to drug 
costs. ICER was lower when the analysis was 




1. Scenario A: KRAS WT pts 
receive weekly Cmab + FOLFOX 
2. Scenario B. Pmab + FOLFOX 






Scenario A vs. B : €4394 
Scenario C vs. B : €4432 
- 1st line oxaplatin combinations of biweekly 
Cmab for WT and Bmab for MT optimise 





1.Predictive biomarker testing 







Lys €26.276 (KRAS testing scenario) 
€9.686 (RAS testing scenario) 
€3.948 (future but achievable 
biomarker scenario) 




1. 3rd line chemotherapy 
(Cmab + Irinotecan) 
2. No 3rd line chemotherapy 
EGFR LYs The range of ICERs was between 
€205,536 and €323,040 
- Cmab + Irinotecan as 3rd line therapy in 
mCRC is promising, but a very expensive 
antibody. Reduced drug cost and/or 




1. No UGT1A1 genotyping + 
SOC 
2. UGT1A1 testing + Reduced 
initial ironotecan dose (20% 
reduction)  
3. UGT1A1 testing + standard 
irinotecan dose+ Prophylactic 












1. Genotyping + reduced initial 
irinotecan dose :  
(African group) : cost-saving 
compared to No genotyping 
strategy  
(Asian group) : US$6,818,203 
(Caucasian group) : cost-saving 
compared to No genotyping 
strategy  
- Genotyping in combination with reduced 
irinotecan dose for genotype pts was cost-
saving for the population of African and 
Caucasian origin. By contrast, genotyping 
was not cost-effective for the population of 
Asian ancestry. The prophylactic use of 
GCSFs in genotype pts was not cost-effective 





2. Genotyping + Prophylatic use 
of GCSF :  
(African group) : US$3,506,260 
(Asian group) : US$7,371,770 




0. BSC (no KRAS test; no 
treatment) 
1a. KRAS testing + Cmab 
1b. No KRAS testing + Cmab 
2a. KRAS testing + Pmab 
2b. No KRAS testing + Pmab 
3a. KRAS testing + Cmab + 
Irinotecan 
3b. No KRAS testing + Cmab + 
Irinotecan 
KRAS QALYs - 0. BSC (no KRAS test; no 
treatment) 
1a. KRAS testing + Cmab : $54,802 
compared to BSC 
1b. No KRAS testing + Cmab : 
Dominated compared to BSC 
0. BSC (no KRAS test; no 
treatment) 
2a. KRAS testing + Pmab : $47,795 
compared to BSC 
2b. No KRAS testing + Pmab : 
$308,236 compared to BSC 
0. BSC (no KRAS test; no 
treatment) 
3a. KRAS testing + Cmab + 
Irinotecan : $42,710 compared to 
BSC 
3b. No KRAS testing + Cmab + 
Irinotecan : $163,396 compared to 
BSC 
All strategies considering KRAS testing found 




1. FOLFIRI + Cmab 
2. FOLFIRI + Bmab 
KRAS, 
RAS 
LYs, QALYs 1. For KRAS WT pts, FOLIFIRI + 
Cmab : US$97297 compared to 
Bmab + FOLFIRI 
1. For KRAS WT pts, FOLIFIRI + 
Cmab : US$122704 compared to 
Bmab + FOLFIRI 
Cmab + FOLFIRI improve health outcomes 
and use financial resource more efficiently 





2. For a subset of RAS WT pts, 
FOLFIRI + Cmab : US$77380 
compared to Bmab + FOLFIRI 
2. For a subset of RAS WT pts, 
FOLFIRI + Cmab : US$99,636 
compared to Bmab + FOLFIRI 
Pichereau 
2010 
1. UGT1A1 genotyping + 
irinotecan therapy 







Genotyping strategy : €942.8 to 
€1090.1 
- UGT1A1 genotype screening before 
irinotecan treatment is a cost-effective 




Strategy 1 (reference strategy: 
EGFRI monotherapy in 3rd 
line).  
1st LINE : 
Bmab+FOLFIRI/FOLFOX (1st 
Line), 2nd LINE : 
FOLFIRI/FOLFOX, 3rd LINE : 
EGFRI  
Strategy 2 (EGFRI and 
Irinotecan in 3L).  
1L : Bmab+FOLFIRI/FOLFOX,  
2L : FOLFIRI/FOLFOX, 3L : EGFRI 
+ irinotecan 
Strategy 3 (EGFRI in 1L). 
1L : EGFRI + FOLFIRI/FOLFOX, 
2L : Bmab + FOLFIRI/FOLFOX, 
3L : best supportive care 
KRAS, 
RAS 
QALYs - Strategy 2 : $119,623 compared to 
Strategy 1  
Strategy 3 : $3,176,591 compared 
to Strategy 1 
1st line of EGFRI is not cost-effective at its 
current pricing relative to Bmab 
Rivera 
2017 
1. Pmab + mFOLFOX6   
2. Bmab + mFOLFOX6   
RAS LYs, QALYs €16,567 €22,794 Pmab+mFOLFOX6 is more cost-effective 
than Bmab+mFOLFOX6 for the first line 
treatment of RAS wild-type mCRC   
Saito 
2017 
No testing strategy: Anti-EGFR 
therapy without testing  
RAS LYs, QALYs RAS screening: JYP2,574,111 RAS screening: JYP3,049,132 Comprehensive screening (comprehensive 





2. RAS screening : RAS 
mutation screening before 
anti-EFGR therapy 
3. Comprehensive screening : 
comprehensive molecular 
profiling before anti-EGFR 
therapy using CancerPlex to 
screen for mutations that 









1. Bmab + Chemotherapy 
2. Cmab + Chemotherapy 
3. Pmab + Chemotherapy 
KRAS QALYs - Cmab+FOLFIRI : £30,665 compared 
to FOLFIRI alone.  
Bmab + FOLFOX : £17,626 
compared to FOLFOX alone. 
Pmab + FOLFOX : £15,326 
compared to FOLFOX alone. 
Cmab plus FOLFIRI is the most cost-effective 
for pts with KRAS WT tumors. ICERs of Cmab 
+ Chemotherapy (CT), Bmab + CT, and Pmab 
+ CT are within the commonly accepted 
threshold of CE in UK 
Shankara
n 2015 
1. FOLFIRI plus Cmab in 
treatment-naïve patients with 
KRAS wt type in mCRC 
2. FOLFIRI plus Bmab 
treatment-naïve patients with 
KRAS wt type in mCRC   
KRAS, 
RAS 
LYs, QALYs KRAS-WT patients:  
Cmab+FOLIFIRI $86,487per LY  
RAS-WT patients:  
Cmab_FOLIFIRI $73,731 per LY 
KRAS-WT patients:  
Cmab+FOLIFIRI $107,630 per QALY 
RAS-WT patients:  
Cmab+FOLIFIRI $93,785 per QALY 




1. KRAS testing + Cmab (WT - 
Cmab, MT - BSC) : Strategy A 
2. No KRAS testing + all Cmab : 
Strategy B 
3. No KRAS testing + all BSC : 
Strategy C 
KRAS LYs, QALYs 1. KRAS testing + Cmab : 
dominant compared to no KRAS 
testing  
2. KRAS testing : US$120,000 
compared to no-Cmab strategy 
3. No KRAS testing : US$160,000 
compared to no Cmab strategy 
1. KRAS testing + Cmab : dominant 
compared to no KRAS testing  
2. KRAS testing : US$180,000 
compared to no-Cmab strategy 
3. No KRAS testing : US$230,000 
compared to no Cmab strategy 
KRAS testing is dominant compared to no-
KRAS testing strategy. However, ICER of 
Cmab + KRAS testing is US$180,000 per 







1. Cmab + Chemotherapy 
2. Chemotherapy alone 
RAS LYs R$56,750 - The addition of Cmab to the standard 
chemotherapy is cost-effective 
Starling 
2007 
1. Cmab + Irinotecan 
2. Active/best supportive care 
(ASC/BSC) 
EGFR LYs, QALYs £42,975 £57,608 ICERs for Cmab+Irinotecan is relatively high 




1. Pmab + FOLFOX 
2. Cmab + FOLFIRI 
RAS LYs Pmab + FOLFOX US$ 21,613.42 
Cmab + FOLFIRI US$ 23,036.94 
- Pmab showed treatment outcomes 
improvement vs. Cmab for wt RAS pts at a 
lower cost per life year. 
Vijayaragh
avan 2012 
1. KRAS testing + Cmab 
2. KRAS testing + Pmab 
3. KRAS testing + Combination 
therapy (Cmab + Irinotecan) 
4. No testing + Cmab 
5. No testing + Pmab 
6. No testing + Combination 
therapy (Cmab + Irinotecan) 
KRAS LYs   1. No testing + Pmab : higher cost 
same effectiveness compared to 
KRAS testing + Pmab 
2. No testing + Cmab : higher cost 
same effectiveness compared to 
KRAS testing + Cmab 
3. No testing + Combination 
therapy : higher cost same 
effectiveness compared to KRAS 
testing + Combination therapy 
- Using KRAS testing to limit use of EGFR 
inhibitors (Cmab/Pmab) to pts with KRAS WT 
results in net savings of $7500 to $12400 
(for USA), while net savings of €3900 to 
€9600 (for Germany) 
Wen 2015 1. Pts with KRAS testing 
treated with Cmab and FOLFIRI 
(KRAS-Cmab) 
2. Pts with RAS testing treated 
with Cmab and FOLFIRI (RAS-
Cmab) 
3. Pts with KRAS testing 








 1st and 2nd line 
KRAS-Bmab $6,145.84 per QALMs 
RAS-Bmab $6,201.34 per QALMs 
RAS-Cmab $6,263.86 per QALMs 
KRAS-Cmab $6,963.70 per QALMs 
RAS screening prior to Cmab seems to be a 
cost-effective strateggy in the time of 
monoclonal antibodies therapies. However, 
KRAS-Cmab strategy dominated by other 3 
strategies. RAS-Bmab seems the most cost-
effective strategy but the gained QALM was 
the shortest. Compared to other 3 
strategies, RAS-Cmab achieved the highest 





*Recalculated compared to No Cmab strategy 
Bmab, bevacizumab; Cmab, Cetuximab; EGFR, epidermal growth factor receptor; ICER, incremental cost-effectiveness ratio; KRAS, kirsten rat sarcoma; RAS, rat sarcoma; LYs, life 
years; NS, not specified; NR, not reported; PAP, patient assistance program; Pmab, panitumumab; QALYs, quality adjusted life years; QALMs, quality adjusted life months; SOC, 
standard of care; WT, wild-type. 
4. Pts with RAS testing treated 
with Bmab and FOLFIRI (RAS-
Bmab) 
Wu 2017 1. Cmab + FOLFIRI (with or 
without patient assistance 
programme)    
2. FOLFIRI  
RAS LYs, QALYs Cmab + FOLFIRI with PAP: 
$12,107 
Cmab + FOLFIRI without PAP: 
$23,393 
 
Cmab + FOLFIRI with PAP: $14,049 
Cmab + FOLFIRI without PAP: 
$27,145 
 
RAS testing with Cmab is cost-effective, 
when PAP is available, at a willingness to pay 
threshold of China ($22,200/QALY) 
Xu 2016 1.Pmab 
2.Cmab 
NR LYs, QALYs - - Pmab dominates over Cmab. Pmab has a 
cost advantage over Cmab 
Zhou 
2016 
















- Analysis I (KRAS-wt vs. RAS-wt):  
1. KRAS-Cmab (Dominated) 
$88,394.09 
2. KRAS-Bmab (Dominated) 
$80,797.82 
3. RAS-Cmab (420,700.50 
compared to RAS-Bmab) 
$82,590.72 
4. RAS-Bmab (n.a) $75.358.42 
Analysis II (RAS wt):  
1. FOLFOX-Cmab (Dominated) 
2. FOLFOX-Bmab (Dominated) 
3. FOLFIRI-Cmab (Dominated) 
4. FOLFOX-Bmab (Undominated) 
Analysis 1 : RAS wt testing is more cost-
effective than KRAS wt testing before 
treatment. It is the first head to head cost-
effectiveness study to evaluate predictive 
testing for extended RAS-wt in mCRC in the 
context of targeting Cmab/Bmab treatment. 
The results demonstrate that it was 
economically favorable to identify pts with 
extended RAS-wt status. Furthermore, 
FOLFIRI plus Bmab was the preferrred 
strategy compared with other strategies in 





APPENDIX 2-5 :  QHES SCORING PER STUDY 
Study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Score 
Annemans 2007 yes yes no no yes yes no no yes yes no yes no no no no 48 
Asseburg 2011 yes yes yes n/a yes yes no yes yes no no yes yes no yes yes 75 
Behl 2012 yes no yes n/a yes yes yes yes yes no no yes yes no yes yes 76 
Blank 2011 yes yes yes n/a yes yes no yes yes yes no yes yes no yes yes 81 
Butzke 2016 yes yes yes n/a yes yes yes yes yes yes yes yes yes yes yes yes 99 
Carvalho 2017 yes yes yes no yes yes no yes yes yes no yes yes no yes yes 81 
Davari 2015 yes yes yes n/a yes yes no no yes no no no no no yes yes 53 
Ewara 2014 yes yes yes n/a yes yes yes yes no yes no yes yes yes yes yes 84 
Gold 2009 yes yes no n/a yes yes no yes no yes no yes yes no yes yes 65 
Graham 2014 yes yes yes n/a yes yes no yes yes yes yes yes yes no yes yes 88 
Graham 2016 yes yes yes n/a yes yes yes yes yes yes yes yes yes no yes yes 93 
Harty 2018 yes yes yes yes yes yes yes yes no yes no yes no no yes yes 72 
Hoyle 2013 yes yes yes n/a yes yes yes yes yes yes no yes yes no yes yes 86 
Huxley 2017 yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes 100 
Lawrence 2013 yes yes yes n/a yes yes no yes yes yes no yes yes no no yes 73 
Mittmann 2009 yes yes yes yes yes yes yes no yes yes yes no yes no yes yes 79 
Norum 2006 yes yes no n/a yes yes no no yes no no yes yes yes yes yes 66 
Obradovic 2008 yes yes no yes yes yes no no yes yes no no no no yes yes 52 
Ontario HTA 2010 yes yes yes yes yes yes yes yes yes yes yes yes yes no yes no 91 





Riesco-Martinez 2016 yes yes no n/a yes yes yes yes yes yes no yes no no yes yes 71 
Rivera 2017 yes yes yes no yes yes yes yes yes yes yes yes yes no yes yes 93 
Saito 2017 yes yes no no yes yes no yes yes yes no yes yes no yes no 70 
Shankaran 2015 yes yes yes n/a yes yes no no yes no no yes yes no yes yes 68 
Shiroiwa 2010 yes yes yes yes yes yes yes yes yes yes no yes yes no yes yes 87 
Starling 2007 yes yes no n/a yes yes yes yes no yes yes no yes no yes yes 69 
Vijayaraghavan 2012 yes yes yes n/a yes no no yes no yes no yes yes no yes yes 67 
Wen 2015 yes yes no n/a yes no no yes no no no yes no no no yes 38 
Wu 2017 yes yes no no yes Yes no yes no yes no yes no no yes yes 58 








APPENDIX 3-１ :  SEARCH STRATEGY/SEARCH TERMS   






6 *Germ cell tumors/ 
7 metastas$.mp. [mp=ti, ot, ab, nm, hw] 
8 tumour$.mp. [mp=ti, ot, ab, nm, hw] 
9 tumor$.mp. [mp=ti, ot, ab, nm, hw] 
10 cancer$.mp. [mp=ti, ot, ab, nm, hw] 
11 neoplasm$.mp. [mp=ti, ot, ab, nm, hw] 
12 carcinoma$.mp. [mp=ti, ot, ab, nm, hw] 
13 lymphoma$.mp. [mp=ti, ot, ab, nm, hw] 
14 sarcoma$.mp. [mp=ti, ot, ab, nm, hw] 
15 leukemia$.mp. [mp=ti, ot, ab, nm, hw] 
16 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 
OR #14 OR #15) 
17 exp "Cost-Benefit Analysis"/ 
18 (value of life or economics, medical or economics, pharmaceutical or models, 
economic or markov chains or monte carlo method or uncertainty).sh. 
19 economics.fs. 
20 economics.sh. 
21 ((econom$ or cost or costly or costing or costed or prices or pricing or discount or 
discounts or discounted or discounting or budget$ or afford$ or 
pharmacoeconomic$ or pharmaco) adj1 economic$).ti,ab. 
22 (decision adj1 (tree$ or analy$ or model$)).ti,ab. 
23 (#17 OR # 18 OR #19 OR #20 OR #21 OR #22) 
24 (Lynparza* or olaparib). mp. [mp=ti, it, ab, nm, hw] 
25 (Talzenna* or talazoparib). mp. [mp=ti, it, ab, nm, hw] 
26 (Rubraca* or rucaparib). mp. [mp=ti, it, ab, nm, hw] 
27 (Iressa* or gefitinib). mp. [mp=ti, it, ab, nm, hw] 
28 (Gilotrif* or afatinib). mp. [mp=ti, it, ab, nm, hw] 
29 (Vizimpro* or dacomitinib). mp. [mp=ti, it, ab, nm, hw] 
30 (Tarceva* or erlotinib). mp. [mp=ti, it, ab, nm, hw] 





32 (Keytruda* or pembrolizimab). mp. [mp=ti, it, ab, nm, hw] 
33 (Tecentriq* or atezolizumab). mp. [mp=ti, it, ab, nm, hw] 
34 (Tibsovo* or ivosidenib). mp. [mp=ti, it, ab, nm, hw] 
35 (Tasigna* or nilotinib). mp. [mp=ti, it, ab, nm, hw] 
36 (Alecensa* or alectinib). mp. [mp=ti, it, ab, nm, hw] 
37 (Xalkori* or crizotinib). mp. [mp=ti, it, ab, nm, hw] 
38 (Zykadia*or ceritinib). mp. [mp=ti, it, ab, nm, hw] 
39 (Tafinlar* or dabrafenib). mp. [mp=ti, it, ab, nm, hw] 
40 (Mekinist* or trametinib). mp. [mp=ti, it, ab, nm, hw] 
41 (Zelboraf* or vemurafenib). mp. [mp=ti, it, ab, nm, hw] 
42 (Cotellic* or cobimetinib). mp. [mp=ti, it, ab, nm, hw] 
43 (Herceptin*or trastuzumab). mp. [mp=ti, it, ab, nm, hw] 
44 (Perjeta* or pertuzumab). mp. [mp=ti, it, ab, nm, hw] 
45 (Kadcyla* or ado-trastuzumab emtansine) 
46 (Erbitux* or cetuximab) 
47 (Vectibix* or panitumumab) 
48 (Idhifa* or enasidenib) 
49 (Venclexta* or venetoclax) 
50 (Gleevec* or Gilvec* or imatinib mesylate) 
51 (Exjade* or deferasirox) 
52 (#26 OR  #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR 
#37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR 
#48 OR #49 OR #50 OR #51) 
53 (#16 AND #23 AND #52) 
54 Limits: humans, full-text, English, 5-year (2014-present) 
 
Database: Embase 
1 exp neoplasm  
2 (neoplasm$) OR (metatas$) OR (carcinoma$) OR (sarcoma$) OR (lymphoma$) OR 
(leukemia) OR (germ adj3 cell adj3 tumor$) OR (tumo?r$) OR (cancer$)  
3 (#1 OR #2) 
4 exp health economics/ or exp economic evaluation/ or exp "cost benefit analysis"/ or 
exp economic aspect/  
5 (cost$ adj2 effective$) OR (cost$ adj2 benefit$) OR (cost$ adj2 utilit$) OR (willingness 
to pay or net benefit$) OR (economic$ adj2 evaluation$) 
6 (decision adj2 (tree$ or analy$ or model$)) 





8 (Lynparza* or olaparib) 
9 (Talzenna* or talazoparib) 
10 (Rubraca* or rucaparib) 
11 (Iressa* or gefitinib) 
12 (Gilotrif* or afatinib) 
13 (Vizimpro* or dacomitinib) 
14 (Tarceva* or erlotinib) 
15 (Tagrisso* or osimertinib) 
16 (Keytruda* or pembrolizimab) 
17 (Tecentriq* or atezolizumab) 
18 (Tibsovo* or ivosidenib) 
19 (Tasigna* or nilotinib) 
20 (Alecensa* or alectinib) 
21 (Xalkori* or crizotinib) 
22 (Zykadia*or ceritinib) 
23 (Tafinlar* or dabrafenib) 
24 (Mekinist* or trametinib) 
25 (Zelboraf* or vemurafenib) 
26 (Cotellic* or cobimetinib) 
27 (Herceptin*or trastuzumab) 
28 (Perjeta* or pertuzumab) 
29 (Kadcyla* or ado-trastuzumab emtansine) 
30 (Erbitux* or cetuximab) 
31 (Vectibix* or panitumumab) 
32 (Idhifa* or enasidenib) 
33 (Venclexta* or venetoclax) 
34 (Gleevec* or Gilvec* or imatinib mesylate) 
35 (Exjade* or deferasirox) 
36 (#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR 
#19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR 
#30 OR #31 OR #32 OR #33 OR #34 OR #34 OR #35) 
37 (#3 AND #7 AND #36) 
38 Limits: humans, full-text, English, 5-year (2014-present) 
 
Database: Econlit  
1. biomark$ OR (molecu$ adj3 mark$) OR (tumo?r adj3 mark$) OR (biologic$ adj3 mark$) 





2. (target adj3 therap$) OR (targeted adj3 therap$) OR (personali#ed adj3 medicine$) OR 
(companion adj3 diagnostic$ OR (precision adj3 medicine$) OR (codependent adj3 
technolog$) 
3. neoplasm$ OR metatas$ OR carcinoma$ OR sarcoma$ OR lymphoma$ OR leukemia OR 
(germ adj3 cell adj3 tumor$) OR tumo?r$ OR cancer$ 
4. Lynparza$ or olaparib 
5. Talzenna$ or talazoparib 
6. Rubraca$ or rucaparib 
7. Iressa$ or gefitinib 
8. Gilotrif$ or afatinib 
9. Vizimpro$ or dacomitinib 
10. Tarceva$ or erlotinib 
11. Tagrisso$ or osimertinib 
12. Keytruda$ or pembrolizimab 
13. Tecentriq$ or atezolizumab 
14. Tibsovo$ or ivosidenib 
15. Tasigna$ or nilotinib 
16. Alecensa$ or alectinib 
17. Xalkori$ or crizotinib 
18. Zykadia$ or ceritinib 
19. Tafinlar$ or dabrafenib 
20. Mekinist$ or trametinib 
21. Zelboraf$ or vemurafenib 
22. Cotellic$ or cobimetinib 
23. Herceptin$ OR trastuzumab 
24. Perjeta$ or pertuzumab 
25. Kadcyla$ OR ado-trastuzumab emtansine 
26. Erbitux$ OR cetuximab 
27. Vectibix$ OR panitumumab 
28. Idhifa$ OR enasidenib 
29. Venclexta$ or venetoclax 
30. Gleevec$ or Gilvec$ or imatinib mesylate 
31. Exjade$ or deferasirox 
32. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 
or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or 
#27 or #28 or #29 or #30 or #31) 






Database: Cochrane via Wiley (technology assessments and economic evaluations) 
1. MeSH descriptor: [Neoplasms] explode all trees  
2. MeSH descriptor: [Sarcoma] explode all trees 
3. MeSH descriptor: [Lymphoma] explode all trees 
4. MeSH descriptor: [Leukemia] explode all trees 
5. (neoplasm$) OR (metatas$) OR (carcinoma$) OR (sarcoma$) OR (lymphoma$) OR 
(leukemia) OR (germ adj3 cell adj3 tumor$) OR (tumo?r$) OR (cancer$)  
6. (#1 OR #2 OR #3 OR #4 OR #5) 
7. MeSH descriptor: [Costs and Cost Analysis] explode all trees 
8. MeSH descriptor: [Cost-Benefit Analysis] explode all trees 
9. MeSH descriptor: [Economics, Pharmaceutical] explode all trees 
10. (cost effective$) OR (cost benefit$) OR (cost utility$) OR (economic evaluation$) 
11. (#7 OR #8 OR #9 OR #10) 
12. Lynparza$ or olaparib OR Talzenna$ or talazoparib OR Rubraca$ or rucaparib OR 
Iressa$ or gefitinib OR Gilotrif$ or afatinib OR Vizimpro$ or dacomitinib OR Tarceva$ or 
erlotinib OR Tagrisso$ or osimertinib OR Keytruda$ or pembrolizimab OR Tecentriq$ or 
atezolizumab OR Tibsovo$ or ivosidenib OR Tasigna$ or nilotinib OR Alecensa$ or 
alectinib OR Xalkori$ or crizotinib OR Zykadia$ or ceritinib OR Tafinlar$ or dabrafenib 
OR Mekinist$ or trametinib OR Zelboraf$ or vemurafenib OR Cotellic$ or cobimetinib 
OR Herceptin$ OR trastuzumab OR Perjeta$ or pertuzumab OR Kadcyla$ OR ado-
trastuzumab emtansine OR Erbitux$ OR cetuximab OR Vectibix$ OR panitumumab OR 
Idhifa$ OR enasidenib OR Venclexta$ or venetoclax OR Gleevec$ or Gilvec$ or imatinib 
mesylate OR Exjade$ or deferasirox 
13. (#6 AND #11 AND #12) 






APPENDIX 3-２ :  PICOS AND INCLUSION/EXCLUSION CRITERIA  
PICOS Inclusion criteria Exclusion criteria 
Population 
Adult patients (>= 16 years) with 
cancer treated with biomarker-
guided therapies 
Patients < 16 years 
Intervention 
Precision medicine  
Personalized medicine  
Biomarker-guided therapies  
Companion diagnostic devices  
Cancer biomarkers for targeted 
therapies  
No companion diagnostics  
No predictive biomarkers for targeted therapies  
No biomarker-guided therapies  
Drugs without assessing companion biomarkers  
Universal screening tools 
Triage procedures 
Severity or progression analyses 
Comparator  Unrestricted 
No comparative treatment 
Surgery 
Outcome 
Biomarker characteristics  
Methodological approaches  
Modelling inputs  
- 
Study type 




No economic evaluations  
No English  
Costing studies  
Cost-minimization studies  
 
Selection of papers followed the eligibility criteria below:  
Population: adult patients with cancer tested with companion biomarkers for targeted therapies. 
Studies conducted on pre-specified patients with a biomarker status confirmed were excluded if 
they did not consider any of biomarker-related characteristics in their evaluations.  
Intervention: companion biomarkers for targeted anti-cancer therapies. These biomarkers are 
used as diagnostic tools to guide the optimal treatment option(s) for patients responsive or 
unresponsive to the corresponding therapeutic products. Biomarker tests without market 
authorizations co-licensed with companion therapeutic products were not of interest in this 
review.  
Comparator: conventional treatments (e.g. chemotherapy, best supportive care) or targeted 
therapies with or without the use of companion biomarker tests.  
Outcome: Methodological or modelling approaches, biomarker characteristics, data inputs of 
biomarker tests. Studies without sufficient information reported on these items (e.g. abstracts) 
were excluded.  





APPENDIX 3-3 :  LIST OF INCLUDING THE CHARACTERISTICS OF COMPANION BIOMARKERS IN THE ECONOMIC 
EVALUATIONS 
Study Q1 Q2 Q3 Q4 Q5 Q6 Q7.1 
Q7.
2 
Q8 Q9 Q10 Q11 Q12 
Aguiar 
2017 (125) 
Yes Yes Yes Yes No No No No No Yes No Yes No 
Chouaid 
2017 (126) 
No Yes No No No No No Yes No No Yes No No 
Curl 2014 
(127) 
No Yes Yes No No No No Yes No No Yes Yes No 
Ewara 2014 
(102) 
No Yes Yes No No No No No No No Yes No No 
Graham 
2014 (87) 
No Yes No No No No No Yes No No Yes Yes Yes 
Graham 
2016 (128) 
No Yes No No No No No Yes No No Yes Yes No 
Harty 2018 
(129) 





No Yes Yes No No No No Yes No Yes Yes No Yes 
Janmaat 
2016 (131) 
No Yes Yes No No No No Yes No Yes No No Yes 
Lim 2016 
(135) 
Yes Yes Yes Yes Yes No No Yes No Yes Yes Yes Yes 
Lu 2018 
(136) 
Yes Yes Yes Yes Yes No Yes  Yes No Yes Yes Yes Yes 
Morgan 
2017 (132) 
No Yes Yes No No No No Yes No No Yes Yes No 
Wen 2015 
(69) 
Yes Yes No Yes No No No Yes No No No Yes No 
Westwood 
2014 (137) 
Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes 
Wu 2017 
(133) 
Yes Yes Yes Yes No No No Yes No Yes Yes Yes Yes 
Zhou 2016 
(72) 
Yes Yes No No No No No Yes No No Yes No No 
Saito 2017 
(68) 
Yes Yes Yes Yes No No No Yes Yes No Yes Yes Yes 
Butzke 
2016 (118) 





APPENDIX 4-1 :  SUMMARY OF PATIENT CHARACTERISTICS  
 Bevacizumab trial1  Dacarbazine trial2  
Number of study cohort N = 35 N = 338 
Median age (range) 63 (26 – 77) 52 (17 – 86) 
ECOG performance status – no. (%)   
                                  0 28 (80) 230 (68) 
                                  1  7 (20) 108 (32) 
Male sex – no. (%) 19 (54) 181 (54) 
1 Schuster C, Eikesdal HP, Puntervoll H, Geisler J, Geisler S, et al. (2012) Clinical efficacy and safety of 
bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early 
hypertension. PLoS ONE 7(6): e38364. Doi:10.1371/journal.pone.0038364 
2 McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R et al. Safety and efficacy of vemurafenib 
in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, 
randomised, open-label study. Lancet Oncol. 2014;15(3):323-32. doi: 10.1016/S470-2045(14)70012-9. Epub 
2014 Feb 7. 
 
APPENDIX 4-2 :  PARAMETERS USED IN THE MODEL 
 (DACARBAZINE) 
KM curve Distribution Survival function Parameters used in the model 
OS  Log-normal 𝑆(𝑡) = 1 −  ϕ (
log(t)− μ 
 σ
) µ = 2.279977 
σ = 1.222045 
PFS Ggamma 𝑆(𝑡) = 1 − 𝐼(𝜅 −2, 𝜅 −2𝑒 𝜅((log(𝑡)−𝜇)/𝜎) )  
(𝜅 > 0) 
k = -.9470793 
µ = .6701823 
σ = .8424385 
 
(Bevacizumab) 
KM curve Distribution Survival function Parameters used in the model 
OS Gompertz 






λ = 0.2072661 
ϒ = -0.124534 
PFS Log-normal 𝑆(𝑡) = 1 −  ϕ (
log(t)− μ 
 σ
) µ = 1.645146 







APPENDIX 4-3 :  VISUAL INSPECTION, AIC AND BIC RESULTS WHEN PARAMETRIC SURVIVAL DISTRIBUTIONS FITTED TO THE KM CURVES 
 
A. Overall survival of Dacarbazine: Model fits for Kaplan-Meier curve by different distributions and AIC/BIC results  
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Fitted distributions for OS KM data AIC BIC 
Exponential 625.7581 629.5812 
Weibull 621.7382 629.3843 
Gompertz 626.7534 634.3995 
Log-normal 612.4530 620.0991 
Log-logistic 617.1194 624.7654 
Ggamma 614.1587 625.6278 
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B. Progression-Free Survival of Dacarbazine: Model fits for Kaplan-Meier curve by different distributions and AIC/BIC results  
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Fitted distributions for PFS KM data AIC BIC 
Exponential 497.2788 501.1018 
Weibull 493.1551 500.8012 
Gompertz 495.8613 503.5074 
Log-normal 434.8525 442.4986 
Log-logistic 436.7084 444.3545 
Ggamma 414.4038 425.8729 
AIC; Akaike information criterion, BIC; Bayesian information criterion  
C. Overall survival of Bevacizumab (HSP27 positive): Model fits for Kaplan-Meier curve by different distributions and AIC/BIC results  
Overall survival – KM curve OS KM curve fitted with Exponential OS KM curve fitted with Weibull 
   










































































   
Fitted distributions for OS KM data AIC BIC 
Exponential 93.06797    94.20347 
Weibull 88.46272 90.7337 
Gompertz 81.27416    83.54515 
Log-normal 81.97873 84.24971 
Log-logistic 84.24971 84.918 
AIC; Akaike information criterion, BIC; Bayesian information criterion  
 































































Overall survival – KM curve OS KM curve fitted with Exponential OS KM curve fitted with Weibull 
   
OS KM curve fitted with Gompertz OS KM curve fitted with Log-normal OS KM curve fitted with Log-logistic  









































































































































APPENDIX 4-4 :   ROC ANALYSIS RESULTS: COMBINATION OF DECISION THRESHOLDS PER HSP27 STAINING 
INDEX  
HSP27 index 1-specificity (x-axis) Sensitivity (y-axis) 
1 - - 
2 100.0% 100.0% 
3 95.8% 90.9% 
4 58.3% 81.8% 
5 50.0% 72.7% 
6 50.0% 72.7% 
7 12.5% 36.4% 
8 12.5% 36.4% 
9 12.5% 36.4% 
10 0.0% 0.0% 
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APPENDIX 4-6: THE PATHOLOGIC TUMOUR-NODE-METASTATES (PTNM) CLASSIFICATION (SOURCED FROM 
SCHUSTER PHD THESIS1) 
 
▪ T-classification in cutaneous melanoma 
T* classification Thickness (mm) Ulceration/mitosis 
T1 ≤ 1.0 a: +/- ulceration and  mitosis < 1/mm2 
b: + ulceration and  mitosis ≥ 1/mm2 
T2 1.01 – 2.0 a: +/- ulceration 
b: + ulceration 
T3 2.01 – 4.0 a: +/- ulceration 
b: + ulceration 
T4 > 4.0 a: +/- ulceration 
b: + ulceration 
 * Primary tumours (T) are classified by tumour thickness and the absence or presence of tumour 
ulceration.  
1 Schuster C. Investigation of predictive markers in patients with metastatic melanoma treated 
with bevacizumab (PhD thesis): University of Bergen, Bergen, Norway; 2016. 
 
▪ N-classification in cutaneous melanoma 
N* classification  Number of metastatic 
nodes 
Nodal metastatic burden 
N0  0 Not applicable 
N1 1 a: micrometastases# 
b: macrometastases^ 
N2 2 – 3 a: micrometastases# 
b: macrometastases^ 
N3 4+ or matted nodes or 
in transit met/satellites 
with metastatic nodes 
c: in transit metastases or satellites 
without metastatic nodes 
 *Node (N)-stage is defined by the number of affected regional lymph nodes   and include in transit  
metastases and microscopic  satellites. 
1 Schuster C. Investigation of predictive markers in patients with metastatic melanoma treated 






▪ M-classification in cutaneous melanoma 
M* classifications Site Serum LDH 
0 No distant metastases Not applicable 
M1a Distant skin, subcutaneous or 
nodal metastases  
Normal 
M1b Lung metastases Normal  
M1c All other visceral metastases 
Any distant metastases 
Normal 
Elevated 
 *Metastases (M) -categories are defined by the site of distant metastases and serum levels of 
lactate dehydrogenase (LDH). 
 
APPENDIX 5-1 :  R CODES FOR STEP 1. TRANSITION PROBABILITY 
a. Vectoring probability data inputs in R 
eff <- 0.25  #Efficacy of targeted therapy compared to usual care. 
pPFS2PD.UC <- 0.2 #transition probability from PFS to PD when treated with UC. 
pPFS2PD.TC <- 0.2 - (0.2*eff) #transition probability from PFS to PD when treated with TC.  
pPD2D <- 0.25   #transition probability from PD to Dead. 
pPFS2D <- 0.05 #transition probability from PFS to Dead. 
state_names <- c("PFS", "PD", "Dead") #names of health states. 
n.states <- length(state_names) #number of health states. 
 
b. Creating transition matrix of PFS for all-UC arm  
t.PFS.UC <- numeric() 
t.PFS.UC[2] <- pPFS2PD.UC 
t.PFS.UC[3] <- pPFS2D 
t.PFS.UC[1] <- 1 - sum(t.PFS.UC[-1]) 
 
c. Creating transition matrix of PFS for all-TC arm  
t.PFS.UC <- numeric() 
t.PFS.UC[2] <- pPFS2PD.UC 
t.PFS.UC[3] <- pPFS2D 
t.PFS.UC[1] <- 1 - sum(t.PFS.UC[-1]) 
 
d. Creating transition matrix of health state PD   
t.PD <- numeric() 
t.PD[1] <- 0 
t.PD[3] <- pPD2D 
t.PD[2] <- 1 - sum(t.PD[-2]) 
 
e. Creating transition matrix of health state Dead  






f. Creating transition matrix for patients treated with biomarker non-guided therapy (also referred 
to as ‘usual care’)   
pTransition.UC <- matrix(c(t.PFS.UC, t.PD, t.Dead),  
                         nrow = 3, ncol = 3, byrow = TRUE, 
                         dimnames = list(state_names,state_names)) 
 
g.  Creating transition matrix for patients treated with biomarker-guided therapy (also referred to 
as ‘targeted care’)   
pTransition.TC <- matrix(c(t.PFS.TC, t.PD, t.Dead),  
                         nrow = 3, ncol = 3, byrow = TRUE, 
                         dimnames = list(state_names,state_names)) 
 
h. Double check if transition probabilities add up to 1  
rowSums(pTransition.UC)  
                rowSums(pTransition.TC) 
 
APPENDIX 5-2 :  R CODES FOR STEP 2. COST AND UTILITY 
a. Vectoring cost data inputs  
cPFS <- 500     #costs in health state of PFS.  
cPD <- 3000     #costs in health state of PD.  
cDead <- 0        #costs in health state of Dead. 
cDrug <- 1000     #costs of targeted therapy. 
cTest <- 100        #costs of biomarker testing. 
 
b. Preparing cost transition matrices 
cTransition.UC <- c(cPFS,cPD,cDead)  #for patients treated with UC. 
names(cTransition.UC) <- state_names 
cTransition.TC <- c(cPFS + cDrug,cPD,cDead) #treated with TC. 
names(cTransition.TC) <- state_names 
 
cTransition.TTC <- c(cPFS + cDrug + cTest,cPD,cDead) # test-treated with TC, if test positive. 
names(cTransition.TTC) <- state_names  
cTransition.TUC <-  c(cPFS + cTest,cPD,cDead) # test-treated with UC, if test negative. 
 
names(cTransition.TUC) <- state_names 
 
c. Vectoring utility data inputs  
uPFS.UC <- 0.75 #utility values for patients treated with UC while in PFS.  
uPFS.TC <- 0.80  #utility values for patients treated with TC while in PFS. 
uPD.UC <- 0.45   #utility values for patients treated with UC while in PD.  
uPD.TC <- 0.65    #utility values for patients treated with TC while in PD.  
uDead <- 0  
 
d. Preparing utility transition matrices 
uTransition.UC <-c(uPFS.UC,uPD.UC,uDead) #patients treated with UC. 
names(uTransition.UC) <- state_names 
uTransition.TC <- c(uPFS.TC,uPD.TC,uDead) #treated with TC. 
names(uTransition.TC) <- state_names 
#Utility values for patients tested and biomarker positive confirmed and thus, treated with TC.   





names(uTransition.TTC) <- state_names 
#Utility values for patients tested and biomarker negative confirmed and thus, treated with UC. 
uTransition.TUC <- c(uPFS.UC - disutility.Test, uPD.UC, uDead) 
                names(uTransition.TUC) <- state_names 
 
APPENDIX 5-3 :  R CODES FOR STEP 3. SIMULATION MODEL FOR ALL-UC ARM 
a. Vectoring data inputs for cohort trace  
n.t <- 1000                 #total number of cycles to run the Markov model.  
pBiomarker <- 0.3    #prevalence/frequency of biomarker status.  
pSensitivity <- 0.95  #biomarker testing accuracy – sensitivity. 
pSpecificity <- 0.65  #biomarker testing accuracy – specificity.  
tp <- pSensitivity      #true positive. 
fp <- 1- pSensitivity    #false positive. 
tn <- pSpecificity      #true negative. 
fn <- 1 - pSpecificity #false negative. 
b. Defining and initializing the matrix for all-UC arm 
MT.UC <- matrix(NA, nrow = n.t + 1, ncol = n.states,  
                           dimnames = list(paste("Cycle", 0:n.t, sep = " "),  
                           state_names)) 
 
c. Starting a hypothetical cohort of all patients from health state of PFS  
MT.UC[1,] <- c(1000,0,0) #initiate first cycle of cohort trace in all-UC arm.  
 
d. Run the model for all-UC arm  
for (t in 1:n.t) {      #loop through the number of cycles. 
  MT.UC[t+1,] <- t(MT.UC[t,]) %*% pTransition.UC 
                 }                                                     
 
APPENDIX 5-4 :  R CODES FOR STEP 4. SIMULATION MODEL FOR ALL-TC, TEST-TREAT ARMS RESPECTIVELY 
a. Defining and initializing matrices and vectors for all-TC arm 
MT.TTC <- MT.TUC <- matrix(NA, nrow = n.t + 1, ncol = n.states,  
                                                dimnames = list(paste("Cycle", 0:n.t, sep = " "),  
                                                state_names)) 
 
b. Defining and initializing matrices and vectors for TT arms 
MT.TTCtp <- MT.TTCfp <- MT.TUCtn <- MT.TUCfn <- matrix(NA, nrow = n.t + 1, ncol = n.states, 
dimnames = list(paste("Cycle", 0:n.t, sep = " "),  
state_names))  
 
c. Starting a hypothetical cohort of all patients from health state of PFS in all-TC arm 
MT.TTC[1,] <- c(1*pBiomarker, 0,0) #initiate first cycle considering prevalence of biomarker 
status in allTC arm and patients were biomarker positive and thus, TC was effective.  
MT.TUC[1,] <- c(1*(1-pBiomarker), 0,0) #initiate first cycle considering prevalence of biomarker 
status in all-TC arm and patients were biomarker negative and thus, TC was not effective.  
 
d. Starting a hypothetical cohort of all patients from health state of PFS in TT arm 
MT.TTCtp[1,] <- c(1*pBiomarker*tp, 0, 0) #true positive patients. 
MT.TTCfp[1,] <- c(1*pBiomarker*fp, 0, 0) #false positive patients.  





MT.TUCfn[1,] <- c(1*(1-pBiomarker)*fn, 0, 0) #false negative patients. 
 
e. Run the model of all-TC arm  
for (t in 1:n.t) {   #loop through the number of cycles.  
  MT.TUC[t+1,] <- t(MT.TUC[t,]) %*%pTransition.UC 
  MT.TTC[t+1,] <- t(MT.TTC[t,]) %*%pTransition.TC   
} 
MT.allTC <- MT.TTC + MT.TUC #summing the cohort traces of MT.TTC and MT.TUC 
 
f. Run the model of TT arm  
for (t in 1:n.t) {    
  MT.TTCtp[t+1,] <- t(MT.TTCtp[t,]) %*%pTransition.TC 
  MT.TTCfp[t+1,] <- t(MT.TTCfp[t,]) %*%pTransition.UC 
  MT.TUCtn[t+1,] <- t(MT.TUCtn[t,]) %*%pTransition.UC 
  MT.TUCfn[t+1,] <- t(MT.TUCfn[t,]) %*%pTransition.UC 
                  }                  #loop through the number of cycles  
 
APPENDIX 5-5 :  R CODES FOR STEP 5. COMPUTING EPIDEMIOLOGICAL OUTCOMES  
a. Creating survival curves of patients in all-UC arm 
matplot(MT.UC, type = 'l',   # "1" for lines, "p" for points. 
             ylab = "Probability of state occupancy", 
             xlab = "Cycle", 
             main = "Cohort Trace of all-UC arm")   #create a plot of the data. 
legend("topright", state_names,  #add a legend to the graph. 
col = 1:n.states,lty = 1:n.states, bty = "n")   
#lty: line type. e.g lty=1 is solid line, lty=2 is dashed line  
#bty: box type. default value bty = 0 or n 
 
b. Creating survival curves of patients in all-TC arm  
MT.allTC <- MT.TTC + MT.TUC  
matplot(MT.allTC, type = 'l',  
             ylab = "Probability of state occupancy", 
             xlab = "Cycle", 
             main = "Cohort Trace of all-TC arm")    
legend("topright", state_names,  
col = 1:n.states,lty = 1:n.states, bty = "n")   
 
c. Survival curves of patients in Test-Treat arm  
MT.TT <-  MT.TTCtp + MT.TTCfp + MT.TUCtn + MT.TUCfn 
matplot(MT.TT, type = 'l',      
ylab = "Probability of state occupancy", 
             xlab = "Cycle", 
             main = "Cohort Trace of TT arm")    
legend("topright", state_names,  
col = 1:n.states,lty = 1:n.states, bty = "n")   
 
d. Creating overall survival of all-UC arm  
OS.UC <- 1 - MT.UC[,"Dead"]  
#alternatively, use this code: OS.UC <- rowSums(MT.UC[, 1:2]) 





       ylim = c(0, 1), 
       ylab = "Survival probability", 
       xlab = "Cycle", 
       main = "Overall Survival of all-UC arm")  
       #creating a plot showing OS curve 
grid(nx = n.t, ny = 10, col = "lightgray", lty = "dotted", lwd = par("lwd"), equilogs = TRUE) # add 
grid 
 
e. Creating overall survival of all-TC arm  
OS.allTC <- 1 - MT.allTC[ , "Dead"] 
plot(OS.allTC, type = 'l', 
       ylim = c(0, 1), 
       ylab = "Survival probability", 
       xlab = "Cycle", 
       main = "Overall Survival of all-TC arm")  
grid(nx = n.t, ny = 10, col = "lightgray", lty = "dotted", lwd = par("lwd"), equilogs = TRUE)  
 
f. Creating overall survival of TT arm  
OS.TT <- 1 - MT.TT[ , "Dead"] 
plot(OS.TT, type = 'l', 
       ylim = c(0, 1), 
       ylab = "Survival probability", 
       xlab = "Cycle", 
       main = "Overall Survival of TT arm")  
grid(nx = n.t, ny = 10, col = "lightgray", lty = "dotted", lwd = par("lwd"), equilogs = TRUE) 
 
g. Estimating life expectancy (LE) 
LE.UC <- sum(OS.UC) #LE of all-UC arm. 
LE.allTC <- sum(OS.allTC) #LE of all-TC arm. 
              LE.TT <- sum(OS.TT) #LE of TT arm. 
 
APPENDIX 5-6 :  R CODES FOR STEP 6. CALCULATING COST-EFFECTIVENESS  
a. Estimating mean QALYs 
uEV.UC <- MT.UC %*% uTransition.UC #QALY for allUC arm. 
uEV.TTC <- MT.TTC %*% uTransition.TC #QALY for allTC arm but actually biomarker positive.  
uEV.TUC <- MT.TUC %*% uTransition.UC #QALY for allTC arm but actually biomarker negative. 
 
# TT arm  
uEV.TTCtp <- MT.TTCtp %*% uTransition.TTC #QALY for test positive and treated with TC. 
uEV.TTCfp <- MT.TTCfp %*% uTransition.TUC #QALY for false positive and thus, TC is not effective 
uEV.TUCtn <- MT.TUCtn %*% uTransition.TUC #QALY for true negative and treated with UC. 
uEV.TUCfn <- MT.TUCfn %*% uTransition.TUC  #QALY for false negative and thus, TC would be 
better but UC was provided. 
 
b. Estimating mean costs  
cEV.UC <- MT.UC %*% cTransition.UC #Cost for all-UC arm. 
cEV.allTC <- MT.allTC %*% cTransition.TC #Cost for all-TC arm.  
 
#TT arm  
cEV.TTCtp <- MT.TTCtp %*% cTransition.TTC #Cost for true positive and treated with TC. 





cEV.TUCtn <- MT.TUCtn %*% cTransition.TUC #Cost for true negative and treated with UC. 
cEV.TUCfn <- MT.TUCfn %*% cTransition.TUC #Cost for false negative and treated with UC. 
cEV.TT <- cEV.TTCtp + cEV.TTCfp + cEV.TUCtn + cEV.TUCfn 
 
c. Generating discounted QALYs 
rDiscount <- 0.035 #equal discount for costs and QALYs by 3.5% 
cycle_rDiscount <- 1/(1 + rDiscount)^(0:n.t) #calculate discount weights for each cycle 
 
uEV.allUC <- t(uEV.UC) %*% cycle_rDiscount #all-UC arm QALY 
uEV.TUC <- t(uEV.TUC) %*% cycle_rDiscount  
uEV.TTC <- t(uEV.TTC) %*% cycle_rDiscount 
uEV.allTC <- d.uEV.TUC + d.uEV.TTC #all-TC arm QALY 
 
uEV.TTCtp <- t(uEV.TTCtp) %*% cycle_rDiscount 
d.uEV.TTCfp <- t(uEV.TTCfp) %*% cycle_rDiscount 
d.uEV.TUCtn <- t(uEV.TUCtn) %*% cycle_rDiscount 
d.uEV.TUCfn <- t(uEV.TUCfn) %*% cycle_rDiscount 
d.uEV.TT <- d.uEV.TTCtp + d.uEV.TTCfp + d.uEV.TUCtn + d.uEV.TUCfn #TT arm QALY. 
 
d. Generating discounted costs  
cEV.allUC <- t(cEV.UC) %*% cycle_rDiscount #all-UC arm Cost. 
cEV.allTC <- t(cEV.allTC) %*% cycle_rDiscount #all-TC arm Cost. 
cEV.TTCtp <- t(cEV.TTCtp) %*% cycle_rDiscount 
cEV.TTCfp <- t(cEV.TTCfp) %*% cycle_rDiscount 
cEV.TUCtn <- t(cEV.TUCtn) %*% cycle_rDiscount 
cEV.TUCfn <- t(cEV.TUCfn) %*% cycle_rDiscount 
cEV.TT <- d.cEV.TTCtp + d.cEV.TTCfp + d.cEV.TUCtn + d.cEV.TUCfn #TT arm Cost. 
 
e. Base-case cost-effectiveness calculation  
uEV <- c(d.uEV.allUC, d.uEV.allTC, d.uEV.TT) 
cEV <- c(d.cEV.allUC, d.cEV.allTC, d.cEV.TT) 
 
list(Cost = cEV,  
     Effect = uEV) #Vectoring the calculated values of cEV and uEV  
 
#ICER calculation   
names.strategy <- c("all-UC", "all-TC", "Test-Treat") 
table.ce <- data.frame(Strategy=names.strategy,  
                       Cost = cEV, Effect = uEV) 
table.ce[order(table.ce$Cost, decreasing = FALSE),] #sort CE table by the order of Cost 
 
icer <- data.frame(cEV,uEV) 
icer.sort <- t(icer[order(table.ce$Cost, decreasing = FALSE),] ) 
 
d.cost1 = icer.sort[1,2] - icer.sort[1,1] 
d.cost2 = icer.sort[1,3] - icer.sort[1,2] 
incr.cost <- c(0, d.cost1, d.cost2) 
 
d.qaly1 = icer.sort[2,2] - icer.sort[2,1] 
d.qaly2 = icer.sort[2,3] - icer.sort[2,2] 






icer1 = d.cost1/d.qaly1  
icer2 = d.cost2/d.qaly2 
icer <- c(0,icer1,icer2) 
icer.sort1 <- icer.sort[1,] 
icer.sort2 <- icer.sort[2,] 
 
v.strategy <- c("all-UC", "Test-Treat", "all-TC") 
v.outcome <- c("Cost", "Incr Costs", "QALY", "Incr QALY", "ICER (/QALY)") 
 
table.icer <- matrix(c((icer.sort1),  
                       c(0, d.cost1, d.cost2), 
                       c(icer.sort2), 
                       c(0, d.qaly1, d.qaly2), 
                       nrow = 4, ncol = 4, byrow=FALSE)) 
icer.sort.cost <- c(0, d.cost1, d.cost2) 
icer.sort.qaly <- c(0, d.qaly1, d.qaly2) 
icer.sort.result <- c(0, d.cost1/d.qaly1, d.cost2/d.qaly2)  
 
ICER.basecase <- format (matrix(c(icer.sort1,icer.sort.cost,icer.sort2,  
                                  icer.sort.qaly, icer.sort.result),  
                                nrow = 5, ncol = 3, byrow = TRUE, 
                                dimnames = list(v.outcome, v.strategy)), digits = 2) 
 
#Alternatively, ICER can be simply computed as below.  
ICER_2allUC <- (d.cEV.TT - d.cEV.allUC)/(d.uEV.TT - d.uEV.allUC) 
ICER_2allTC <- (d.cEV.TT - d.cEV.allTC)/(d.uEV.TT - d.uEV.allTC) 
ICER_2allUC #ICER of TT compared to allUC arm. 
                ICER_2allTC #ICER of TT compared to allTC arm.  
Example base-case ICER output in R  
 
> ###### 03.4 ICER calculation  
> ICER_2allUC <- (d.cEV.TT - d.cEV.allUC)/(d.uEV.TT - d.uEV.allUC) 
> ICER_2allTC <- (d.cEV.TT - d.cEV.allTC)/(d.uEV.TT - d.uEV.allTC) 
 
> ICER_2allUC #ICER of TT compared to allUC arm  
         [,1] 
[1,] 11660.24 
> ICER_2allTC #ICER of TT compared to allTC arm 




APPENDIX 5-7 :  R CODES FOR STEP 7. PERFORMING SENSITIVITY ANALYSIS 
a. Defining the PSA model run  
psa.model.run <- function(eff, pPFS2PD.UC, pPD2D, pPFS2D, 
                          pBiomarker, pSensitivity, pSpecificity, 
                          cPFS, cPD, cTest, 
                          uPFS.UC, uPFS.TC, uPD.UC, uPD.TC)  
{ 
# source (appendix - basically, same as the base case analysis but assigning and selecting a 
random value from the distributions around input parameters defined above as psa.model.run)  
cost = list(costUC = d.cEV.allUC,  





                costTT = d.cEV.TT) 
qaly = list(qalyUC = d.uEV.allUC,  
                qalyTC =d.uEV.allTC,  
                qalyTT = d.uEV.TT) 




b. Sampling the parameters for PSA output  
n.sim <- 1000 #PSA size 
set.seed(1) 
psa_eff <- rbeta(n.sim,0.1,0.3) #drug efficacy 
psa_pPFS2PD.UC <- rbeta(n.sim, 34,136) 
psa_pPD2D <- rbeta(n.sim,32,95) 
psa_pPFS2D <- rbeta(n.sim, 41 ,770) 
psa_pBiomarker <- rbeta(n.sim, 30, 69)  #prevalence of biomarker 
psa_pSensitivity <- rbeta(n.sim, 1.18, 0.06) 
psa_pSpecificity <- rbeta(n.sim, 14, 7.7) 
psa_cPFS <- rgamma(n.sim, 43, 12) 
psa_cPD <- rgamma(n.sim, 43, 70) 
psa_cTest <- rgamma(n.sim, 43, 2.34) 
psa_uPFS.UC <- rbeta(n.sim, 9.92, 3.31) 
psa_uPFS.TC <- rbeta(n.sim, 7.73, 1.93) 
psa_uPD.UC <- rbeta(n.sim, 23, 28) 
psa_uPD.TC <- rbeta(n.sim, 14, 7.7) 
 
c. Running the PSA  
for (i in 1:n.sim){ 
  
  psa.results[[i]] <- psa.model.run(psa_eff[[i]], psa_pPFS2PD.UC[[i]],  
                                    psa_pPD2D[[i]], psa_pPFS2D[[i]], 
                                    psa_pBiomarker[[i]],psa_pSensitivity[[i]], 
                                    psa_pSpecificity[[i]],psa_cPFS[[i]], 
                                    psa_cPD[[i]], psa_cTest[[i]],  
                                    psa_uPFS.UC[[i]], psa_uPFS.TC[[i]],  
                                    psa_uPD.UC[[i]], psa_uPD.TC[[i]]) 
} 
 
d. Calculating incremental cost and qalys  
psa.results_dataframe <- data.frame(Reduce(rbind,psa.results))  
 
incCosts_TT_UC <- psa.results_dataframe[,"costTT"] – psa.results_dataframe[,"costUC"] 
incCosts_TT_TC <- psa.results_dataframe[,"costTT"] – psa.results_dataframe[,"costTC"] 
incQalys_TT_UC <- psa.results_dataframe[, "qalyTT"] – psa.results_dataframe[, "qalyUC"] 
incQalys_TT_TC <- psa.results_dataframe[, "qalyTT"] – psa.results_dataframe[, "qalyTC"] 
incCosts_TC_UC <- psa.results_dataframe[, "costTC"] – psa.results_dataframe[, "costUC"] 













e. Calculating ICER  
psaICER_TT_UC = mean(incCosts_TT_UC)/mean(incQalys_TT_UC) 
psaICER_TT_TC = mean(incCosts_TT_TC)/mean(incQalys_TT_TC) 
psaICER_TC_UC = mean(incCosts_TC_UC)/mean(incQalys_TC_UC) 
lambda <- 5000 #Willingness to pay threshold 
incNB <- incQalys_TT_UC*lambda - incCosts_TT_UC 
summary(incNB) 
 
f. Plotting the CE plane  
#CE plane of TT compared with all-UC strategy  
plot(incCosts_TT_UC ~ incQalys_TT_UC, ylim = c(-0.5, 0.5) * lambda, xlim = c(-0.5, 0.5), main = 
"CE plane") 
abline(h = 0) 
abline(v = 0) 
abline(0, lambda, col = 2) 
#CE plane of TT compared with all-TC strategy  
plot(incCosts_TT_TC ~ incQalys_TT_TC, ylim = c(-1, 1) * lambda, xlim = c(-1, 1), main = "CE plane") 
abline(h = 0) 
abline(v = 0) 
abline(0, lambda, col = 2) 
#CE plane of all-TC compared with all-UC strategy  
plot(incCosts_TC_UC ~ incQalys_TC_UC, ylim = c(-1.3, 1.3) * lambda, xlim = c(-1.3, 1.3), main = 
"CE plane") 
abline(h = 0) 
abline(v = 0) 
                abline(0, lambda, col = 2) 
Example PSA output in R  
#Cost-effective scatterplot of Test-Treat arm compared with Treat-all with UC arm 
 



































Supplementary R codes for DSA simulation  
 
#1. Assign parameters for DSA simulation  
dsa_rate <- 0.3 #discount rate 
dsa_eff <- c(eff*(1-dsa_rate), eff*(1+dsa_rate)) 
dsa_pPFS2PD.UC <- c(pPFS2PD.UC*(1-dsa_rate), pPFS2PD.UC*(1+pPFS2PD.UC)) 
dsa_pPD2D <- c(pPD2D*(1-dsa_rate), pPD2D*(1+dsa_rate)) 
dsa_pPFS2D <- c(pPFS2D*(1-dsa_rate), pPFS2D*(1+dsa_rate)) 
dsa_pBiomarker <- c(pBiomarker*(1-dsa_rate), pBiomarker*(1+dsa_rate)) 
dsa_pSensitivity <- c(pSensitivity*(1-dsa_rate), pSensitivity*(1+dsa_rate)) 
dsa_pSpecificity <- c(pSpecificity*(1-dsa_rate), pSpecificity*(1+dsa_rate)) 
dsa_cPFS <- c(cPFS*(1-dsa_rate), cPFS*(1+dsa_rate)) 
dsa_cPD <- c(cPD*(1-dsa_rate), cPD*(1+dsa_rate)) 
dsa_cTest <- c(cTest*(1-dsa_rate), cTest*(1+dsa_rate)) 
dsa_uPFS.UC <- c(uPFS.UC*(1-dsa_rate), uPFS.UC*(1+dsa_rate)) 
dsa_uPFS.TC <- c(uPFS.TC*(1-dsa_rate), uPFS.TC*(1+dsa_rate)) 
dsa_uPD.UC <- c(uPD.UC*(1-dsa_rate), uPD.UC*(1+dsa_rate)) 
dsa_uPD.TC <- c(uPD.TC*(1-dsa_rate), uPD.TC*(1+dsa_rate)) 
 
#2. Define the DSA model run  
dsa.model.run <- function(eff)  
dsa.model.run <- function(pPFS2PD.UC)  
dsa.model.run <- function(pPD2D)  
dsa.model.run <- function(pPFS2D)  





dsa.model.run <- function(pSensitivity)  
dsa.model.run <- function(pSpecificity)  
dsa.model.run <- function(cPFS)  
dsa.model.run <- function(cPD)  
dsa.model.run <- function(cTest)  
dsa.model.run <- function(uPFS.UC)  
dsa.model.run <- function(uPFS.TC)  
dsa.model.run <- function(uPD.UC)  
dsa.model.run <- function(uPD.TC)  
{ 
 
#3. Repeat model run used in Step 6.  
 
#4. Generate the OWSA results  
dsa.results1 <- list() #Set up an empty dataframe for results. 
for (i in 1:2) { 
  dsa.results1 [[i]] <- dsa.model.run(dsa_eff[[i]]) #Generating the DSA result per parameter. 
} 
save(dsa.results,file="dsa_eff_out.rdata") #save the result  
 
dsa.results2 <- list() 
for (i in 1:2) { 
  dsa.results2 [[i]] <- dsa.model.run(dsa_pPFS2PD.UC[[i]]) #dsa for transition probability to PD state. 
} 
save(dsa.results,file="dsa_pPFS2PD.UC_out.rdata") #save the result.  
 
dsa.results3 <- list() 
for (i in 1:2) { 




dsa.results4 <- list() 
for (i in 1:2) { 
  dsa.results4 [[i]] <- dsa.model.run(dsa_pPFS2D[[i]]) #dsa for transition probability from PFS to dead.  
} 
 
dsa.results5 <- list() 
for (i in 1:2) { 
  dsa.results5 [[i]] <- dsa.model.run(dsa_pBiomarker[[i]]) #dsa for biomarker prevalence/frequency.  
} 
 
dsa.results6 <- list() 
for (i in 1:2) { 
  dsa.results6 [[i]] <- dsa.model.run(dsa_pSensitivity[[i]]) #dsa for testing sensitivity.  
} 
 
dsa.results7 <- list() 
for (i in 1:2) { 







dsa.results8 <- list() 
for (i in 1:2) { 
  dsa.results8 [[i]] <- dsa.model.run(dsa_cPFS[[i]]) #dsa for health state costs in PFS. 
} 
 
dsa.results9 <- list() 
for (i in 1:2) { 
  dsa.results9 [[i]] <- dsa.model.run(dsa_cPD[[i]]) #dsa for health state costs in PD. 
} 
 
dsa.results10 <- list() 
for (i in 1:2) { 
  dsa.results10 [[i]] <- dsa.model.run(dsa_cTest[[i]]) #dsa for testing cost.  
} 
 
dsa.results11 <- list() 
for (i in 1:2) { 
  dsa.results11 [[i]] <- dsa.model.run(dsa_uPFS.UC[[i]]) #dsa for utility value in PFS (treated with UC). 
} 
 
dsa.results12 <- list() 
for (i in 1:2) { 
  dsa.results12 [[i]] <- dsa.model.run(dsa_uPFS.TC[[i]]) #dsa for utility value in PFS (treated with TC).  
} 
 
dsa.results13 <- list() 
for (i in 1:2) { 
  dsa.results13 [[i]] <- dsa.model.run(dsa_uPD.UC[[i]]) #dsa for utility value in PD (treated with UC).  
} 
dsa.results14 <- list() 
for (i in 1:2) { 
  dsa.results14 [[i]] <- dsa.model.run(dsa_uPD.TC[[i]]) #dsa for utility value in PD (treated with TC). 
} 
 
dsa.results <- data.frame(dsa.results1,dsa.results2) #Create the dataframe of all DSA results.  
for (i in 1:14) { 
} 
 
#5. Calculate the incremental costs and QALYs  
#convert the dataset in the from of 'list' to the form of 'data.frame'  
dsa.results_dataframe <- data.frame(Reduce(rbind,dsa.results))  
incCosts_TT_UC <- dsa.results_dataframe[,"costTT"] - dsa.results_dataframe[,"costUC"] 
incCosts_TT_TC <- dsa.results_dataframe[,"costTT"] - dsa.results_dataframe[,"costTC"] 
incQalys_TT_UC <- dsa.results_dataframe[, "qalyTT"] - dsa.results_dataframe[, "qalyUC"] 
incQalys_TT_TC <- dsa.results_dataframe[, "qalyTT"] - dsa.results_dataframe[, "qalyTC"] 
incCosts_TC_UC <- dsa.results_dataframe[, "costTC"] - dsa.results_dataframe[, "costUC"] 













#6. Calculate ICER 
dsaICER_TT_UC = mean(incCosts_TT_UC)/mean(incQalys_TT_UC) 
dsaICER_TT_TC = mean(incCosts_TT_TC)/mean(incQalys_TT_TC) 
dsaICER_TC_UC = mean(incCosts_TC_UC)/mean(incQalys_TC_UC) 
 
